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The goal of the study was to develop antioxidant polymeric nanoparticles as a new 
delivery system for food and pharmaceutical applications. Natural antioxidants like alpha-
tocopherol, vitamin C, and carnosine, are responsible to protect biological systems against free 
radicals attack. The conjugation of vitamin C-vitamin E (EC) and alpha-tocopherol-carnosine 
(VECAR) were performed to obtain antioxidant surfactants which were used for polymeric 
nanoparticle synthesis. The surfactant made of α-tocopherol (vitamin E) and ascorbic acid 
(vitamin C) of antioxidant properties dubbed as EC was used to make poly(lactic-co-glycolic) 
acid (PLGA) nanoparticles. Self-assembled EC nanostructures and PLGA-EC nanoparticles were 
made by nanoprecipitation, and the nanoparticle physical properties were studied at different salt 
concentrations, surfactant concentrations, and polymer:surfactant ratios. EC was soluble in polar 
solvents, and Span 80 was selected as a control due to its similar surfactant properties. The 
PLGA-EC nanoparticles and EC surfactant showed antioxidant activity based on DPPH 
technique and EPR study, which is not characteristics to commercially available Span80. The 
newly synthesized EC surfactant was found successful in forming uniform, small size polymeric 
nanoparticles of intrinsic antioxidant properties.  
 The next step was to synthesize VECAR, an antioxidant molecule made of carnosine and 
alpha-tocopherol derivative. The designed molecule looks for protection of low density 
lipoproteins (LDL) from oxidation by placing at the LDL interface two potent natural 
antioxidants. The LDL protection can impact the development and outcome of atherosclerosis. 
The approach followed was to use the phytyl chain as active site for coupling of carnosine. The 
synthesis process involved 8 steps starting with esterification of Trolox and finishing with the 
deprotection of the hydroxyl group of the alpha-tocopherol moiety. The antioxidant behavior of 
VECAR (0.0236 mM) was tested by DPPH assay which showed values similar to pure alpha-
tocopherol (0.0229 mM). The values suggested full recovery of the active hydroxyl group of the 
alpha-tocopherol derivative. More studies are needed to test antioxidant behavior in the presence 
of lipids and ability of VECAR to protect LDL oxidation in vitro; in vivo analysis of LDL 
oxidation in the presence of VECAR is required to understand the fate of VECAR in more 




CHAPTER 1. INTRODUCTION 
The present work focuses on surfactants, antioxidants, self-assembly, and polymeric 
nanoparticles as interactive entities for prevention and treatment of oxidative stress related 
diseases. Polymeric nanoparticles have been identified as a promising system for treatment of 
disease by delivery of active components at specific places in a controlled manner [1-7], which 
translates into a reduction in side effects, increased therapeutically effects, and higher treatment 
efficiency. 
In general, there are two main approaches to synthesize polymeric nanoparticles: top-
down and bottom-up techniques. The bottom-up techniques require monomers to build up 
nanostructures. This involves polymerization using initiators and surfactants (emulsion 
polymerization technique). The top-down techniques involves reduction of already formed 
structures by application of external forces like sonication or a physical-chemistry process (e.g. 
solvent diffusion, solvent-antisolvent properties). Examples of top-down techniques are emulsion 
evaporation, nanoprecipitation, and salting out [2]. All of these techniques involve surfactants 
that stabilize the nanostructures formed by application of external forces and reduce their 
aggregation when suspended in water [8,9]. Surfactant concentration commonly used in 
nanoparticles synthesis can reach up to 5-8 %wt. Safety of these surfactants is an issue. Sodium 
dodecyl sulfate (SDS) for example, is a good anionic surfactant but its use is restricted for food 
applications (e.g. less than 125 ppm is allowed in liquid & frozen egg whites). Polysorbates such 
as sorbitan monostearate is only allowed in finished whipped edible oil topping at concentrations 
lower than 0.4% [10]). To reduce the amount of surfactants present in the final formulations, 
washing steps are required. Centrifugation, ultra-filtration, and dialysis are examples of common 
techniques used, but they add extra cost and time to the synthesis. One approach to reduce or 
limit washing steps is to use bio-friendly and highly efficient surfactants in the polymeric 
nanoparticle synthesis.  
The unique role of the polymeric nanoparticles is to act as carriers for the drug selected 
for treatment entrapped into the polymeric core. It is expected that the next generation of 
nanosystems will be more proactive; they will “sense” the environment and will react to the 
external stimuli to produce a controlled beneficial effect. Not only will they act as a carrier, but 
also as active agents. To accomplish this goal, the components of the system must possess 
characteristics that allow specific chemical and physical interactions with the environment. One 
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way to control these specific interactions of the nanoparticles with environment is to use a 
surfactant of desired properties in the nanoparticles synthesis. For example, functional 
surfactants with antioxidant action provide the option to synthesize colloidal nanostructures with 
inherent antioxidant activity. These structures could be useful in treating oxidative-stress related 
diseases such as atherosclerosis and cancer, among others, in addition to playing their obvious 
role as vehicles for drug transport and delivery. Polymeric nanoparticles formed with these 
surfactants would not require washing. 
Antioxidants and vitamins are fundamental for human health. Natural antioxidants like 
vitamin E (α-tocopherol), vitamin C, flavonoids, and carotenoids are compounds that could 
potentially modulate oxidative stress. Antioxidants are defined as “any substance that, when 
present in low concentrations compared to that of an oxidisable substrate, significantly delays or 
inhibits the oxidation of that substrate” by Halliwell & Gutteridge [11]. Oxidation of substrates is 
promoted by highly reactive species such as free radicals. Free radicals (i.e. superoxide anion, 
hydroxyl and peroxyl radical), and non free radicals (i.e. hydrogen peroxide, hypochlorous acid, 
and peroxynitrite) are present in all biological systems and can trigger oxidative processes with 
harmful consequences for the biological entity that result in aging, cancer, diabetes, 
cardiovascular disease, inflammatory responses, degenerative diseases, cataract, and others [12-
20]. Hence, many of the principal diseases affecting human health that are related with the 
oxidative process can be prevented by antioxidants which limit cell damage produced by reactive 
oxygen and nitrogen species (ROS and NOS) [21-24]. 
Atherosclerosis has been related to the oxidative process, in that high levels of oxidant 
molecules or low levels of antioxidants were shown to be responsible for high oxidative stress 
triggering the atherosclerosis process. The oxidation theory of atherosclerosis attributes great 
importance to the oxidation process and deems free radicals as precursors for the first steps in the 
development of the disease [19,25-27]. In this context, great importance has been attributed to 
vitamin E, especially α-tocopherol, as the main lipophilic natural antioxidant present in the 
lipophilic phase of every cell. LDL is composed by a core of cholesterol and triglycerides 
surrounded by fatty acids, cholesteryl esters, apolipoproteins, and phospholipids [28-31]. 
Lipophilic antioxidants avoid oxidation of the lipid fraction of LDLs, but apolipoproteins are not 
protected from oxidation even in the presence of lipophilic antioxidants [32-36]. The limitations 
of lipophilic natural antioxidants can be overcome with an adequate design of an alternative 
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“natural” antioxidant formed by covalently linking the hydrophobic antioxidant (alpha-
tocopherol) with a hydrophilic molecule with antioxidant properties (vitamin C or carnosine). 
The resulting amphiphilic molecule will insure that the antioxidant activity will be localized 
closer to apolipoproteins (present at the surface of the low density lipoproteins), for better 
antioxidant performance, with a potential synergetic behavior due to antioxidant-coantioxidant 
phenomena (vitamin E & vitamin C, vitamin E & carnosine). In addition, these new molecules 
(EC and VECAR) will have surfactant characteristics and could be used in synthesis of 
polymeric nanoparticles of inherent antioxidant characteristics.   
The first approach followed to combat oxidative stress with polymeric nanoparticles was 
to synthesize particles with entrapped antioxidants such us superoxide dismutase, catalase, and 
melatonin into the polymeric matrix for the treatment of diseases related with oxidative damage 
[37-39]. The newer approach was to form antioxidant nanoparticles with inherent antioxidant 
activity due to the presence of antioxidant molecules (antioxidant surfactants) in the nanoparticle 
structure. Figure 1-1 depicts the concept of using antioxidant surfactants in the synthesis of 
polymeric nanoparticles with antioxidant properties.   
The present dissertation presents three main chapters to show the current status and 
development of the concept of antioxidant nanoparticles as a new delivery system. Following the 
introduction, the second chapter shows a review on polymeric nanoparticles as delivery systems 
for antioxidants and vitamins. The information presented stresses the availability and importance 
of antioxidant molecules and the current status of nanosystems with entrapped antioxidants. 
Chapter 3 is focused on the development and use of a new surfactant (EC), a molecule 
synthesized by using natural antioxidant molecules: alpha-tocopherol (vitamin E) and ascorbic 
acid (vitamin C). Alpha-tocopherol is hydrophobic, and vitamin C is hydrophilic. Thus, the 
amphiphilic EC surfactant results when the two are linked. The chapter presents work that 
describes the chemical vitamin E-vitamin C conjugation to form the EC surfactant, synthesis of 
nanostructures by self-assembly of the surfactant EC, and synthesis of polymeric nanoparticles 
by nanoprecipitation in the presence of EC. The nanostructures characterization (size, 
polydispersity, morphology, and antioxidant action) is presented relative to nanostructures 
formed under similar conditions in the presence of Span 80 as a surfactant. Chapter 4 presents 
information about synthesis of a new antioxidant molecule VECAR synthesized with vitamin E 
analog and carnosine (dipeptide). Detailed chemical synthesis of VECAR is presented step by 
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step, and study of the antioxidant action of VECAR is evaluated by DPPH and TBARS assay. 
The final two chapters present the conclusions and future work that could be pursuit based on 
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CHAPTER 2. ENCAPSULATION AND CONTROLLED 
RELEASE OF ANTIOXIDANTS AND VITAMINS VIA 
POLYMERIC NANOPARTICLES1 
2.1 Introduction 
 Antioxidants and vitamins are fundamental for human health. Natural antioxidants like 
vitamin E (α-tocopherol), vitamin C, flavonoids (i.e. quercitin, catequin, among others), are 
compounds which could potentially modulate oxidative stress. Many of the principal diseases 
affecting human health are related with the oxidative process, among which cardiovascular 
diseases, atherosclerosis, and cancer are the most prevalent. Antioxidants can prevent these 
diseases by reducing the reactive oxygen species (ROS) and thus limiting cell damage by ROS.  
Natural antioxidants are prone to degradation and their bioavailability is limited by low 
absorption and degradation during delivery. The encapsulation of antioxidants and vitamins in 
polymeric nanoparticles is a promising way of improving the bioavailability of these 
components. Nanoparticles can be designed to deliver the antioxidant/vitamin to the specific site 
of action with minimal degradation of the bioactive component during delivery. The 
antioxidant/vitamin is then potentially released in a controlled manner by controlling the 
degradation profile of the polymer, or by using “smart” polymers which interact with the cell 
environment (temperature, pH, enzymes, ionic strength, and other) in a predictable way.  
In this chapter, the importance of antioxidants to human health will be addressed, the 
advantages of nanoencapsulation of these components over more traditional delivery methods 
will be discussed, the top-down techniques available to entrap antioxidants and vitamins in 
biodegradable and biocompatible polymeric nanoparticles will be discussed, the methods 
available for polymeric nanoparticles characterization will be briefly mentioned, and some 
insights on the release profile of antioxidants and vitamins from polymeric nanoparticles will be 
presented. The chapter will close with conclusions and future research directions. 
 
 
                                                 
 
1 Reprinted with permission from Woodhead Publishing Limited. Delivery and controlled release of bioactives in 
foods and nutraceuticals, edited by N. Garti, ISBN 1 84569 145 8, ISBN-13: 978 1 84569 145 5, Woodhead 
Publishing limited, UK. 
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2.2 Antioxidants and Vitamins in Protecting Human Health 
2.2.1 Reactive Oxygen Species and Oxidation Process 
Halliwell & Gutteridge [1] defined antioxidants as “any substance that, when present in 
low concentrations compared to that of an oxidisable substrate, significantly delays or inhibits 
the oxidation of that substrate”. Enzymatic and nonenzymatic antioxidants prevent cellular 
damage surged from chemical reactions that involve reactive oxygen species (ROS) [2-4]. The 
reactive oxygen species play beneficial roles in the cell metabolism influencing cell growth, 
energy production, and intracellular signaling, but ROS can be damaging to different tissues due 
to their involvement in lipid peroxidation, DNA modification, carbohydrates oxidation, and/or 
protein alteration. Damage caused by ROS has been related to cancer, diabetes, cardiovascular 
disease, inflammatory responses, degenerative diseases, aging, liver injury, cataract, and others 
[5-25]. 
Figure 2-1: Schematic representation of oxidative damage and defense systems. The oval shapes 
represent the defense system against reactive oxygen species. Adapted from Young and 
Woodside (2001) [4]. 
Intracellular ROS are mainly generated by autooxidation of small molecules and from the 
activity of certain enzymes like oxidases, peroxidases, lipoxygenases, dehydrogenases, and 
cyclooxygenases; they can also be generated by exogenous sources (i.e. pollutants, cigarettes). 
The cellular sites of reactive oxygen species generation are mitochondria, peroxisomes, 
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The state of a biological system exposed to excessive formation of ROS and limited 
antioxidant defense is defined as oxidative stress [30-32]. The human body has developed an 
internal defense against oxidative stress (Figure 2-1). Metal binding proteins control the 
concentration of free metal ions and reduce the potential risk of antioxidant molecules to act as 
pro-oxidants. Enzymatic and natural antioxidants act mainly as suppressors of radicals, 
protecting the cellular environment from oxidative damage by ROS which could otherwise result 
in oxidative stress related diseases. Enzymatic antioxidants and proteins are mainly hydrophilic 
and therefore act in a hydrophilic environment. The natural antioxidants (acquired from food) act 
in a hydrophilic or hydrophobic environment, based on their chemical makeup, which 
complement the enzymatic defensive system and enhance the protection of intracellular 
hydrophobic molecules. Lastly, if oxidative stress occurs, the repair system, consisting of 
different enzymes (i.e. lipases, DNA repair enzymes, proteases, and others) can repair the 
damage originated from the oxidation process [27]. 
Figure 2-2: Localization of different antioxidant molecules in the cell. The distribution of natural 
antioxidants in the cell components is dictated by their chemical tendencies to be soluble in a 


























A balanced food intake which includes vegetables, legumes, fruits and nuts has been 
suggested to ensure optimal tissue levels of antioxidants [33] necessary to maintain a balance 
between ROS formation and antioxidant defense. The distribution of natural antioxidant 
molecules in the cell is depicted in Figure 2-2. The different sites of action of natural 
antioxidants suggest that it is important to maintain adequate concentrations of both hydrophobic 
and hydrophilic antioxidant molecules to reduce the risk of oxidative stress in all cell 
compartments.  
The understanding of the antioxidant characteristics is crucial for designing an adequate 
delivery and targeting system for the specific antioxidants of interest. In the next section, several 
chemical components of demonstrated antioxidant activity are described with emphasis on how 
nanoencapsulation can improve their delivery and function. 
2.2.2 Natural Antioxidants in Biological Systems: Characteristics and Human 
Health   
Natural antioxidants and vitamins can be classified based on their solubility in two 
classes, hydrophobic (water insoluble) and hydrophilic (water soluble). Examples of hydrophilic 
antioxidants are vitamin C and carnosine, whereas vitamin E, coenzyme Q10, and carotenoids are 
examples of hydrophobic antioxidants. 
Vitamin E is a hydrophobic vitamin which has been intensively studied due to its 
antioxidant properties and non-antioxidant actions [34-38]. The vitamin E family is composed of 
four tocopherols (α, β, γ, δ) and four tocotrienols (α, β, γ, δ) (Figure 2-3). Sources of vitamin E 
are wheat-germ oil, sunflower seed, almond, cereals, and others. The daily recommended intake 
of α-tocopherol is 22.7 mg for adults and 18.7 mg for lactating women [39]. 
Vitamin E is absorbed in the intestine [40] to form chylomicron particles. Circulation of 
chylomicron particles (a structure formed with fatty acids, phospholipids, cholesterol, vitamin E 
and other hydrophobic molecules) in plasma is one mechanism for vitamin E transfer to muscles, 
adipose tissue and brain. Once delivered to the tissue, tocopherols are localized in the cellular 
membranes with the chromanol nucleus located in the phospholipid bilayer [41]. The role of 
vitamin E supplementation in prevention of several diseases such as cardiovascular diseases, 
atherosclerosis, cancer, arthritis, Alzheimer’s, and Parkinson’s, among others has been 
documented and linked to its ability to trap peroxyl radicals and to break the chain reaction of 
lipid peroxidation [34,42-49]. Targeted delivery of vitamin E to the cytoplsamatic compartments 
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achieved with polymeric nanoparticles may increase its efficiency as an antioxidant and may aid 
in prevention and treatment of oxidative stress related diseases.  
 
Figure 2-3: Chemical structure of selected natural antioxidants and vitamins.  
Coenzyme Q10 is a hydrophobic molecule which is synthesized by humans (Figure 2-3). 
It can act as an electron carrier and proton translocator. Coenzyme Q10 is also found in plants, 
animals, and in most microorganisms. The amount of Coenzyme Q10 that can be provided by the 












































































found in beef heart, 17 µg/g in chicken leg, 27 µg/g in herring fish, 2.2 µg/g in spinach, and 2.2 
µg/g in oranges [50]. Coenzyme Q10 plays fundamental roles in energy conversion, regeneration 
of other antioxidant molecules, and cell death inhibition and cell growth regulation [50-53]. The 
intestinal absorption of coenzyme Q10 seems to be similar to the vitamin E absorption mainly due 
to its lipophilic characteristics [54]. The absorption is enhanced in the presence of lipids. In the 
small intestine, coenzyme Q10 is assimilated into chylomicrons to reach the plasma via the 
lymphatic system. The plasma concentration of coenzyme Q10 in healthy people can range from 
0.4 to 0.6 (µmol/l) which is increased with supplementation [54-56]. The toxicity of coenzyme 
Q10 is extremely low. Supplementation of coenzyme Q10 up to 1200 mg/day has been used in 
trials without any adverse effects [54]. 
It should be noted that the plasma level of coenzyme Q10 decreases with aging [57] and 
supplementation or stimulation of Q10 biosynthesis are needed to increase the cellular levels of 
coenzyme Q10. Supplements of Q10 have been used for their potential benefits against 
cardiovascular and neurodegenerative diseases, cancer, aging, migraine, and others [58-67]. 
Supplements of coenzyme Q10 administered orally have been shown however to have a low 
absorption efficiency (around 3-5%), mainly due to the hydrophobic characteristics of the 
bioactive component. Oil, emulsion, and powder formulations have been used in an attempt to 
increase the coenzyme Q10 absorption, with the solubilized forms being most effective 
[54,68,69]. Tikhaze et al. [70] found that the solubilized form of ubiquinone increased the 
antioxidant activity of this component by more than 36 times as opposed to its insoluble form. 
Nanoparticle formulation of coenzyme Q10 may show improved bioavailability characteristics 
yet as compared to the emulsion formulations.  
Carotenoids are a class of antioxidants composed of more than 500 identified components 
(Figure 2-3). Carotenoids are abundant in vegetable pigments and are found mainly in carrots, 
broccoli, spinach, apricots, tomatoes, peas, and orange peppers among others [71]. The 
carotenoids level in the US population ranges between 0.05 to 0.5µg/ml [72]. The characteristic 
of carotenoids is the unsaturated 40 carbons skeleton which confers the hydrophobicity specific 
to this compound. The most abundant carotenoids found in humans are α- and β-carotene, 
lycopene, zeaxanthin, cryptoxanthin and lutein [73]. Absorption of carotenoids is passive by 
intestinal absorption and it is similar to the absorption of tocopherol and coenzyme Q10. The 
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carotenoids plasma concentration should be around 0.4-0.5 µM for good health, as suggested by 
Albertini et al. [24]. 
The lipophilicity and structure of carotenoids affect their distribution in the cellular 
systems, in vivo. These components are poor water soluble and are usually associated with other 
components for improved absorption (i.e. lipoproteins). The lipophilic cell components are the 
main locations where carotenoids are found (i.e. plasma membranes, mitochondria membranes, 
Golgi membranes). Improved distribution of carotenoids in the cytoplasm or other cellular 
hydrophilic compartments can be achieved by nanoencapsulation and delivery with polymeric 
nanoparticles dispersable in aqueous mediums.  
Polyphenols (i.e. flavonoids) are natural compounds found in many vegetables, fruits, 
nuts, cereals, and herbs [74-76]. Polyphenols is a family composed of more than 4000 identified 
molecules with the general structure depicted in Figure 2-3. The daily intake of polyphenols can 
reach 800 mg/day [77], with a mean intake of 23 mg/day in western countries [78]. In a normal 
diet, the plasma concentration of flavonoids is less than 1 µM [79]. The importance of flavonoids 
is represented by three characteristics, inhibitions of certain enzymes, potent antioxidant 
properties, and iron chelator ability [78,80-83].  
The potential health benefits of flavonoids are related to anti-inflammatory, anti-
hepatotoxic, antiviral, antimicrobial, anti-allergic and anti-tumor activities, and to vascular 
protection, regulation and control of diabetic cataracts, among others [75,84-88]. For those 
individuals less inclined to consume fruits and vegetables, sources of polyphenols, 
supplementation of the diet with nanoencapsulated flavonoids may be the lead to a healthier life.  
Ascorbic acid is a water soluble vitamin fundamental in metabolic reactions, and as a 
cofactor of various enzymes involved in the hydroxylation process; it cannot be synthesized by 
humans (Figure 2-3). Different natural sources provide the necessary amounts of ascorbic acid, 
such as fruits (i.e. orange, papaya, strawberries) and vegetables (i.e. broccoli, red or green 
pepper, brussels) [32,89,90]. Albertini et al. [24] suggested that the optimal concentration of 
plasma vitamin C should be at least 40-50 µM for antioxidant purposes.  
Vitamin C has been widely reported as a potent co-antioxidant with vitamin E, due to the 
synergism between the two antioxidants [91]. The process involves α-tocopherol regeneration 
from α-tocopheryl radicals in lipoproteins and membranes in the presence of vitamin C. A 
synergetic action has also been suggested between vitamin C, vitamin E, and β-carotene against 
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the oxidative damage generated by peroxynitrite anion and nitrogen dioxide [92]. Efficient co-
delivery of synergistic antioxidants and vitamins can be achieved by entrapping and delivering 
these components in a controlled manner with polymeric nanoparticles.  
 Carnosine is a hydrophilic dipeptide (β-alanyl-L-histidine) which is found exclusively in 
animal tissue and in the brain (Figure 2-3). This histidine containing dipeptide is part of the ω-
aminoacylamino acids family. Other compounds are anserine, homocarnosine, and homoanserine 
[93]. It has been shown by different studies that carnosine acts as an anti-oxidant, carbonyl 
scavenger (anti-glycating agent), and metal ion chelator [94-97]. Due to its hydrophilic nature, 
carnosine protects proteins from oxidation [96,98-102]. It has also been pointed out that 
carnosine could be beneficial for people with diabetes, especially to control the secondary effects 
of this disease [101,103]. Hipkiss [104] found that carnosine has a potential therapeutic effect on 
neurodegenerative diseases related with high levels of zinc such as Alzheimer’s disease. 
Protection of carnosine against degradation during delivery to the site of action by entrapment in 
a polymeric matrix is a viable method to increase its bioavailability and efficiency in vivo. 
To conclude this section, there is a wide variety of natural antioxidants and vitamins 
which have been shown to possess beneficial properties and could potentially improve human 
health. The antioxidant efficiency of these components in vivo is related not only to their 
chemical reactivity, but also to their localization and mobility. Bioavailability, synergetic 
inhibition of the oxidation process, and pro-oxidant effects of natural antioxidants are other 
important factors to consider in the evaluation of potential antioxidant activity of different 
compounds in vivo [105]. Scientific proof of the advantages offered by encapsulation and 
delivery of antioxidants/vitamins with polymeric nanoparticles are presented below. 
2.3 Advantages of Encapsulation over Traditional Delivery Methods  
Nanoparticles can offer several advantages over traditional delivery methods for 
antioxidants and vitamins, which include protection of the bioactive component, an increase in 
its bioavailability, delivery of the component to the site of action in a controlled manner, as well 
as the possibility to integrate the bioactive component in various foods for enhanced food quality 
(Figure 2-4).  
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2.3.1 Protection and Bioavailability 
Bioavailability of antioxidants and vitamins can be enhancecd by delivering the bioactive 
components via polymeric nanoparticled due to several factors, the antioxidant is protected 
against harsh conditions (i.e. low stomach pH, enzymatic and microflora intestinal degradation), 
the extra-cellular interaction between the components of interest and other molecules is 
minimized, and low absorption of some antioxidants and vitamins (mainly hydrophobic) is 
improved.  
 
Figure 2-4: Description of the nanoparticle antioxidant system with emphasis on the advantages 
offered by nanoparticle delivery systems.  
Several studies available in the literature are focused on protection of the bioactive 
component against natural degradation by nanoencapsulation. For example, the stability against 
UV and thermal degradation of nanoencapsulated Q10 was studied by Kwon et al. [106]. The 
polymer used to entrap Q10 was poly(methyl methacrylate) (PMMA), and the nanoparticles were 
prepared with different surfactants (i.e. poly(vinyl alcohol), sodium dodecyl sulfate). The 
entrapped coenzyme Q10 proved to be structurally more stable against UV and high temperature-
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Chen and Subirade [107] tested biodegradable nanoparticles made from chitosan and β-
lactoglobulin designed for oral delivery of nutraceuticals. The protein, β-lactoglobulin protected 
the active component against pepsin and acid degradation in the gastric environment.  The study 
suggested that these nanoparticles could protect the nutraceuticals entrapped against degradation 
by adverse conditions during food processing, or in the gastro-intestinal tract, and the absorption 
of these components could therefore be improved. 
An improvement in the intestinal absorption of antioxidants is a means to improve their 
bioavailability. The attachment of ligands like lectins, invasins, folic acid, vitamin B12, biotin, 
glycoproteins (i.e. transferrin), membrane transduction sequences [108] was proved to improve 
intestinal uptake of nanoparticles with entrapped poor absorbable antioxidant molecules.  
2.3.2 Targeting and Cellular Uptake 
Polymeric nanoparticles can be surface functionalized to improve half life circulation and 
to minimize opsonins recognition of the nanoparticles (i.e. by addition of PEG), to improve the 
intestinal absorption (i.e. by using of a cationic polymer such as chitosan), to improve cellular 
uptake (i.e. by addition of a membrane disruption agent or agents which promote endosomal 
release), or to ensure that the antioxidant/vitamin reaches intra-cellular targets such as 
mitochondria (i.e. by attachment of lipophilic triphenylphosphonium). 
Nanoparticle functionalization with vitamins is an interesting means to improve the 
cellular uptake of the nanoparticles. Vitamin H (biotin) was covalently attached to pullulan 
acetate, a hydrophobized polysaccharide by Na et al. [109] to form nanoparticles with a mean 
size of 99±52 nm (20 vitamin H groups per 100 anhydroglucose units of pullulan acetate), with 
entrapped adriamycin as a drug model. The release profile of adriamycin loaded nanoparticle 
was controlled by vitamin H content attached to pullulan; a specific interaction of the 
functionalized particle with hepatoma cell line (HepG2) by ligand-receptor interaction was 
proved and showed responsible of increased nanoparticle uptake. 
The antioxidant action can be enhanced by targeting, when the antioxidant molecule is 
addressed to the specific site into the cell, such as mitochondria, nucleus, or endoplasmic 
reticulum, where oxidative stress occurs and causes damage associated to several diseases like 
Parkinson’s disease, diabetes, ischemia reperfusion, and others. A significant decrease in heart 
dysfunction, cell death, and mitochondrial damage was shown after ischemia- reperfusion with 
oral administration of a target functionalized system (ubiquinol plus lipophilic 
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triphenylphosphonium) in rats. In comparison, ubiquinol delivered without targeted 
functionalization was ineffective for cardiac ischemia-reperfusion injury [13].   
Muro et al. [110] entrapped an antioxidant molecule (catalase) in a functionalized 
nanoparticle, called anti-ICAM1. This system targeted endothelial cells and entered the cell via 
an amiloride-sensitive endocytic pathway. The anti-ICAM nanoparticle system was effective in 
offering protection to endothelial cells against oxidation for over 2 h after cellular uptake. It was 
suggested that due to the targeting ability of the nanoparticulate system, the oxidants were 
intercepted near their sites of generation or at sites where sensitive damage occurred and 
therefore a better protection against oxidative damage was possible. 
2.3.3 Controlled Release 
The polymeric matrix degradation as a result of interaction with different environmental 
parameters (temperature, enzymes, pH, ionic strength, and other) allows control of the amount of 
antioxidant released over time. Several studies published in the literature focus on the release of 
vitamin E, a model component for hydrophobic vitamins and antioxidants. 
Shea et al. [111,112] entrapped vitamin E into a PEG-decanyl polymeric nanoparticle. 
The antioxidant property of the released alpha-tocopherol was tested in human neuroblastoma 
cells (SH-SY-5Y). The vitamin E added in the preparation was 20 mg, equivalent to 20% w/w 
(there is no information about the entrapment efficiency and size of the nanoparticle 
synthesized). The results showed that encapsulated vitamin E was more effective against ROS as 
compared to free vitamin E. The free vitamin E was effective only if administered before or 
during treatment with amyloid-β (a neurotoxic peptide which accumulates in Alzheimer’s 
disease), but was not effective in protection against oxidation if administered 1 hr after the 
addition of amyloid-β to the cell culture. The encapsulated form of vitamin E was effective even 
when administered 1 hr after the amyloid-β treatment against ROS.  
Duclairoir et al. [112] used wheat gliadin nanoparticles for vitamin E encapsulation by 
nanoprecipitation method. The mean size of the nanoparticle obtained was 900 nm. The 
entrapment efficiency ranged from 77% to 95%; the entrapment efficiency of vitamin E 
decreased as more vitamin E was added relative to the gliadin protein weight. The release profile 
showed an initial fast release (burst effect) and a further slower release. The release studies were 
perfomed for 100 h at 25 °C under nitrogen and in dark conditions.  
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Zigoneanu et al. [113] entrapped vitamin E in PLGA nanoparticles at two initial loadings 
of 8 and 16%. The nanoparticles synthesized by emulsion evaporation method measured less 
than 100 nm for nanoparticles prepared with SDS as a surfactant (Figure 2-5), and about 200 nm 
for nanoparticles prepared with PVA. The entrapment efficiency of α-tocopherol in the 
polymeric matrix was approximately 89% and 95% for nanoparticles with 8% and 16% α-
tocopherol theoretical loading, respectively. The release profile showed an initial burst followed 
by a slower release of the α-tocopherol entrapped inside the PLGA matrix, similar to the findings 
of Shea et al. and Duclairoir et al. [111,112].  
 
Figure 2-5: PLGA-SDS nanoparticles with entrapped vitamin E (16% w/w). The mean 
nanoparticle size as measured by DLS is 55 ± 3 nm. 
2.3.4 Integration and Safety 
The nanoencapsulated antioxidants and vitamins can be integrated into foods and 
beverages to enhance the quality (sensorial, chemical, and microbiological properties) of the 
food. Chen and Wagner [114] entrapped vitamin E in starch sodium octenyl succinate 
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nanoparticles designed for beverage applications. The mean size obtained was 112 nm which 
was dependent on the number of homogenization cycles used in the preparation. The vitamin E 
nanoparticles were more stable in terms of turbidity and aggregation over time as compared to 
the non-nanoparticle systems. The suspension with nanoparticles did not change in turbidity over 
6 months and no perceptible creaming and/or ringing were observed over the same period of 
time. The stability of the nanoparticle suspension in apple juice also presented low turbidity 
without change over time (6 months). The vitamin E used was vitamin E acetate, and the stability 
studies were performed after pasteurization at 75 °C for 10 min. There is no information about 
the entrapment efficiency and release profiles of the vitamin. 
It should be noted that prior to integration of nanoparticles in food systems it is necessary 
to develop a thorough understanding of the nanoparticle physico-chemical characteristics, and 
very importantly of their safety for human consumption. The safety of the nanoparticles is 
dictated by their components (polymer, surfactant, antioxidant, additives), by the properties of 
the nanoparticle (size, size distribution, surface characteristics), and by the nanoparticle bio-
interaction (bioavailability, cellular uptake, targeting). Limited information is available in the 
literature regarding the safety of nanoparticles to human health, whether for pharmaceutical or 
food uses.  
Several steps can be taken to insure nanoparticle safety for human consumption. 
Biocompatible, biodegradable components should be selected for nanoparticle synthesis. 
Synthetic polymers and natural macromolecules (i.e. albumin, chitosan) have been extensively 
researched as colloidal materials for nanoparticle production designed for drug delivery. 
Synthetic polymers have the advantage of high purity and reproducibility over natural polymers. 
Among the synthetic polymers, the polyesters family (i.e. poly(lactic acid) (PLA), poly(e-
caprolactone) (PCL), poly(glycolic acid) (PGA)) are of interest in the biomedical area because of 
their biocompatibility and biodegradability properties. In particular, poly(lactide-co-glycolide) 
(PLGA) has been FDA approved for human therapy [115]. Food biopolymers (i.e. albumen, 
chitosan, dextran, alginate, etc) on the other hand are the alternative option when considering the 
safety of the nanoparticles for human food consumption.  
The size and size distribution of the polymeric nanospheres used for delivery of 
antioxidants and vitamins, among other physical characteristics, are affected by the technique 
used for the nanoparticle production and the pertinent synthesis parameters, i.e. polymer used, 
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polymer molecular weight and concentration, the addition of active components, surfactants, 
solvents, and other additives, shear stress, evaporation rate, and other physical parameters [115-
123]. These characteristics, such as size, size distribution and surface characteristics affect the 
behavior of the nanoparticles and their interaction with a biological system and ultimately their 
safety. It is important to understand how the physical characteristics relate to the efficiency of the 
delivery of the active components in question at the site of action. Entrapment and delivery of 
antioxidants with polymeric nanoparticles may be very efficient as compared to the delivery of 
the free component (i.e. non-nanoencapsulated), in which case the safety of the antioxidant 
delivered in high amounts becomes an issue which must be addressed.  
 
 
Figure 2-6: Polymeric nanoparticle synthesis techniques for encapsulation of antioxidants. A. 





























Synthesis of polymeric nanoparticles and the parameters that affect the nanoparticle 
physical characteristics have been intensively investigated during the last decade [121,124-131]. 
Methods available for nanoparticle synthesis can be divided into two classes: bottom-up and top-
down techniques. The bottom-up techniques such as emulsion or microemulsion polymerization, 
interfacial polymerization, and precipitation polymerization, employ a monomer as a starting 
point (Figure 2-6). Polymerization methods require the addition of the antioxidant during 
polymerization, and cross-linking of the antioxidant with the polymer synthesized during the 
nanoparticle formation is possible. The cross-link modifies the antioxidant molecules with 
further loss of its antioxidant activity. The top-down techniques minimize the damage to the 
active components entrapped (vitamin E, flavonoids, carotenoids, and others) as compared to the 
polymerization methods. Some details on the top-down techniques are presented below. 
2.4 Top-down Techniques Used for Encapsulation of Antioxidants and 
Vitamins in Polymeric Nanoparticles 
Emulsion evaporation, emulsion diffusion, solvent displacement, and salting out are top-
down techniques in which the nanoparticles are synthesized from pre-formed polymers. The 
characteristics of these methods are presented in Table 2-1.  
2.4.1 Emulsion Diffusion Method  
In this synthetic scheme, the polymer is dissolved in a suitable organic phase (e.g., benzyl 
alcohol, propylene carbonate, ethyl acetate), which must be partially miscible in water. The 
organic phase is then emulsified with an aqueous solution of a suitable surfactant (i.e. anionic 
sodium dodecyl sulfate (SDS), non-ionic polyvinyl alcohol (PVA), or cationic didodecyl 
dimethyl ammonium bromide (DMAB), under stirring. The diffusion of the organic solvent and 
the counter diffusion of water into the emulsion droplets induce polymer nanoparticle formation 
[132]. Important parameters that affect the nanoparticle size synthesized by emulsion 
evaporation are: copolymer ratio, polymer concentration, solvent nature, surfactant polymer 
molecular weight, viscosity, phase ratios, stirring rate, solvent nature, temperature and flow of 
water added [133-138].  
2.4.2 Salting Out Method 
In this method, the polymer is dissolved in the organic phase, which should be water-
miscible, like acetone or tetrahydrofuran, ethanol. The organic phase is emulsified in an aqueous 
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phase, under strong mechanical shear stress. The aqueous phase contains the emulsifier and a 
high concentration of salts which are not soluble in the organic phase. Contrary to the emulsion 
diffusion method, there is no diffusion of the solvent due to the presence of salts. The fast 
addition of pure water to the o/w emulsion, under mild stirring, reduces the ionic strength and 
leads to the migration of the water-soluble organic solvent to the aqueous phase inducing 
nanosphere formation [120]. The final step is purification by cross flow filtration or 
centrifugation required to remove the salting out agent. Common salting out agents are 
electrolytes (sodium chloride, magnesium acetate, or magnesium chloride) or non-electrolytes, 
such as sucrose [129,139-141]. Important parameters to be considered to control the physical 
characteristics of the synthesized nanoparticles by this method are: polymer concentration and 
molecular weight, stirring rate and time, nature and concentration of surfactant and solvent, and 
cryoprotectans. 




















Low Low Low Medium 
Water 
requirements 
High Medium High Low 
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concentration 
Linear relation with 
Np size 
Medium-high 
Low to not affect Np 
size 
Medium-high without 
increase Np size 
Hydrophobic 
antioxidants 
High entrapment High entrapment High entrapment High entrapment 
Hydrophilic 
antioxidants 
Low entrapment Low entrapment Medium entrapment 
Medium entrapment (by 
double emulsion) 
Additives for size 
control 
Recommended Recommended Recommended Recommended 
Process time Medium-high Medium High Reduced 
Purification Medium High Medium Medium 
Observations Solvent limitation Presence of salts Polar solvents 
Single emulsion or 
double emulsion  
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2.4.3 Nanoprecipitation (Solvent Diffusion, or Solvent Displacement) Method 
This method can be mainly used for hydrophobic antioxidant entrapment. Polymer and 
drug are dissolved in a polar, water-miscible solvent such as acetone, acetonitrile, ethanol, or 
methanol. The solution is then poured in a controlled manner (i.e. drop-wise addition) into an 
aqueous solution with surfactant. Nanoparticles are formed instantaneously by rapid solvent 
diffusion. Finally, the solvent is removed under reduced pressure by evaporation. Important 
parameters to be considered in controlling the nanoparticle size, among other physical 
characteristics are: polymer/surfactant ratio, polymer concentration, surfactant nature and 
concentration, solvent nature, viscosity, additives, active component, and phase injection rate 
[142-151]. 
2.4.4 Emulsion Evaporation Method 
Emulsion evaporation is the oldest method used to form polymeric nanoparticles from 
preformed polymers. The method is based on the emulsification of an organic solution of the 
polymer in an aqueous phase followed by the evaporation of the organic solvent. Normal 
emulsions of oil in water (o/w) or water in oil (w/o) and double emulsions (w/o/w) can be used to 
accommodate the entrapment of active components with different properties. The o/w emulsion 
can be used for entrapment of hydrophobic compounds, whereas w/o/w double emulsion is used 
for the entrapment of hydrophilic compounds. The method is widely used for microencapsulation 
because it is easy to scale up, it does not require high shear stress, and it can be adjusted (by use 
of the double emulsion method) to encapsulate water soluble drugs [152-160]. More details of 
single and double emulsion evaporation methods are presented below. 
2.4.4.1 Single Emulsion Method (o/w) 
The method is based on the emulsification of an organic solution which contains the 
polymer and the active component in an aqueous phase, followed by the evaporation of the 
organic solvent. Different surfactants such as poly(vinyl alcohol), sodium dodecyl sulfate, 
pluronic F68 can be dissolved in the aqueous phase. The size reduction of the emulsion droplet is 
accomplished by sonication or microfluidization for miniemulsion formation. The evaporation 
step is required to eliminate the organic solvent present in the organic phase. This leads to the 
precipitation of the polymer as nanoparticles with a diameter in the nanometers range. Important 
parameters which affect the nanoparticle size are: polymer molecular weight and concentration, 
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copolymer ratio and end groups, surfactant nature, phase ratio, solvent nature, evaporation rate, 
drug entrapment, additives, shear stress, and sterilization [160-165]. 
2.4.4.2 Double Emulsion Method (w/o/w) 
The first step of the double emulsion method is the formation of a water in oil (w/o) 
emulsion where the aqueous solution contains the hydrophilic active component and the organic 
phase contains the polymer and a suitable surfactant (Span 80, pluronic F 68, and others) of a 
low HLB. The miniemulsion is formed under strong shear stress (i.e. sonication, 
microfluidization, high speed homogenization). Next, the (water in oil) in water (w/o/w) 
emulsion is formed and sonicated or homogenized for droplet size reduction. This second size 
reduction should be controlled to minimize the hydrophilic active component diffusion to the 
external aqueous phase. Evaporation, the final step, is used to remove the organic solvent. 
Evaporation is done under vacuum to avoid polymer and active component damage, and to 
promote final nanoparticle size reduction.   
The main drawback of the double emulsion method is the large size of the nanoparticles 
formed and the leakage of the hydrophilic active component, responsible for low entrapment 
efficiencies. The coalescence and Ostwald ripening [166-168] are the two important mechanisms 
that destabilize the double emulsion droplets, and the diffusion through the organic phase of the 
hydrophilic active component is the main mechanism responsible for low levels of entrapped 
active component by this method [168]. The leakage effect can be reduced by using a high 
polymer concentration and a high polymer molecular weight, accompanied by an increase in the 
viscosity of the inner water phase, and an increase in the surfactant molecular weight [169]. 
Important parameters which affect nanoparticle size are: polymer/surfactants ratio, polymer 
concentration, surfactant nature, viscosity, solvent nature, shear stress, evaporation, additives, 
and first/second phase ratios [161,162,165,170-178].  
 Following the synthesis, the polymeric nanoparticles specifically designed for antioxidant 
and vitamins delivery are characterized in terms of morphology, size, size distribution, surface 
charge, surface characteristics and others.  
2.5 Characterization Methods  
The methods most broadly used to characterize nanoparticle morphology are transmission 
electron microscopy (TEM), scanning electron microscopy (SEM), cryogenic transmission 
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electron microscopy (cryo-TEM) and atomic force microscopy (AFM). Dynamic light scattering 
(DLS) is the most widely technique used to determine size and size distribution of the polymeric 
nanoparticles. Laser Doppler Anemometry is used to measure zeta potential, an important 
parameter when considering the stability of the nanoparticles in vitro. For chemical 
characterization, Fourier transform infrared spectroscopy (FT-IR) is used to analyze surface 
modification of the nanoparticles by the attachment of specific components. The quantitative 
determination of the active component entrapped in the nanoparticles is done by extraction of the 
drug and measurement of the drug concentration by spectroscopy at defined wavelengths (related 
to the active component) or by high pressure liquid chromatography (HPLC).  
Figure 2-7: Typical release profile. In general, hydrophilic drugs release faster as compared with 
hydrophobic drugs. The diffusion forces are predominant initially, after which the degradation 
process is more predominant as the time elapses. The nanoparticle degradation can occur by bulk 
erosion (a), or surface erosion (b).  
 











2.6 Controlled Release of Antioxidants and Vitamins and Parameters That 
Affect the Release 
The release of the active components from the nanoparticles is critical in understanding 
the effects of the active components at the site of action. The release profiles of the 
antioxidant/vitamin will impact the availability, interactions, pharmacokinetics, and the 
formation of metabolites at the site of action. Different parameters affect the release profile of 
the antioxidant, which include the chemical structure of the active component, amount of drug 
entrapped, polymer hydrophobic/hydrophilic behavior, temperature, pH, presence of enzymes, 
sterilization, polymer structure (i.e. copolymer ratio, crystallinity), polymer molecular weight, 
and nanoparticle size, among others. 
The common mechanisms which explain the drug release from polymeric nanoparticles 
are the natural degradation of the polymeric matrix (passive release), and diffusion of the drug 
through the matrix (active release). The diffusion process is dominant at the beginning of the 
active component release with minimum degradation of the particle. During this process, the 
active component diffuses from the polymeric matrix to the hydrophilic external environment 
and water molecules diffuse into the nanoparticle polymeric matrix.  The diffusion rate is 
controlled by the hydrophilicity of the polymeric matrix and that of the active component. 
Diffusion is followed by a constant release of the drug over time which is controlled by the 
erosion process of the polymer (degradation of the whole matrix with final mass loss). These 
mechanisms will result in a typical release profile for active components entrapped in polymeric 
nanoparticles consisting of an initial fast release (burst effect), followed by a more constant 
release over time (Figure 2-7). The burst effect can be beneficial when an initial high release 
improves the action of the active component or detrimental when a constant release of the 
antioxidant over time is required. 
The release studies are usually performed in vitro with buffer solutions incubated at 
37°C. The main methods used to quantify the release studies are depicted in Figure 2-8. The 
main parameters that affect the release profile are summarized below. 
2.6.1 Active Component (Type and Amount) 
The drug entrapped interacts with the polymer matrix by hydrophobic-hydrophilic 
interaction, ionic interactions, van der Waals forces, steric effect, and others. The chemical and 
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physical interactions play a fundamental role in the degradation and diffusion of the entrapped 
antioxidant [143,172].  
Figure 2-8: Summary of the common procedures used to quantify in vitro drug release profiles. 
The first method (a) uses centrifugation to separate the drug released from the nanoparticles 
suspension, the second one (b) uses filtration for separation. The suspension media usually is 
PBS (phosphate bovine serum). The temperature is maintained at 37°C with gentle agitation. The 
volume is maintained constant, in the first method, by addition of PBS in the same amount 
extracted for analysis. The other approach is to divide the sample in as many sub-samples as 
needed to study the release profile for the desired period of time. The second approach needs to 
maintain the concentration gradient necessary for the diffusion process to occur.  
The amount of entrapped active component (i.e. antioxidant or vitamin) affects the 
release, in that the higher the initial amount of active component, the faster the release is. The 
amount of entrapped active component is expressed by two parameters, the entrapment 
efficiency and the drug content. The drug content is defined as mass of drug in the nanoparticles 
divided by mass of nanoparticles, usually expressed in % w/w. Normal value for the drug content 
ranges from 0.5 to 4 %w/w for hydrophilic drugs, and 10 to 15 %w/w for hydrophobic drugs. 
The entrapment efficiency is calculated by dividing the amount of drug entrapped by the 
theoretical amount of drug (the initial amount used in the nanoparticles formation). Entrapment 
efficiency for hydrophobic drugs ranges from 80 to 95%, and for hydrophilic drugs from 30 to 
70 %.  
(b) 
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2.6.2 Polymer (Type, Copolymer Ratio, MW) 
Different polymers have been used for nanoparticles synthesis. Chitosan, dextran, albumin, 
pullulan, poly(lactic acid) (PLA), poly(lactide-co-glycolide acid), poly(ethyle oxide) (PEO), 
poly(caprolactone), poly(3-hydroxybutyrate) and others are natural and synthetic polymers used 
for nanoparticle synthesis. The degradation profiles of these components affect the drug release 
profile. For example, poly(lactic acid), poly(lactide-co-glycolide acid) (PLGA) and PEO-PLGA 
nanoparticles appear to degrade homogeneously in time without autocatalysis [140,179,180]. 
The degradation rate of PEO-PLGA nanoparticles is slightly higher than that of PLGA particles. 
The hydrophilicity (hydrophilic-hydrophobic ratio) of the polymer impacts the release profile 
of the active component entrapped. An example is the PLGA polymer which is a hydrophobic 
copolymer formed with lactide and glycolide monomers. Changing the copolymer ratio, the 
PLGA copolymer can be more or less hydrophilic (50:50, 75:25, and 85:15 PLGA molar ratios 
are the most common copolymer ratios available commercially) which affects the polymer 
degradation profile. PLGA copolymers formed from D,L-PLA and PGA are amorphous in nature 
while L-PLA and PGA are crystalline [130,181]. The copolymer 75/25 showed faster drug 
release as compared with 85/15; after 15 hours 95 wt% was released from 75/25, and only 80 
wt% for 85/15 copolymer ratio [178]. Nanoparticles with higher amount of lactide monomers 
showed a slower release rate. The more hydrophobic the polymer, the more intense hydrophobic 
interaction between polymer and drug entrapped, and thus a slower release profile [148,182-
187].  
The molecular weight of the polymer impacts the degradation process which affects the 
release profile, mainly during the degradation step. Polymer molecular weight ranges from a few 
thousands Daltons to over one hundred thousands of Daltons. Polymers with higher molecular 
weight present a slower degradation associated with a prolonged constant drug release over time. 
Diffusion processes are affected by the polymer molecular weight if the drug is mainly entrapped 
in the nanoparticle core [115,183,184,188]. 
2.6.3 Nanoparticle Size 
Particle size is dictated by the polymer used, the method used, the drug entrapped, and the 
physical and chemical interactions between the drug and the polymer. The nanoparticle size, in 
turn can affect the release profile. Bigger nanoparticles degrade slower, and present slower active 
component diffusion through the polymeric matrix which affects the release profiles. The initial 
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burst effect is reduced with a further prolonged slow release due to slow nanoparticle 
degradation [189,190]. The drug released from microparticles is relatively slower than release 
from nanoparticles because of the higher surface area and smaller size of nanoparticles 
[130,178,191]. 
2.6.4 Environmental Conditions (pH, Temperature, Release Medium) 
Temperature, pH, ionic strength, among other environmental conditions affects the drug 
release profile due an increase or decrease in polymeric degradation rates and changes in the 
diffusion process. The polymer behavior changes as a function of pH, temperature or other 
parameters. For example, poly(ortho esters) are stable at alkaline pH with increased degradation 
at acidic pH [192]. It would be ideal to use the internal cellular characteristics to release the drug 
in a controlled time dependent manner. Pullulan, hystidine base peptides, amine base polymers, 
poly(vinylpyrrolidone-co-dimethylmaleic anhydride) and others are examples of pH sensitive 
polymers that release the drug entrapped differently at different pHs. It is important to note that 
indeed physiological pH is around 7, but organelles have a different pH, endosomes are more 
acidic, and lysosomes have a pH as low as 5. At this pH, the nanoparticles suffer chemical 
alterations that activate degradation mechanisms or polymer reconfiguration which affect the 
release of the drug entrapped. Temperature can affect the stability of the nanoparticles, which in 
turn affects the release of the active component. The polymers poly(butyl methacrylate) and 
poly(N-isopropylacrylamide) are examples of temperature dependent drug release polymers 
[193-198].  
The affinity between the drug and the release medium affect the release. Redhead et al. [199] 
worked with release of a hydrophilic component in different mediums. The release profiles 
performed in PBS showed an initial fast release, between 40 to 60 % of the hydrophilic active 
component was released in 24 hours. When serum was used, the release rates were faster with 
almost 50% of drug released in 1 hour. At 24 hours, almost 100 % was released. This difference 
was attributed to the presence of serum proteins and the affinity between the proteins and the 
drug [199]. The configuration that polymers can acquire (i.e. random coil, oval, rod, and other) 
in presence of good, ideal or bad solvents could also affect the drug release profile which adds 




Conjugation of the polymer with the active component causes a decrease in the diffusion 
process of the drug, and the degradation process becomes the dominant mechanism for the 
release of the active component. Yoo et al. [200] studied the anti-tumor activity of entrapped 
doxorubicin into nanoparticles. The non-conjugated drug entrapped in the matrix showed a fast 
release with almost 80% in the first day, and 100% of release was after 5 days. The sample with 
drug conjugated to PLGA (PLGA M.W of 5 kDa) showed slower release with 40% after one day 
which was continued up to 24 days, when 100 % of the drug was released.  
2.7 Conclusions  
Natural antioxidants and vitamins have been shown to possess beneficial properties that 
could potentially improve human health. Targeted delivery of vitamins and antioxidants via 
polymeric nanoparticles can offer several advantages over traditional delivery methods, which 
include protection of the bioactive component from degradation, an increase in the 
bioavailability of the vitamin, delivery of the component to the site of action in a controlled 
manner, as well as the possibility to integrate the bioactive component in various foods for 
enhanced food quality. Safety of the polymeric nanoparticles for antioxidant and vitamin 
delivery is a very important factor which must be considered in designing and building 
polymeric nanoparticles for targeted controlled delivery of antioxidants and vitamins.  
Several methods are available to synthesize polymeric nanoparticles with entrapped 
antioxidants/vitamins, by starting with a preformed polymer. Each method has its advantages and 
disadvantages; the selection of the most suitable method should be based on the chemical 
characteristics of the active component and that of the polymer, as well as on the final use of the 
nanoparticles. The methods which are based on the diffusion of the organic solvent to form 
nanoparticles are limited to low polymer concentration for nanoparticle mean sizes of less than 
200 nm. Methods that involve solvent evaporation are more time consuming and are more 
expensive, but are less sensitive to changes in the polymer concentration. Emulsion evaporation, 
in particular, can be used to entrap hydrophilic (w/o/w emulsion) or hydrophobic (w/o emulsion) 
antioxidants, which is an advantage. The salting-out method is suitable for formation of 
nanoparticles at higher polymer concentration, but the involved purification process is a 
limitation of this synthesis method. Surfactant concentration, polymer concentration, polymer 
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molecular weight, solvents, surfactant concentrations, and phase ratios play an important role in 
controlling the size of the nanoparticles in all methods available for nanoparticles formation.  
The methods most broadly used to characterize nanoparticles in terms of morphology, 
size and size distribution, surface characteristics, entrapment efficiency, and release of the 
entrapped component, are the following, transmission electron microscopy (TEM), scanning 
electron microscopy (SEM), cryogenic transmission electron microscopy (cryo-TEM), atomic 
force microscopy (AFM), Dynamic light scattering (DLS), laser Doppler anemometry, Fourier 
transform infrared spectroscopy (FT-IR), spectroscopy, and high pressure liquid chromatography 
(HPLC).  
The release of the active component consists of two steps, diffusion and polymer 
degradation. The diffusion process is predominant at the initial states of the release, followed by 
the release of the active component due to the polymer degradation. Different parameters affect 
the release profile, which include chemical structure of the active component, amount of drug 
entrapped, polymer hydrophobic/hydrophilic behavior, temperature, pH, presence of enzymes, 
method of sterilization, polymer structure (i.e. copolymer ratio, crystallinity), polymer molecular 
weight, and nanoparticle size, among others.  
2.8 Future Trends  
The entrapment and delivery of antioxidants and vitamins with polymeric nanoparticles is 
anticipated to become a significant research field in the near future, due to the extensive benefits 
that nanoencapsulation can offer. The single antioxidant entrapment approach will be enhanced 
by including multiple action antioxidants with potential synergetic effects in a single 
nanoparticle delivery system.  
Nanoparticle size, among other physical characteristics, affects the release profiles of the 
bioactive component, and many researchers are continually attempting to decrease the average 
nanoparticle size with better control. There are important advances in the literature on 
understanding the mechanisms involved in manipulation and control of the nanoparticle 
characteristics and the improvement in the drug entrapment efficiency by carefully controlling 
these parameters.  
The antioxidants entrapped into polymeric nanoparticle will present release profiles 
strictly modulated by carefully designing the particle to interact with the environment (i.e. pH, 
temperature) in a predictable way. Formation of nanoparticles that can interact with the human 
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body and can modify their responses based on changes in the environment is an important 
research area in the field. Several questions will be addressed to reach this goal, such as tailor-
synthesis of new polymers for modulated responses and a better performance.  
Very importantly, the understanding of the safety of the nanoparticle delivery system is 
critical for the final use of the system designed in food. It involves analysis of the complex 
interactions between the nanoparticles and the cellular environment, and the mechanism involved 
in the delivery of the antioxidant/vitamin at the site of action. 
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CHAPTER 3. ANTIOXIDANT PLGA NANOPARTICLES MADE 
WITH NOVEL ALPHA-TOCOPHEROL-ASCORBIC ACID 
SURFACTANT 
3.1 Introduction 
Polymeric nanoparticles have been extensively researched as delivery systems of 
different active components such as anti-cancer drugs, vitamins, proteins, peptides, and others 
[1-6]. The advantages are numerous. For example, polymeric nanoparticles protect the drug 
against degradation while releasing it in a controlled manner which translates into lower toxicity 
and less side effects. Also, drug targeting can be achieved by surface attachment of moieties such 
as proteins, peptides, and other molecules (e. g. folic acid and lectins) of specific interaction with 
the target [7-11]. Despite all these advantages, polymeric nanoparticles, in and of themselves, do 
not provide any benefit in the treatment of disease, but rather, they act as carriers for the drug. 
Nanoparticles with inherent properties, such as antioxidant activity, could be useful in treating 
oxidative-stress related diseases such as atherosclerosis and cancer, in addition to playing their 
obvious role as vehicles for drug transport and delivery.  
Antioxidant nanoparticles of promising characteristics in the treatment of diseases related 
with oxidative damage have been built already. The first approach was based on the entrapment 
of an antioxidant agent into the polymeric matrix to be protected and transported by the blood 
stream to the site of action. Superoxide dismutase (SOD) was entrapped, for example, into 291 
nm PLGA nanoparticles synthesized by double emulsion method. The purpose was to protect 
human cultured neurons against oxidative damage promoted by hydrogen peroxide (H2O2). The 
results showed protection for 6 h compared to SOD in solution and pegylated SOD (PEG-SOD) 
at a dose of 100 U [12]. In another study, melatonin was entrapped in poly(methacrylic acid-co-
methyl methacrylate) nanoparticles with Span 80© and Tween 80© as surfactants. The method 
used was nanoprecipitation, and the nanoparticle size was 241 ± 55 nm with a zeta potential of -
33 ± 0.3 mV. The melatonin loaded nanoparticles showed better antioxidant protection compared 
with melatonin in solution at doses of 1 mg/kg and 10 mg/kg [13]. The entrapment of catalase 
(an enzyme that dissociates hydrogen peroxide into water and oxygen) into poly(ethylene grlycol 
(PEG) nanocarriers (spheres and filaments) by double emulsion was performed by Simone et al. 




The catalase entrapped in nanoparticles of 300 nm in size was more resistant to proteases attack, 
especially when catalase was conjugated to PEG [14].  
A different approach was to provide antioxidant activity to the nanoparticles itself, by 
employing antioxidant materials in the making of the nanoparticle. The work of Williams et al. 
showed that conjugation of PEG with gluthatione (scavenger of hydroxyl radicals, superoxide 
radicals, singlet oxygen) self-assembled into nanoparticles. It was suggested that PEG formed the 
shell and glutathione formed the core by extended hydrogen bonding. The mean particle size as a 
function of PEG molecular weight ranged from 283 ± 23 nm to 315 ± 39 nm (Mn of 300 to 700 
g/mol) measured by dynamic light scattering (DLS). When disulfide glutathione-PEG conjugate 
were used, the particle size increased to 400 nm approximately. The glutathione-PEG 
nanoparticle protected the human brain neuroblastoma cells against oxidative damage at 
comparable levels with free glutathione [15]. Nie et al. synthesized surface functionalized gold 
nanoparticles with synthetic antioxidant Trolox© (water soluble vitamin E analog). The data 
collected suggested that gold-Trolox nanoparticles with a mean size of 4.5 ± 0.7 nm were better 
antioxidants than Trolox in solution. The rate constant obtained by DPPH assay was 8 times 
higher for gold-Trolox nanoparticles than Trolox in solution [16]. In a different attempt to create 
nanoparticles of inherent antioxidant properties, the antioxidant α-lipoic acid was covalently 
conjugated to obtain molecules of different hydrophilicities which assembled into 200 to 600 nm 
nanoparticles (as a function of hydrophobicity) synthesized by nanoprecipitation. The 
nanoparticles showed an increased antioxidant activity as compared with α1-lipoic acid in 
solution [17]. 
Another approach, which was followed in this study, was to form polymeric 
nanoparticles by well established methods such as emulsion evaporation or in the presence of 
antioxidant surfactants. In this case, the final system consists of a polymeric core, a layer of 
antioxidant surfactant on the surface, and the active component (antioxidant or not) entrapped in 
the polymeric matrix. In this study, natural antioxidant molecules, alpha-tocopherol (vitamin E) 
and ascorbic acid (vitamin C) were used to synthesize a new surfactant (EC) of antioxidant 
properties. Vitamin E is hydrophobic and vitamin C is hydrophilic, thus when the two are linked, 
an amphiphilic EC surfactant results. The selection of the two components was based on 
compelling information that vitamins E and C are some of the most potent natural antioxidants. 




peroxidation) protecting hydrophobic molecules against reactive oxygen radicals (ROS) [18-21]; 
it has been documented that alpha-tocopherol acts mainly against peroxyl radicals and 
perhydroxyl radicals with rate constant of 2 x 105 l mol-1 s-1 [22]. On the other hand, at 
physiological pH, vitamin C is present in the ascorbate form. Ascorbate interacts with alpha-
tocopheroxyl radical to regenerate alpha-tocopherol suggesting a synergetic effect between the 
two molecules (rate constant of 1.55 x 106 l mol-1 s-1) [22]. Vitamin C reacts with perhydroxyl 
radicals at a rate constant of 1.6 x 104 l mol-1 s-1 [22]. It prevents damage by peroxynitrate, acts 
as a scavenger of hydroxyl radical, hypochlorous acid, thyl and sulphenyl radicals, and others 
[23]. Other natural antioxidant molecules such as polyphenols, carotenoids, coenzyme Q10, uric 
acid, albumins are important agents that defend biological systems against radicals attack [18] 
and could be further studied as viable components for synthesis of new surfactants of antioxidant 
properties. 
While a literature review indicates that vitamin C and vitamin E derivatives have been 
synthesized as new synthetic antioxidants in an attempt to improve the antioxidant properties of 
the starting vitamin, or to form new surfactants [24-34], it was our goal to synthesize a novel 
surfactant of antioxidant properties from vitamin E and vitamin C to be used in nanoparticle 
synthesis. The present work describes the chemical vitamin E-vitamin C conjugation to form the 
EC surfactant, synthesis of nanostructures by self-assembly of the surfactant EC, as well as 
synthesis of polymeric nanoparticles by nanoprecipitation in the presence of EC. The 
nanostructures were characterized in terms of size, polydispersity, morphology, stability, and 
antioxidant activity were compared with nanostructures formed under similar conditions in the 
presence of Span80 as a surfactant.  
3.2 Materials and Methods 
3.2.1 Materials 
Poly(lactide-co-glycolide acid) (PLGA) 50:50, molecular weight 30000-75000 g/mol, 
ascorbic acid, alpha-tocopherol, 2,2-diphenyl-1-picryl-hydrazyl (DPPH), 5,6-
Isopropylideneascorbic acid, alpha-tocopherol, ethyl chloroformate, maleic anhydride, and 
anhydrous sodium acetate were purchased from Sigma-Aldrich (St. Louis, MO). Acetone, 
ethanol, 1-propanol, hexane, acetonitrile, diethyl ether chloroform, ethyl acetate were HPLC 




3.2.2 Synthesis of EC Surfactant (Vitamin E-Vitamin C)  
The synthesis of EC was performed in three steps (Figure 3-1), following a procedure 

































































Figure 3-1: Reaction steps involved in EC synthesis 
3.2.2.1 Synthesis of Maleic Acid Mono-Alpha-Tocopherol 
Alpha-tocopherol (10.2 g, 0.024 mol), maleic anhydride (6.3 g, 0.064 mol), anhydrous 
sodium acetate (3.2 g, 0.39 mol) were placed in 65 ml of reagent grade acetone in a 100 ml 
round-bottomed flask and heated at reflux with stirring for 1 hour. The acetone was then 
removed by rotary evaporation. The reaction mixture was dissolved in 100 ml of diethyl ether 
and aqueous saturated ammonium chloride solution (50 ml) was added. This solution was stirred 
at room temperature for 20 minutes. The aqueous layer was removed and the organic layer was 




was removed by rotary evaporation to yield a golden-orange oil which slowly crystallizes (12.0 
g, 96%). No further purification techniques were performed as the compound decomposes on 
silica gel.  
1H-NMR (300 MHz, CDCl3) δ0.84 (s), 0.87 (s), 0.88 (s), 0.89 (s), 0.97-1.18 ( br m), 1.26 
(br s), 1.28-1.40 (br m), 1.49-1.59 (br m), 1.70-1.90 (br m), 2.00 (s), 2.04 (s), 2.12 (s), 2.62 (br t, 
J = 9 Hz), 6.65 (1H, d, J = 13 Hz), 6.71 (1 H, d, J = 13 Hz). 
13C-NMR (75.5 MHz, CDCl3) δ11.91, 12.20, 13.04, 19.64, 19.71, 19.78, 20.61, 21.03, 
22.66, 22.76, 24.46, 24.83, 28.00, 32.69, 32.80, 37.28, 37.35, 37.39, 37.45, 37.51, 39.37, 75.33, 
117.69, 123.47, 124.37, 125.98, 128.07, 137.67, 139.74, 150.03, 164.68, 166.32. 
3.2.2.2 Synthesis of 5,6-Isopropylideneascorbic Acid-2-O-Maleic Acid-Alpha-Tocopherol 
Diester 
 Maleic acid mono-alpha-tocopherol (6.3 g, 0.012 mol), triethylamine (4.1 g, 0.041 mol), 
and chloroform (33 ml) were combined in a 100 ml round-bottomed flask fitted with a septum 
and cooled to 0° C on an ice bath. Ethylchloroformate (2.0 g, 0.018 mol) was added dropwise. 
The reaction mixture was stirred at 0° C for 10 minutes. 5,6-Isopropylideneascorbic acid (3.6 g, 
0.017 mol) in 45 ml acetonitrile was quickly added and the solution stirred at 0° C for 15 minutes 
and then warmed to 5° C over a 30 minute period with continued stirring. The solvent was then 
removed by rotary evaporation at room temperature. The reaction residue was then taken up in 
40 ml of ethyl acetate, and this organic solution was washed with 2 N HCl (9.8 ml) and then with 
water (2 X 25 ml). The ethyl acetate solution was dried over MgSO4, filtered, and the solvent 
was removed by rotary evaporation. This yielded a golden oil (6.6 g, 76%). The compound was 
not further purified as it decomposed on contact with silica gel.  
1H-NMR on crude product (300 MHz, CDCl3) δ0.86 (s), 0.87 (s), 0.90 (s), 0.89 (s), 1.10-
1.19 ( br m), 1.24-1.27 (br m), 1.36 (s), 1.40 (s), 1.50-1.58 (br m), 1.74-1.86 (br m), 2.00 (s), 
2.04 (s), 2.11 (s), 2.60 (br t, J = 6 Hz), 4.13 (sextet, J = 7 Hz), 4.38 (m), 4.70 (d, J = 3 Hz), 6.67 
(s).  
3.2.2.3 Synthesis of L-Ascorbic Acid-2-O-Maleic Acid-Alpha-Tocopherol Diester 
 5,6-isopropylideneascorbic acid-2-O-maleic acid-alpha-tocopherol diester (6.6 g, 0.0091 
mol) was placed in 28 ml ethanol and 8 ml of 2N HCl solution. This solution was stirred at 60° C 




dissolved in 35 ml of ethyl acetate. This was washed with water (2 X 10 ml). The ethyl acetate 
layer was dried with MgSO4, filtered and solvent was removed by rotary evaporation. The 
resulting oil was dissolved in 8.3 ml 1-propanol and 19 ml of hexanes. The solution was placed 
in the freezer overnight and crystals were collected by suction filtration. The crystals were 
recrystallized in 1:3 (v/v) 1-propanol: hexanes solution to yield a first crop of very light yellow 
solid which were dried for 7 hours under vacuum at room temperature (0.6388 g, 10 %).   
1H-NMR (300 MHz, d6-DMSO) δ0.80 (s), 0.82 (s), 0.83 (s), 0.84 (s), 0.85 (s), 0.95-1.13 
(br m), 1.18-1.24 (br m), 1.35-1.55 (br m), 1.73 (br t), 1.95 (s), 1.97 (s), 2.01 (s), 2.55 (br t), 3.33 
(t, J = 7 Hz), 3.81 (t, J = 7 Hz), 4.95 (s), 6.66 (d, J = 12 Hz), 7.08 (d, J = 12 Hz). 
13C-NMR (75.5 MHz, CDCl3) δ10.52, 11.64,12.02, 12.88, 19.54, 19.62, 19.65, 19.68, 
20.00, 22.52, 22.61, 23.80, 24.25, 25.70, 28.85, 32.04, 32.09, 32.13, 36.67, 36.75, 36.78, 36.83, 
38.84, 61.74, 62.52, 68.63, 74.84, 74.86, 75.54, 111.71, 117.09, 117.40, 121.89, 125.23, 126.56, 
139.64, 148.82, 161.23, 163.42, 164.26, 167.41. 
3.2.3 Nanoparticle Synthesis 
EC and Span80 nanostructures in the absence or in the presence of poly(lactic-co-glycolic 
acid) were synthesized by a modified version of the nanoprecipitation method. An organic phase 
was made of acetone (0.5 ml) with dissolved PLGA (0 to 1.2 mg/ml) -when the polymer was 
used, and EC surfactant or Span80 (at various concentrations, 1 to 5 mg/ml). The organic phase 
was added to 5 ml of nanopure water (Thermo Scientific Barnstead Nanopure, Dubuque, IA) by 
a syringe under stirring on a magnetic stir plate (Corning, NY). Next, the sample was placed in a 
Buchi R-124 roto-evaporator (Buchi Corporation, New castle, DE) to remove the organic 
solvent, acetone. Evaporation was performed for 10 minutes under vacuum and nitrogen 
injection for fast solvent evaporation. The nanoparticle suspension was collected and stored for 
further analysis at 4 °C, under dark conditions.  
3.2.4 Size, Size Distribution, and Zeta-Potential 
The nanoparticle size and polydispersity index (PI) were evaluated by dynamic light 
scattering (DLS) using a Malvern Zetasizer Nano ZS (Malvern Instruments Ltd., Worcestershire, 
UK). Zeta potential measurements were obtained by Malvern Zetasizer Nano ZS with a MPT-2 
autotritator required to study aggregation of particles against pH. The samples were diluted to a 




3.2.5 Morphology of Antioxidant Nanoparticles 
Transmission Electron Microscopy (TEM) with a JEOL 100-CX (JEOL USA Inc., 
Peabody, MA) microscope was used to study nanoparticle morphology. A droplet of the sample 
was mixed with a contrast agent (Uracyl acetate, 2%) and a carbon grid was passed on the 
surface of the droplet to create a film over the grid. The sample was placed in the TEM after 15 
minutes for analysis.  
3.2.6 DPPH Radical Scavenging Assay  
A stock solution of DPPH in methanol at 0.4 mM was prepared and kept at -20 °C in the 
dark prior to use. The nanoparticle sample was diluted with acetic acid solution to 1 ml. The 
nanoparticle sample was added to dilute DPPH stock in methanol to obtain a final sample 
volume of 2 ml with a 0.1 mM DPPH concentration. The ratio between water and methanol was 
1 to 1 v/v. The blank was prepared with 1 ml of acetic acid solution and pure methanol. The 
controls were prepared for each sample, with 1 ml of acetic solution and 1 ml of DPPH in 
methanol solution. Absorption readings were taken after 30 min at 518 nm using a Geminys 6 
spectrophotometer (Thermo Scientific, Waltham, MA). The formula used to calculate the rate of 
oxidation was  
% change in activity = ((Abscontrol – Abssample)/Abscontrol)*100    [1] 
The measurements were performed at 5 nanoparticle concentrations (0.025-0.1 mM). The 
data collected was used to obtain the best fit for the linear regression used to estimate the IC50, 
which is the point at which 50% of the nanoparticles had been oxidized. Antioxidant activity of 
EC was measured at the same concentrations used for the nanoparticles synthesis.  
3.2.7 DPPH Radical Scavenging Measurements by Electron Paramagnetic 
Resonance (EPR) Technique 
The DPPH radical is widely used as a test radical to assess antioxidant capacity and 
activity of organic compounds. The EPR spectroscopy is one of the most sensitive techniques to 
detect and follow the behavior of the DPPH radical directly. Scavenging of the DPPH radical 
was followed by measuring the decrease in the EPR signal intensity. 
EPR measurements were conducted on a Bruker EMX-20/2.7 EPR spectrometer (X-
band) with dual cavities, modulation and microwave frequencies 100 kHz and 9.516 GHz, 
respectively. The typical parameters were: sweep width 100 G, EPR microwave power of 10 




factors were calculated using Bruker’s WINEPR program which is a comprehensive line of 
software, allowing control of the Bruker EPR spectrometer, data-acquisition, automation 
routines, tuning, and calibration programs on a Window-based PC [http://us.bruker-
biospin.com/brukerepr/winepr.html].  
The samples were prepared as described in the DPPH assay method. The following 
solutions were subjected to the EPR examination; EC (0.1mM) mixed with DPPH (0.1mM) at 
ratio 1:1, EC–PLGA nanoparticles (NP) (0.1mM EC) mixed with DPPH (0.1mM) at ratio 1:1. As 
a reference, 0.1mM DPPH in 1:1 methanol:water solution was used. The solutions were prepared 
right before EPR measurements. A 30 µl sample was transferred into EPR capillary tube (i.d. ~ 
1mm, o.d. 1.55mm) and the end was sealed by a critoseal (Fisherbrand). Then, the capillary was 
inserted in an ordinary 4 mm EPR tube and was placed into the EPR resonator to measure the 
EPR spectra of the DPPH radicals over time. The delay time was between 1 and 2 minutes after 
mixing of EC or NP with DPPH before the first EPR measurement was performed.  
A kinetic measurement of DPPH radical scavenging upon mixing of EC (or NP) with 
DPPH was also performed. A volume of 30 µl sample was transferred into the EPR tube (o.d = 
3mm, i.d. = 2mm), positioned in the cavity, and the same quantity of DPPH was injected rapidly 
to the solution by syringe through the tiny PVC hose (i.d =.0.3 mm) located directly in solution 
(close to the bottom of EPR tube).  
The magnetic field was fixed at a specified value (at the strongest peak of the DPPH 
radical) and the EPR signal intensity was monitored as a function of time (vide infra, cf. Figure 
3-12, top line).   
3.2.8 Statistical Analysis 
The statistical analysis was performed in SAS (Cary, NC). Anova proc mixed procedure 
with Tukey adjustment was used and significant differences were declared at a p value of 0.05. 
All the analyses were performed in triplicate.  
3.3 Results and Discussions 
EC exhibited poor water solubility, but it was soluble in polar solvents such as acetone. 
Hence, acetone was used to dissolve EC and/or surfactant Span80, as well the polymer PLGA. 
Upon addition of the organic phase to water and subsequent diffusion and evaporation of 




polymeric nanoparticles stabilized by the surfactant (EC or Span80) were formed. The technique 
described is a modified version of nanoprecipitation, technique which allows formation of 
nanostructures by using diffusion properties of polar solvents and anti-solvent properties of 
polymers [36]. The effect of salts and surfactant concentration on the size of nanostructures 
formed from pure EC and Span 80 surfactants was studied. Next, polymeric particles with PLGA 
and each surfactant were made, and the effect of surfactant, PLGA ratio on nanoparticle size, and 
polydispersity was assessed. Finally, a mixture of EC and span 80 was used to analyze the effect 
of EC: span80 ratio on PLGA particle size and polydispersity. The antioxidant behavior was 
analyzed by DPPH and EPR. 
3.3.1 Nanostructures Formed by Self-Assembly of EC and Span 80- Effect of Salt 
Type and Concentration 
The effect of the type and concentration of salts present in the aqueous phase on the size 
and polydispersity of the nanostructures formed by EC and Span 80 surfactants was studied 
(Figure 3-2). The EC nanostructures formed in an aqueous solution of sodium bicarbonate 
showed a smaller particle size (Figure 3-2A) as compared to the size of the nanostructured 
formed in the presence of sodium chloride (statistically different). The EC nanoparticle size 
ranged between 12 and 30 nm for the salt concentrations studied (0-100 mM). In contrast, the 
polydispersity index (>0.5) was higher for these particles as compared to polydispersity of 
particles made in the presence of NaCl (Figure 3-2B). 
The EC nanostructures synthesized in the presence of sodium chloride showed a mean 
size of 22 to 138 nm in diameter with a polydispersity index that ranged from 0.175 to 0.267. 
The tendency was for the size to increase as the salt concentration increased from 0 to 100 mM. 
The size increase was expected because the addition of salts increases the hydration of the 
electric double layer with a subsequent reduction of the electric repulsion by screening effect of 
the counter-coions which promoted aggregation. The aggregation number increases and critical 
micelle concentration (cmc) decreases with concentration of salt added [37,38]. Samples 
synthesized with sodium bicarbonate presented the smallest nanostructure size ranging from 
11.6±1.6 to 30.9 ±6.9, with a minimum nanostructure size at 15 mM of sodium bicarbonate. The 
difference in nanostructure size formed in the presence of sodium chloride and sodium 
bicarbonate is explained by the counterions–coions localized in the electric double layer. The 
radii of chloride ions (1.8 Å) is bigger than OH- and HCO3




hydration size. When chloride ions are present in the electric double layer, the repulsion is 
smaller compared with the other ions, so bigger structures are formed by aggregation. The higher 















The nonionic Span 80 self-assembled into bigger nanostructures as compared to EC 
(statistically different, Appendix B). When synthesized in an aqueous solution of sodium 
bicarbonate, the mean Span80 particle size ranged from 157 to 182 nm (Figure 3-2). The 
polydispersity index obtained varied between 0.052 and 0.144. At the lower salt concentration 
monodisperse Span80 nanostructures, represented by a polydispersity index value lower than 0.1, 
were formed. The Span80 samples synthesized in the presence of sodium chloride showed an 
increase in the particle size as a function of salt concentration. Moreover, the nanostructures 
synthesized with 99 mM sodium chloride in the aqueous phase presented phase separation 
following evaporation of acetone. The presence of chloride and sodium ions at high 
concentrations promoted less hydrogen bond interactions with the OH groups of Span 80 and the 
salting out process was responsible for the observed precipitation. 
TEM pictures revealed that spherical shaped EC nanostructures were formed when 
sodium chloride was used in the aqueous phase (Figure 3-3). The size observed by TEM was in 














Figure 3-2: Effect of salt concentration on the size and polydispersity of Span 80 and EC 
nanostructures. (a) Nanostructure diameter and (b) Polydispersity index for Span 80 and EC 
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size. Contrary to EC, hydrophobic Span 80 had a tendency to form bilayers similar to those 
formed by phospholipids, tendency which reflected in the bigger size of the Span 80 








































Figure 3-4: TEM pictures of Span 80 self-assembled nanostructure in sodium bicarbonate 
solution. Note: Contrast was enhanced by adding aqueous gold nanoparticles (4 nm Sigma 
Aldrich, 50 µL) to the organic phase in a concentration of 0.1 mg/ml prior to the TEM analysis 




















3.3.2 Nanostructures Formed by Self-assembly of EC and Span 80- Effect of 
Surfactant Type and Concentration  
Particle size increased with an increase in the concentration of the surfactant for both EC 
and Span 80. Polydispersity of self-assembled EC and Span 80 (non-ionic surfactant) increased 
as well, as the concentration of the components increased (Figure 3-5). The EC nanostructures 
showed a particle size that did not change at low surfactant concentrations (1-5 mM), but at 
concentrations exceeding 5 mM the size of the EC nanostructures increased sharply in acetic acid 
Samples formed with sodium bicarbonate were more stable, but the particle size increase was 
observed still at 7.28 mM EC. The increase in the amount of EC promoted aggregation which 
reflected in the high values of polydispersity index (Figure 3-5B) for the sample with acetic acid 
(0.749 for 7.3 mM of EC). For EC concentrations of 1.5 to 4.4 mM the polydispersity values 
were 0.149 to 0.171 which indicated formation of a monodisperse suspension. The particles 
synthesized in sodium bicarbonate presented a higher polydispersity value (0.516 to 0.241) in the 
1.5 to 4.4 mM EC concentration range. At an EC concentration of 7.28 mM, the polydispersity 
was smaller (0.277) as compared to the sample formed in acetic acid (0.749). 
Particles synthesized with Span80 without salt in the aqueous phase showed bigger 
particle size than the EC particles, with a stable particle size increase as the surfactant 
concentration was increased between 140.8 to 264.8 nm for 1.5 to 23.3 mM of Span 80, 
respectively. The polydispersity showed a stable increment from 0.074 to 0.335. Higher 


















Figure 3-5: (A) Size and (B) polydispersity index of nanostructures synthesized at different EC 
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3.3.3 Synthesis of Nanostructures with a Mixture of EC and Span 80 
The effect of using a mixture of Span 80 and EC was evaluated on the nanostructures size 
and polydispersity (Figure 3-6). The tendency was for the particle size to increase when more 
Span 80 was added to the mixture (statistically different for each surfactant mixture 
concentration, appendix B). In the other side, the polydispersity tended to decrease to values of 
monodisperse suspensions (polydispersity < 0.1) with the addition of more Span 80. The data 
suggested that a reduction in the aggregation process promoted by the non-ionic surfactant Span 
80 was achieved with the addition of the anionic EC surfactant, which promoted ionic repulsion 












3.3.4 PLGA Nanoparticles Synthesized with EC and Span 80 Surfactants- Effect of 
PLGA/Surfactant Ratio  
The PLGA-EC nanoparticles presented a mean size ranging from 54 to 130 nm (Figure 
3-7) as a function of the amount of PLGA entrapped in the core; the tendency was for the 
nanoparticle size to increase as the amount of PLGA increased. The size was relatively uniform 
over the different PLGA concentrations used. Addition of PLGA to the EC nanostructures did 
not increase aggregation, and the structures were more uniform compared with those formed by 
EC alone. The polydispersity index varied from 0.113 to 0.151. The reason of a more uniform PI 
compared to the nanostructures formed by EC alone is that PLGA promoted a more stable EC 
particle by adding a hydrophobic core which interacted with the hydrophobic tail of vitamin E 











Figure 3-6: (A) Size and (B) polydispersity index values for nanostrucutres synthesized with a 
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nanoparticles synthesized with Span 80 presented a bigger size in comparison with the PLGA-
EC nanoparticles, and ranged from 155 to 216 nm. The polydispersity index was similar to that 























 TEM pictures (Figure 3-8 and Figure 3-9) of polymeric PLGA nanoparticles synthesized 
with EC and span 80 showed that the EC-PLGA nanoparticles presented a uniform size 
distribution with limited aggregation. The PLGA core promoted a uniform anchor to the 
hydrophobic vitamin E moiety of EC surfactant. The vitamin C moiety most likely placed itself 
at the interphase, facing the aqueous environment and allowing particle suspension in water. The 








Figure 3-7: Size (A) and polydispersity (B) of polymeric PLGA nanoparticles synthesized 









Figure 3-8: PLGA-EC nanoparticles (ratio PLGA to EC was 0.8 to 1) in sodium bicarbonate 



























































(Figure 3-9). A less uniform sample, with a tendency to aggregate was formed with PLGA and 
Span 80. The sample showed a mixture of two different structures, one formed of Span 80 alone, 
grey in appearance, in the form of vesicles (similar to those presented in Figure 3-4), and 














3.3.5 Antioxidant Properties of PLGA Nanoparticles Assessed by DPPH Assay 
 The DPPH technique was used to evaluate the antioxidant activity of PLGA-EC 
nanoparticles (PLGA-span80 particles had no antioxidant activity). Linear regression was used to 
calculate the 50 % inhibition of DPPH (Figure 3-10). The IC50 ranged from 30.6 to 37.4 µM for 
various PLGA concentrations, values which were not significantly different. The data suggested 
that the PLGA, size, and PI did not affect the antioxidant properties of the PLGA-EC 
nanoparticles with IC50 measuring 37.4 µM, 30.6 µM, 31.6 µM, and 33.4 µM for PLGA-EC 
particles made with polymer concentrations of 0 to 120% PLGA. The vitamin C moiety of the 
EC surfactant molecule contributed to the antioxidant activity of the polymeric antioxidant 
nanoparticle. The EC surfactant prepared with methanol water (1:1 volume ratio) showed similar 
IC50 to the nanoparticles synthesized with EC (30.1 µM). The pure vitamin C and E showed IC50 













Figure 3-9: PLGA-Span80 nanoparticles (ratio PLGA to EC was 0.8 to 1) in NaHCO3 (15 
mM); two types of nanostructures are present, PLGA-Span 80 (white structures) and Span 80 





and C with EC in solution and EC in nanoparticles were explained by the loss of an active OH 
group by the covalent link to vitamin C while rendered vitamin E moiety inactive.  
 
 
Figure 3-10: Rate of radical inhibition of PLGA-EC nanoparticles as a function of PLGA 
concentration as measured by the DPPH method 
3.3.6 Electron Paramagnetic Resonance Measurements  
Scavenging of DPPH radical by EC or EC-NPs was followed by measuring the decrease 
in the EPR signal intensity, DI/N, Figure 3-11 (green triangles for NP and black circles for EC). 
The free DPPH radicals degraded at a noticeable rate during first 30-40 minutes, stabilizing at 
value of DI/N = ~ 8, and then degraded at a slower rate, while the degradation of DPPH after 30 
min was minimum (Figure 3-11). The degradation of DPPH radicals was remarkable in the 
presence of free EC or EC-NPs which was reflected in the strong decay in the first 1 to 2 
minutes. The initial concentration of DPPH radicals dropped from DI/N = 12 units to ~ 7 units 
by scavenging either by free EC and EC-NPs. The DPPH radicals still interacted effectively with 
EC and EC-NPs after the initial 2 minutes of reaction time; degradation slowed down over time 
and ended in 50 - 60 minutes.  
A remarkable degradation of DPPH radicals occurred not only in the first two minutes, 
but in fact during the first 5 - 6 seconds of mixing of EC or NP with DPPH. For instance, a rapid 
injection of DPPH solution into an EPR tube containing EC-NPs (or EC) solution showed a 
typical fast degradation curve, (Figure 3-12, top line), with ~ 40 % of initial DPPH degraded 
during first 5-6 seconds in diffusion regime. The comparison of antioxidant activity of organics 
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in this region, where the reaction time is measured in seconds, a fast mixing technique must be 
applied [16]. Another alternative is to compare scavenging activity of EC and EC-NPs over the 
time period, when the degradation rates of DPPH radicals are not fast and might be detected 
easily, for instance between 2 and 10 minutes after mixing of components  (Figure 3-11). Using 
this approach, it was found that the antioxidant (scavenging) activity of EC was twice higher 
than that of EC-NPs (at the same EC concentration) when we compared the maximum slopes (at 
the beginning) for EC in relative units of intensity (0.21 units per minute) with the slope for EC-




While EC was founded twice more potent than EC-NPs, EPR measurements clearly 
indicated that both EC and EC-NPs exhibited antioxidant activity. Three regions of interaction of 
DPPH with EC or EC-NPs were identified and used to account for different mechanisms of 
interaction between the antioxidant and DPPH over time; within seconds, the antioxidant activity 
of free EC or EC-NPs was similar. Within the intermediate region between 2 and 10 minutes 
incubation, the activity of EC was almost twice higher in comparison with EC- NPs. During the 
slow region, at times longer than 10 minutes incubation, the activity of EC in free EC and EC-
NPs was comparable.  
 
 
Figure 3-11: Scavenging of DPPH radicals by EC (triangles) and NP (black circles). Blue 
quadrates represent self degradation of DPPH radicals as a reference. (DI/N value is the double 
integrated (DI) intensity of the EPR spectrum that has been normalized (N) to account for the 





















A new antioxidant surfactant made of vitamin E and vitamin C was successfully 
synthesized and it was used to form PLGA polymeric nanoparticles 
The EC surfactant was hydrophobic with a good solubility in polar solvents. Nanoprecipitation 
technique was used to synthesize self
polymeric PLGA-span 80 and PLGA
and measured between 12 and 140 nm
Smaller EC nanostructures (11.6±1.6 nm) were obtained when sodium bicarbonate was used in 
the aqueous phase. In the presence of
particle sizes ranging from 22.0±1.3 to 137.8±17.4 nm at NaCl concentration of 1.5 to 99 mM. 
The polydispersity index was smaller for particles made in NaCl, and measured 0.267 to 0.175 at 
1.5 to 99 mM NaCl concentration, as compared to values of 0.575 to 0.524 for the same 
concentration range in sodium bicarbonate. Span 80 formed vesicles of 
polydispersity index representative to a monodisperse suspension.
nanoparticle synthesized with the synthetic hydrophobic Span 80 surfactant showed a bigger 
particle size (180.1±12.4 to 216±27.3 nm) as compared to the PLGA
to 126.2±3.9 nm). The polymeric PLGA
of 36.3 to 42.1 mM as measured by DPPH assay). The capacity to provide antioxidant action was 
Figure 3-12: Time dependence of DPPH radical degradation 
(0.1mM): DPPH (0.1mM) = 1:1 in
spectrum of DPPH radicals with g value 2.0037
66 
with antioxidant activity. 
-assembled EC and Span 80 nanostructures, as well as 
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 depending on the salt and surfactant concentration. 
 sodium chloride, bigger particles were formed, with 
136 to 460 nm
 The PLGA polymeric 
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-EC nanoparticles showed an antioxidant act
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provided by the vitamin C moiety of the EC surfactant which localized at the interface between 
the PLGA hydrophobic core and water. In comparison, the PLGA-span80 particles did not show 
any antioxidant activity. The antioxidant activity of EC and EC-PLGA nanoparticles has been 
confirmed by EPR measurements. Even though the scavenging activity of EC was about twice 
higher than that of EC-PLGA NPs, the antioxidant properties were in a similar range. The newly 
synthesized EC surfactant was therefore found successful in forming polymeric nanoparticles of 
intrinsic antioxidant properties. 
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CHAPTER 4. SYNTHESIS OF VITAMIN E-CARNOSINE 
(VECAR): NEW ANTIOXIDANT MOLECULE WITH 
POTENTIAL APPLICATION IN ATHEROSCLEROSIS 
4.1 Introduction 
The antioxidant theory links oxidative stress with cardiovascular diseases and major 
diseases such as cancer, acute inflammation, Parkinson’s, and Alzheimer’s [1-26]. In 2007, an 
estimated $430 billion were spent to treat around 80 million people suffering from some type of 
cardiovascular disease [27, 28]. Antioxidant agents play a vital role in the defense system against 
free radicals and oxidant molecules by avoiding radical propagation (chain reaction) via radical 
scavenging, metal ion chelation, and coantioxidant action (antioxidant regeneration) and may 
play a role in disease prevention and treatment. The balance between oxidative species and 
antioxidant systems (natural molecules, enzymes, and proteins) defines the oxidative stress of a 
living system, and the oxidative stress level determines if a biological system is under high risk 
for diseases [32]. 
Atherosclerosis in particular has been related to the oxidative process, in that high levels 
of oxidant molecules or low levels of antioxidants were shown to be responsible for high 
oxidative stress triggering the atherosclerosis process. The oxidation theory of atherosclerosis 
attributes great importance to the oxidation process and deems free radicals as precursors for the 
first steps in the development of the disease [33-36]. In this context, great importance has been 
attributed to vitamin E, especially α-tocopherol, as the main lipophilic natural antioxidant present 
in the lipophilic phase of every cell. Among the lipophilic antioxidants, α-tocopherol is more 
potent. To highlight the importance of α-tocopherol in humans, it has been shown that a specific 
enzyme α-tocopherol transfer protein (α-TTP) is responsible for α-tocopherol transport into 
lipoproteins. Lipoproteins then act as a main vehicle for α-tocopherol transport to different 
tissues [30, 37-52]. The transport protein α-TTP is responsible for the high levels of α-tocopherol 
(80% of the vitamin Es) in the cells as compared with the other seven isomers of vitamin E. 
Other important lipophilic antioxidants are coenzyme Q10 and carotenoids [8, 14, 53, 54]. 
The uptake of lipophilic molecules such us alpha-tocopherol from the diet occurs in the 
intestine through formation of structures called chylomicrons. Chylomicrons are mixtures of 




Chylomicrons are in the micrometer range (1-10 µm) in size and are the precursors of very low 
density lipoproteins (VLDL), intermediate density lipoproteins (IDL), low density lipoproteins 
(LDL), and high density lipoproteins (HDL) produced in the liver. Several differences exist 
among these “lipophilic vehicles” based on their density, presence of protein components (apos), 
or size as the more predominant characteristics.   
LDL is composed by a core of cholesterol and triglycerides surrounded by fatty acids, 
cholesteryl esters, apolipoproteins, and phospholipids. The outer layer is more hydrophilic due to 
the protein presence as compared to the core, which is more hydrophobic due to the presence of 
cholesterol and triglycerides [31, 55-60].  Oxidation of LDLs is associated with the development 
of atherosclerosis. The ox-LDL (i.e. the oxidized form of LDL) acts at different levels 
stimulating the host response and formation of foam cells. Lipophilic antioxidants avoid 
oxidation of the lipid fraction of LDLs, but apolipoproteins are not protected from oxidation 
even in the presence of lipophilic antioxidants [61-67].  
The limitations of lipophilic natural antioxidants can be overcome with an adequate 
design of an alternative “natural” antioxidant formed by covalently linking the hydrophobic 
antioxidant with a naturally occurring hydrophilic molecule with antioxidant properties; the new 
structure will insure that the new component will be localized closer to apolipoproteins, have 
better antioxidant performance, and have potential synergetic behavior due to antioxidant-
coantioxidant phenomena.  
Hydrophilic antioxidants have the ability to protect proteins, DNA, and carbohydrates 
from oxidative molecules, and to regulate oxidative molecules for signaling purposes. Among 
hydrophilic molecules, vitamin C and carnosine play important roles in the protection of proteins 
and DNA from oxidative molecular attacks. Other molecules, such as flavonoids, uric acid, 
micronutrients, peptides, and proteins, have been researched for their potential antioxidant 
actions [54, 68-90].  
The dipeptide carnosine (β-alanyl-L-histidine) has been researched as a protective agent 
against aging due to its antioxidant properties and ability to suppress protein glycation and 
crosslinking [26, 47, 54, 68, 72, 91-100]. Carnosine has also been suggested as an important 
agent in controlling secondary problems in diabetes [76, 82, 83, 101-120]. 
During the last 30 years, antioxidants and their impacts on biological systems have been 




attempt to design better synthetic antioxidant compounds. There are several synthetic 
antioxidants (i.e. Trolox, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), 
propyl gallate, and others) and vitamin E derivatives (i.e. Trolox, 3-oxa-chromanol type, 
brominated alpha-tocopherol methano-dimer, raxofelast, vitamin EC, probucol, etc.) used for 
different purposes [121-134]. Several synthetic antioxidant molecules reported in the literature 
use the OH group of α-tocopherol to attach other molecules to α-tocopherol, or modify the 
chromanol ring in the synthesis. These molecular changes of α-tocopherol decrease the 
specificity of α-TTP interaction for α-tocopherol. The α-tocopherol structure should be 
maintained as close as possible to the natural RRR conformation to protect the antioxidant 
properties of α-tocopherol and to insure that α-tocopherol is recognized and transported by α-
TTP. Reactions should be performed in the phytyl chain, which is not a required moiety for the 
protein α-TTP to recognize α-tocopherol [49, 51, 135, 136]. In order to achieve this conjugation, 
the following criteria must be met: 1. the chromanol ring cannot be modified, 2. the phytyl chain 
should be long to confer hydrophobic behavior to the new molecule, and 3. the second natural 
antioxidant component should be covalently linked to the end of the phytyl chain. This new 
approach allows molecules such as carnosine or vitamin C to be linked to α-tocopherol, so they 
can be introduced into LDLs and lipophilic sections of cells (i.e. plasma membrane) by action of 
α-TTP. The new molecule can provide improved antioxidant properties as compared with initial 
natural antioxidants (α-tocopherol and carnosine), and offer an improved defense of LDL from 
oxidation, which has been postulated as an important event in atherosclerosis. 
The main goal of this project was to synthesize and characterize a new antioxidant 
molecule based on α-tocopherol and carnosine (VECAR), with potential applications in 
prevention of atherosclerosis, but VECAR could be successfully used to prevent other oxidative 
stress related diseases.   
4.2 Oxidation and Its Effect on Atherosclerosis 
It is accepted that reactive oxygen species (ROS), which involves oxygen centered 
radicals and other oxidative molecules, such as reactive nitrogen species (RNS), and reactive 
sulfur species (RSS) act at different cellular levels and result in oxidation of native molecules. 
The oxidation process is associated with damage of proteins, lipids, DNA, and carbohydrates 




4.2.1 Reactive Oxygen Species and Oxidation Process 
The reactive oxygen species play significant roles in the cell metabolism such as cell 
growth, energy production, intracellular signaling, and antimicrobial action, but ROS can be very 
harmful by damaging different tissues due to lipid peroxidation, carbohydrates oxidation, or 
protein and DNA modification. The oxidative damage of all aforementioned molecules had been 
related to cancer disease, diabetes, cardiovascular disease, inflammatory responses, degenerative 
diseases, aging, liver injury, cataract, and others [2-4, 20, 54, 70, 76, 98, 111, 114, 137-159].  
Antioxidants prevent cellular damage surged from chemical reactions that involve free 
radicals. Halliwell & Gutteridge defined antioxidants as “any substance that, when present in low 
concentrations compared to that of an oxidisable substrate, significantly delay or inhibit the 
oxidation of that substrate”. Free radicals are molecules that contain unpaired electrons [160]. 
There are several radical species with potential oxidative actions, such as reactive oxygen species 
(oxygen radical centered), reactive sulfuric species (sulfur radical centered), and reactive 
nitrogen species (nitrogen radical centered) (Table 4-1). All of these radical species or non 
radical molecules can act at cellular levels in metabolic, cellular signaling, and degenerative 
processes due to endogenous or exogenous sources of oxidant molecules (OM). 
Intracellular free radicals are mainly generated by the autooxidation of small molecules 
and by activity of certain enzymes like oxidases, peroxidases, lipoxygenases, dehydrogenases, 
and cyclooxygenases. The cellular sites of reactive oxygen species generation are mitochondria, 
peroxisomes, lysosomes, endoplasmic reticular membranes, nuclear membranes, and plasma 
membranes [19, 161-163]. 
One important source of superoxide anions is the mitochondria (1 to 5 % of the oxygen 
used in the respiratory metabolism form superoxide anions [164]). ROS can result from the 
activity of several enzymes (e.g. cytochrome p450 oxidase), and can be formed by vascular 
endothelium, and phagocyte cells. Hydrogen peroxide is generated with superoxide anions by 
spontaneous dismutation and enzymatic reactions [17]. Figure 4-2 depicts the basic chemical 
reaction for biological aerobic system in which oxygen is reduced to water for energy supply. If 
the electrons are passed one at a time, ROS intermediates can be formed. Also, the reaction 
between metal ions and superoxide anions is responsible for radical formation (Figure 4-1). 
Other important oxidizing molecules that are not free radicals are singlet oxygen (1O2), 




singlet oxygen is associated with ionizing radiation (i.e. UV exposure) in which the oxygen 
electron reaches a higher energy state than the ground state.   
Table 4-1: Reactive species with biological effect.  
Name Formula Characteristics 






Oxygen is reduced by transfer of a single electron to its outer shell to form superoxide 
anion. O2•
- It can be produced by different cells like monocytes, macrophages, by 
autoxidation reaction and other mechanisms.  
Hydroxyl radical •OH 
•OH reacts with most biomolecules at diffusion controlled rates with main action at the 




H2O2 is the main source of hydroxyl radicals in the presence of transition metal ions. It 
is also involved in the production of HOCl by neutrophils. The superoxide anion 
generated probably undergoes a dismutation reaction generating hydrogen peroxide. It 




HOCl formation is by myeloperoxidase action on chloride ions in the presence of 
H2O2. It can originate from chloramines and amino acid derived aldehydes. It can 
oxidize apolipoprotein B-100. 
Peroxyl radical ROO• 
ROO• is formed by the addition of oxygen to alkyl radicals or from the breakdown of 
organic peroxides. 




NO• is a common gaseous free radical. It is produced by vascular endothelium, 
neutrophils and macrophages from arginine using the enzyme nitric oxide synthetase. 
Nitric oxide radical can form nitrogen dioxide radical (NO2•) from reaction with O2. 
Peroxynitrite  ONOO- 
ONOO- is formed by the reaction of nitric oxide with superoxide anion. It can cause 
oxidation of proteins with –SH groups, and it can be decomposed to nitrogen dioxide 
(NO2•). It can oxidize apolipoprotein B-100. It reacts with CO2 forming nitrating, 
nitrosanting species. 
 
ROS formation in cells is a process that under normal conditions reaches steady state; the 
imbalance of this process can generate diverse diseases due to oxidative stress. Oxidative stress 
describes a state of a biological system exposed to excessive formation of oxidative molecules 
(ROS, RSS, and RNS), and limited antioxidant defense, resulting in a harmful environment for 
proteins, DNA, and lipids [165]. In many diseases oxidative stress is a consequence and not a 
cause of the primary disease, but it is generally accepted that oxidative stress plays a vital role in 




The damage generated by the action of 
oxidative molecules (OM) at the cellular level 
can be controlled by different defensive 
systems, which can be enzymes and non-
enzyme systems [17,21,159]. The importance of 
understanding the interaction and potential 
unknown synergistic effect of the antioxidants 
against oxidative molecules (OM), especially 
under high levels of oxidative stress is critical.  
The human system is a dynamic and an 
extremely complex system for studying 
antioxidants in vivo. As discussed before, 
oxidant molecules act at several levels, and not 
all the reactions have a negative impact on the 
body. The antioxidant mechanism of several 
natural molecules has been demonstrated in 
vitro and in vivo studies. Human studies showed 
unclear results for disease prevention related to 
oxidative stress, however in some studies the results were disappointing [166,167]. However, 
supplementation with antioxidant molecules from the diet is expected to positively impact human 
health based on the positive results shown in animal studies.  
This is a complex area of discussion, and several points of view have been developed to 
explain the problem. The antioxidant efficiency in vivo is related to their localization and not 
only the chemical reactivity of antioxidants. Mobility of lipophilic antioxidant molecules in the 
membrane, the presence in lipoproteins, fate of the radicals formed, synergetic inhibition of 
oxidation process, pro-oxidant effects, and pharmacokinetic of antioxidants, are important issues 
to consider in the antioxidant evaluation of potential antioxidant compounds in vivo [168]. The 
methods available to define the oxidative status of an individual are not well developed and 
standardized, and a combination of methods may show more accurate data than any individual 
method [169]. Moreover, it has been stressed that many cellular studies overestimate the 
exposure of cells for oxidative stress due to high levels of oxygen used (normally 21%). An 
O2 + 4e





•‾ + e- + 2H+ 
H2O2 + e
- + H+ 









Figure 4-2: Reduction of an oxygen molecule. 
It requires four electrons. If the electrons are 
passed one at a time, it can form the 





Fe2+ + H2O2 
 Fe3+ + •OH + OH‾
 
Fe2+ + ROOH  Fe
3+ + RO• + OH‾
 
or 
Figure 4-1: Superoxide anion also is involved 
in the Haber-Weiss reaction to form hydroxyl 
or alkoxyl radicals. The reaction is catalyzed 




atmosphere of 3-4 % of oxygen should be used to work with the same physiological conditions 
[28,157,170]. 
There are several natural antioxidants vital to our metabolism and health, which can be 
acquired from food. For an optimum tissue level of antioxidants, a balanced food intake with 
vegetables, legumes, fruits, and nuts is recommended [171]. The different sites of action of 
natural antioxidants suggest that it is important to maintain adequate concentrations of both 
hydrophobic and hydrophilic antioxidant molecules to reduce the risk of oxidative stress in all 
cell compartments. A good antioxidant performance is achieved with a pool of different 
molecules acting at specific locations in the cell. The specificity and location play an important 
role in the balance between oxidants and antioxidants.  
Many diseases, including atherosclerosis, have been related to the oxidative process. The 
oxidation theory of atherosclerosis is based on the presence of oxidized LDL when the disease is 
detected. The oxidized LDL can induce monocyte adhesion to endothelium, promote foam cell 
formation, induce migration and proliferation of smooth muscle cells, promote pro-coagulant 
properties of vascular cells, platelet adhesion, and other steps in atherogenesis [36,63,172,173]. 
This theory is supported by studies which show that antioxidants inhibit or delay lesions in 
animal models, as discussed in the next section.   
4.2.2 Atherosclerosis Oxidation Theory 
Free radicals and oxidative molecules are responsible for molecular modification of 
compounds by oxidation, which affects their normal behavior contributing to harmful 
consequences for human health. Atherosclerosis is a disease with a high impact on human health. 
The advances made in understanding the atherosclerosis process lately have been outstanding. 
The oxidation theory is one of the most popular theories developed; it attributes key roles to 
oxidation molecules in the initial steps of atherosclerosis. 
The basis of this theory is that the oxidative processes change the artery walls with 
further monocyte macrophage recruitment from the bloodstream and excessive lipid deposition. 
In the process, the LDL is oxidized in the sub-endothelial space. A typical structure of LDLs is 
presented in Figure 4-3. The apoB-100 protein is located at the surface as well as more polar 
fatty acids, phospholipids, and unesterified cholesterol. The core is formed by neutral lipids such 




40%, cholesteryl esters, 20% protein, 10% unesterified cholesterol, 5% triglycerides, and 5% 
other lipophilic components .The LDLs range size is from around 20 to 26 nm [31, 55, 174-176]. 
The LDL molecule, in its oxidized form, can stimulate expression of adhesive molecules on 
endothelial cells, can be chemotactic, and can regulate cell scavenger receptors [36]. Figure 4-4 
shows a sketch of LDL oxidative action in the sub-endothelial space. Wall thickening, vessel 
narrowing, and plaque formation can result in further thrombosis and plaque rupture. 
In the 1980s, it was suggested that oxidized low density lipoproteins (ox-LDL) could 
promote cell damage [36]. The cell damage was studied by the incubation of ox-LDL with 
endothelial cells that presented a high uptake for macrophages with further modifications 
concluding with foam cell formation (Figure 4-4). The interesting observation was that the 
process described before, observed in the presence of ox-LDL, was not present when native LDL 
(not oxidized) was used [34, 59, 177-179].  
The lipoprotein fractions isolated from atherosclerotic lesions have been shown to 
contain lipoprotein particles with some characteristics of oxidized LDL, such as increased 






Lipoproteins (i.e. APO-B100 for LDL) 
Figure 4-3: Sketch of low density lipoprotein (LDL) structure with main components. The 
center of LDL is formed of cholesterol and triglycerides, which are highly hydrophobic. There 
is a layer of more polar lipids formed mainly by phospholipids and polyunsaturated fatty acids 
on the surface. The other components can be α-tocopherol (6-12 per LDL molecule), γ-
tocopherol (0.5 per LDL molecule), coenzyme Q10 (mean < 1 per LDL molecule), carotenoids 
(0.4 per LDL molecule), and others [31]. 




181]. The results do not establish if these products arose from the atheroma or that they were 
present in the LDL before. The oxidation hypothesis is supported by studies using knockout 
mice. Suzuki and coworkers [182] reported that targeting scavenger receptor A (SRA) by 
homologous recombination reduced the rate of progression of atherosclerosis in apoE-deficient 
mice. This receptor recognized oxidatively modified LDL but not native LDL. It is suggested 
that the observed protection was due to a decrease in uptake of ox-LDL with further reduction in 
the accumulation of foam cells in the sub-endothelial space. The deficiency of macrophage 
scavenger receptors (CD36, SAR, SR-B1, and others) which binds to oxidized LDL has been 
associated with atherosclerosis events reduction [36]. There are other studies showing that other 
mechanisms can be involved in the protection observed when it was modified by the scavenger 
receptors because the genetic modifications can affect the presence of antibodies. The presence 
of circulating antibodies, which act against oxidized LDL, affects the atherogenesis, so the 
immune system can modulate atherogenesis. Data of experiments with immunization of 
hypercholesterolemic animals with ox-LDL had shown decrease of atherosclerotic lesion 
progression [183]. Studies suggest that LDL oxidation occurs through endothelial and smooth 
muscle cells, but other studies argue that LDL oxidation is mainly favored by monocyte-derived 
macrophages [34, 179, 184]. Physiological mechanisms of LDL oxidation in vivo are not clear, 
but studies suggest that superoxide, myeloperoxidase, peroxynitrite, thiols, and other molecules 
can participate in the oxidation process [17, 36, 172, 185, 186]. 
It has been suggested that α-tocopherol supplementation can decrease the low density 
lipoprotein (LDL) susceptibility to oxidation; however, it does not affect its glycation, which 
increases LDL oxidative susceptibility, or AGEs (advanced glycosilation end products) 
formation [63, 187-191]. Moreover, inhibitions of platelet adhesion, aggregation, and smooth 
cell proliferation have been related to α-tocopherol supplementation [192, 193]. It has been 
showed that α-tocopherol supplementation decreases CD36 expression (scavenger receptors that 
bind to oxidized LDL found in atherosclerotic lesions) and cholesteryl ester accumulation in 
human macrophages. Other tested antioxidants (β- or γ-tocopherol) failed to decrease CD36 
[194].  
The work developed by Stocker and colleagues [31, 55, 180, 188, 189, 195-209] 
suggested that α-tocopherol can be a pro-oxidant or antioxidant, and the switch in its behavior is 




promoting lipid peroxidation; at high oxidative stress, α-tocopherol acts as an antioxidant. The 
occurrence of oxidative products in LDLs particles in the presence of α-tocopherol (antioxidant) 
supports this theory. The oxidized products that present a cis, trans configuration is favored 
when α-tocopherol is present in LDL particles. If the LDL is oxidized without the presence of 
vitamin E, the oxidized products obtained show a trans configuration. The animal LDL oxidized 
products tested were in the cis, trans configuration, which suggests that oxidation in vivo can 
occur in the presence of α-tocopherol [31, 189, 200, 208]. The tocopherol mediated peroxidation 
(TMP) theory mentions that the co-antioxidants are important to keep up the antioxidant 
behavior of α-tocopherol. The coenzyme Q-10 plays an important role as co-antioxidant and its 
supplementation can decrease atherosclerotic lesions [77, 84, 195, 210].  
Moreover, it has been suggested that two electron redox (2e-redox) reactions could play a 
more important role than radical reactions in the oxidation processes of atherosclerosis [211]. 
The experiment was performed with probucol, probucol dithiobisphenol, and probucol 
bisphenol. The formulations with sulfur molecules (probucol and probucol dithiobisphenol) 
showed good results in avoiding macrophage accumulation, stimulating reendothelization, and 















Figure 4-4: A sketch of arterial obstruction by atheroma from oxidized low density lipoproteins. 





that the induction of heme oxygenase-1 (OH-1) by probucol is an important factor for the 
protective effect showed by probucol and probucol dithiobisphenol. Phenolic compounds such as 
α-tocopherol act by 1 electron redox reaction. An example of 2e-oxidant is hypochlorite and 
peroxynitrite which are involved in atherogenesis process.  
It should be noted that two other theories that explain the atherosclerosis process exist. 
The first theory is based on the response to injury hypothesis, which highlights that the initial 
event is injury to endothelial and smooth muscles. Some causes to the endothelial dysfunction 
are hypertension, diabetes mellitus, genetic alterations, elevated levels of LDL, infectious 
microorganisms, and others. The injuries increase the adhesiveness of the endothelium, its 
permeability, and inflammatory response, which finally produces the accumulation of different 
compounds in the growing injured area such as ox-LDLs [212]. The response to the retention 
hypothesis, second theory, establishes that the retention and accumulation of LDL and other 
atherogenic lipoproteins in the artery wall is the initial cause of atherosclerosis [213]. The second 
theory has been researched extensively in recent years because it offers a better explanation to 
the correlation of high levels of apoB-lipoproteins and higher incidence of cardiovascular 
disease. The interaction between glucosaminoglycans and apoB-100 of LDL and VLDL is 
responsible of the LDLs accumulation in the subendothelial wall. The interaction involves basic 
amino acids in apoB-100 (residue 3359-3369), which bind ionically to negatively charged 
sulphate groups of glucosaminoglycans. The oxidation of LDLs is a cause of the accumulation 
and other interactions [60, 214, 215]. These other two theories stress initial process for 
atherosclerosis, but they include oxidation of LDLs as important vehicle for atherogenesis. 
Another interesting observation is that HDL can prevent atherogenesis. High levels of 
circulating HDL are associated with a lower risk of atherosclerosis. The studies related to HDL 
have focused on the apolipoprotein A-I (apoA-I), which acts by lowering the excess cholesterol 
from tissue and by transporting it to the liver for excretion. The identification of a mutation of 
this protein called apo A-I Milano has been a big step to use “HDL therapy in atherosclerosis” 
due to higher efficiency in cholesterol elimination from tissue. The studies performed with the 
synthetic drug showed a good performance; using a recombinant apoA-I conjugated with 
phospholipids lead to a significant reduction of coronary plaque burden after five weeks of 




In vivo and in vitro assays have shown that Vitamin E is effective in protecting LDL from 
oxidation. This finding had triggered clinical trials and epidemiological studies in order to 
understand vitamin E effect in humans [33,217-219]. Unfortunately, These clinical trials showed 
dissimilar results, giving rise for more questions and theories. The clinical trial that showed 
positive results was the CHAOS trial [220], which used vitamin E doses of 400 to 800 IU daily 
in patients with angiographically-proven coronary artery disease. The study was followed over 5-
years and showed 47% fewer myocardial infarcts (fatal plus nonfatal) for vitamin E 
supplemented patients, but the total mortality was not reduced. Other clinical trials showed no 
impact of vitamin E supplementation on atherosclerosis in the populations studied like the ATBC 
trial, which used 50 mg of vitamin E supplemented daily with no effect on cardiovascular end 
points [218]. The HOPE and GISSI trial used supplementation of 300 to 400 mg of vitamin E per 
day showed no effect on atherosclerosis [217,221].  
These studies reflect that there is a need for more research to better understand the 
mechanisms involved in atherosclerosis, which would allow for a better design of drugs and 
systems for treatment of the disease possibly based on combinations of antioxidants.   
4.3 Natural Antioxidants 
Oxidants and free radicals are associated with different diseases and cellular 
degeneration. Natural antioxidants together with enzymes, proteins, and genes play important 
roles as defense systems against oxidation. A balance between oxidants and antioxidants is 
necessary for adequate cellular survival and proliferation. In this framework of molecular 
interaction, natural antioxidant molecules act at different cellular levels. They can be localized in 
the cytoplasm, cellular membranes, nucleus, mitochondria, organelles, and in all types of tissues. 
The wide distribution of natural antioxidants is based on differences in their chemical structures 
that confer different properties such as hydrophilic-hydrophobic balance (HLB) to these 
components.  The complete understanding of natural antioxidants action in the mammalian 
system is not a trivial pursuit; it is a challenging task that has been producing flourishing 
research in the last decade. Natural antioxidants such as flavonoids, uric acid, vitamin E, vitamin 
C, coenzyme Q10, retinol, and carnosine are molecules that can be synthesized by the 
mammalian body or come from food intake. One of the most important lipophilic antioxidant 
molecule studied is vitamin E, due to its major action in protection of lipids against lipid 




of cellular machinery and are not protected against oxidation by lipophilic antioxidants such as 
alpha-tocopherol. Carnosine, on the other hand, has been highlighted as an important antioxidant 
for proteins in vitro and in animal models [118, 222-224]. Vitamin E and carnosine are adequate 
molecules, which through conjugation by covalent linkage allow the study of the potential 
benefits of a new antioxidant formed from a hydrophilic and a hydrophobic molecule. 
Information related to the structure, sources, mechanism, and roles of α-tocopherol and carnosine 
is presented in the following sections. 
4.3.1 Vitamin E 
Vitamin E is a lipophilic vitamin that 
has been the object of extensive research due to 
its antioxidant properties and non-antioxidant 
actions. The Vitamin E family is composed of 
four tocopherols (α, β, γ, δ) and four 
tocotrienols (α, β, γ, δ), the difference being that 
tocotrienols have unsaturated phytyl chains. The 
positions of the methyl group over the aromatic 
ring are different for each tocopherol and 
tocotrienol (Figure 4-5). In addition to the eight 
vitamin E components, other similar members 
have been identified in high levels in some fish 
species native to cold water such as marine 
derived tocopherol (MDT) or tocomonoenol, 
found in palm oil [225, 226] (Figure 4-5). 
The main sources of vitamin E are 
wheat-germ oil, sunflower seed, almond, and 
cereal. Each natural source of vitamin E has 
different amounts of tocopherols, with soybean 
oil, corn oil, corn and soybean margarines, 
linseed oil, and others rich in γ-tocopherol [227]. The daily recommended intake of α-tocopherol 
is 22.7 mg/day for adults and 18.7 mg/day for lactating women [228], but it has been suggested 
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that higher values (i.e. 537 or 805 mg/day) are needed when supplementation of vitamin E 
addresses therapeutic issues [33]. Plasma concentration of α-tocopherol in healthy humans range 
from 20 to 40 µM [229]. The upper recommended limit intake of α-tocopherol is 1000 mg/day or 
1500 IU/day [230].  
Trapping peroxyl radicals and breaking the chain reactions of lipid peroxidation are the 
main functions of vitamin E as antioxidant. In addition, vitamin E quenches and reacts with 
superoxide anions (O2•
-), singlet oxygen (1O2), and hydroxyl radicals (•OH), and it prevents 
nitric oxide (NO) from reacting with O2•
- [18].  
Oxidation of α-tocopherol is a two electron process [231]. The non-radical oxidation 
process of α-tocopherol always forms para-quinoid and ortho-quinone methide, a transition state 
(Figure 4-6). The reactions occur in 5-position for all vitamin E members including γ-tocopherol, 
which does not have a methyl group in 7-position [232]. The antioxidant activity of vitamin E is 
related to the methylation pattern and amount of methyl groups present in the phenolic ring, 
which is higher for α > β > γ > δ tocopherols [233].  
The reaction of α-tocopherol with peroxyl radicals forms α-tocopheroxyl radical, which is 
resonance stabilized (Figure 4-6). The final product can be a dimer formed by two α-
tocopheroxyl radicals, tocopherol quinone, or the α-tocopheroxyl radical can react with another 
molecule (i.e. vitamin C) to regenerate α-tocopherol [234,235]. The metabolite of vitamin E is 
2’-carboxyethyl)6-hydroxy chroman (CEHC). High α-tocopherol intakes are associated with an 
increase of α-CEHC in urine, which also holds true for the synthetic form of the vitamin [236]. 
The pathway involves oxidation of the phytyl chain to the corresponding hydrophilic metabolites 
without modification of the chromanol ring.  
The pro-oxidant activity of vitamin E  is based on the reduction of Cu2+ to Cu+ (or Fe3+ to 
Fe2+), which generates tocopheryl radicals that can react with polyunsaturated fatty acids 
(PUFAs) at very low rates [18,237,238]. α-tocopherol, in the presence of Cu2+ ions, can induce 
oxidative damage to DNA in vitro. The oxidation of α-tocopherol produces Cu+, which reacts 
with molecular oxygen to form superoxide anion, H2O2 by dismutation, and further 
●OH which 
has been identified as responsible for DNA damage [239]. The pro-oxidant action of vitamin E 
has not yet been proven in mammals, most probably due to low levels of iron and copper ions 
which bind to proteins like ceruloplasmin and ferritin, respectively. It has been suggested by Dr. 




α-tocopherol can act as a pro-oxidant upon mild oxidative stress and in the presence of low 
concentrations of co-antioxidant compounds (i.e. coenzyme Q-10, ascorbic acid). When the 
oxidative stress is higher, and co-antioxidants are present in high concentrations, α-tocopherol 
acts as an antioxidant [31, 55, 188, 189].    
Cadenas and coworkers [240] suggested that higher doses of vitamin E provide enough 
protection against lipid peroxidation in guinea pigs (doses of 1500 mg/kg) under normal levels of 
vitamin C. In humans with a balanced diet, the normal intake of vitamin E is around 15-30 IU/d 
(10 to 20 mg/day) [33]. Researchers have suggested that moderate supplementation can be 
beneficial for heart-healthy behavior [33, 241], with doses of 400 UI/day (270 mg/day). The 
recommendation is based on doses used for animal studies and the safety of vitamin E. One 
drawback of α-tocopherol supplementation is the reduction of plasma and tissue levels of γ-
Figure 4-6: Chemical structures of α-tocopherol reaction products with peroxyl radicals, and α-
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tocopherol [242]. Also, α-tocopherol supplementation is not recommended for patients taking 
anticoagulants, because tocopherols act synergistically with vitamin K antagonists and aspirin, 
resulting in an increased tendency to bleed 
 
Figure 4-7: Absorption and transport of tocopherols (vitamin E). Tocopherol absorption and 
transport are linked to lipid absorption mechanisms. The small intestine is responsible for the 
formation of chylomicrons, which transports all to
Chylomicrons are catabolized to chylomicron remnants by lipoprotein lipase (LPL) present in 
different tissues (endothelial-bound enzyme), which hydrolyze triglycerides and transfers 
tocopherols to different tissues. T
to nascent VLDL with incorporation of α
the circulation by LPL and hepatic triglyceride lipase (HTGL) to form VLDL remnants and 
LDL. The α-tocopherol is finally transported to different tissues by LDLs. The tocopherols 
excess is excreted by the liver to the pancreas or urine. 
86 
[228,243]. 
copherols (not a selective mechanism). 
he chylomicrons remnants that reach the liver are transformed 





Supplementation with vitamin E has not shown conclusive results in the prevention and 
control of several diseases like cardiovascular disease, cancer, and atherosclerosis, but patients 
with pre-existing cardiovascular disease can benefit from supplementation of α-tocopherol (up to 
800 IU/day or 537 mg/day) as suggested in some clinical trials [16]. Some studies with humans 
(small groups) have shown positive benefits of vitamin E supplementation with the addition of 
micronutrients like coantioxidants and selenium [33]. Elsayed research group showed that 
inhalation of oxidative air pollutants by rats was associated with a significant increase in vitamin 
E levels in lung tissue [244]. The theory is that oxidative stress could activate some signal 
transduction pathways, which mobilize antioxidants to the target. The location of vitamin E in 
cells and tissue differs; for example, vitamin E is present in neuronal membrane in unique 
locations, suggesting neurological function [245]. 
The potential of vitamin E is hopeful, but there is need for more research; the positive 
aspects are that treatment with vitamin E is not expensive and that there are no side effects due to 
the intake of vitamin E up to 400 IU/day [246]. Miller’s research group performed a statistical 
study designed to find a relationship between vitamin E supplementation and total mortality (end 
point). The study was based on results published from 19 different clinical trials performed from 
1966 to 2004 around the world on 135,000 participants suffering from diseases such as 
atherosclerosis, diabetes, Parkinson’s, and others. It suggested that intakes of vitamin E 
supplements higher than 400 IU/day (approximately 180 mg/day) may increase mortality [246]. 
Cellular transport and absorption of vitamin E is by specific and nonspecific uptake. 
Figure 4-7 presents the main steps in the absorption and transport of tocopherols and α-
tocopherols. The regulated uptake is specific for α-tocopherol. The non-specific uptake is for all 
other vitamin E family components [232]. The intestine takes up α-tocopherol and γ-tocopherol 
in a non-selective process in comparable proportions [247] via chylomicron particles. The first 
step is the micelle formation in the small intestine by bile salts, lipophilic compounds, and 
products of lipid hydrolysis by pancreatic lipases. The next step is formation of chylomicron 
particles in the Golgi apparatus of enterocytes (intestinal cells) [48, 248]. Chylomicrons particles 
are formed from different lipophilic compounds (tocopherols, cholesterols, fatty acids) together 
with apo proteins (Apo-B48), phospholipids and triglycerides. The chylomicrons are secreted to 
the plasma, where they are catabolized by endothelial-bound enzyme lipoprotein lipase (LPL) 




catabolism is one mechanism for vitamin E transfer to muscles, adipose tissue, brain tissue, and 
other tissues. Deficiency in LPL does not cause vitamin E deficiency in plasma, but it produces 
low levels of α-tocopherol in adipose tissues [234]. The cholesteryl ester transfer protein (CETP) 
acts at this level by exchanging cholesteryl esters from HDL to the remnants, and triglycerides 
from remnants to HDL [250]. Also, the chylomicrons remnants can acquire apolipoprotein E 
from HDL. Once the chylomicrons remnants reach the liver, they are used as substrate for 
secretion of very low density lipoproteins (VLDL). 
VLDL and LDL act as a main transport pathway for α-tocopherol into the cells [40, 42, 
188, 242, 251, 252].The protein α-tocopherol transfer protein (α-TTP) is responsible to add α-
tocopherol to nascent VLDL. The steps of this process are not clear, but the animal studies and 
patients with deficiency in α-TTP showed that the protein is vital to achieve high levels of α-
tocopherol in plasma. The work of Hosomi et al. evaluated α-TTP specificity for different 
vitamin E analogs and showed 100% affinity for RRR-α-tocopherol, 38% for β-tocopherol, 9% 
for γ-tocopherol, 2% for α-tocopherol acetate, 9% for Trolox [253]. VLDL is catabolized next by 
lipoprotein lipase (LPL) and hepatic triglyceride lipase (HTGL) in plasma. At this step, α-
tocopherol can be transferred to HDL, or can continue with VLDL and ending into LDLs, or can 
return to the liver with the VLDL remnants (intermediate density lipoprotein, IDL). The liver can 
secret the vitamin E excess to the pancreas by the ATP binding cassette family of transporters 
(ABCB4) and p-glycoproteins, or the excess of vitamin E can be catabolized to carboxymethyl 
hydroxychroman (CEHC) by cytochrome p-540 [254-257]. 
4.3.2 Carnosine (β-alanyl-L-histidine) 
Carnosine is a hydrophilic dipeptide (β-alanyl-L-histidine) synthesized exclusively by 
mammals. It is found in high concentrations in muscle and brain tissue, which suggest 
antioxidant activity considering the high oxidative stress in these tissues. A high oxidative stress 
is found in muscle tissues during anaerobic glycolysis (i.e. high levels of exercises) producing 
lactic acid, which reduces the pH in muscles [258]. Human skeletal muscle levels of carnosine 
are range from 2 to 20 mM. In the brain, carnosine is non-uniformly distributed with higher 
levels (up to 5 mM) in olfactory epithelium and bulbs [120,258]. The dipeptide carnosine and its 
analogs homocarnosine and anserine can be degraded by the enzyme carnosinase which is a 




This histidine containing dipeptide is part 
of the ω-aminoacylamino acids family (Figure 
4-8). Other compounds are anserine, 
homocarnosine, and homoanserine [259]. It has 
been shown in different studies that carnosine acts 
as an anti-oxidant, carbonyl scavenger (anti-
glycating), and metal ion chelator [115,260-266]. 
The imidazole moiety of carnosine has 
been identified as responsible for its antioxidant 
properties. It was suggested that the protons on the 
nitrogen ring and on the methylene carbon next to 
the imidazole ring are required for antioxidant 
purposes. The imidazole molecule has higher 
antioxidant activity (around seven times higher) 
than 1-methylimidazole which lacks the proton on 
the ring. Homocarnosine, and anserine showed 
antioxidant activity comparable to carnosine [258]. 
The inhibition of deoxyguanosine oxidation, which 
was induced by ascorbic acid and copper ions in 
the presence of carnosine and anserine, suggested 
effective copper chelating properties. Another 
aspect studied was the effect of carnosine’s buffering capacity on its antioxidant activity. A 
decrease in pH reduced the capacity of antioxidant molecules to act as antioxidants; carnosine 
maintains the pH at physiological values (7 - 7.2), so its antioxidant activity is not diminished 
[258].  
An interesting property of carnosine is its ability to protect proteins from oxidation 
[102,103,118,120,263,267]. Reactive oxygen species can easily oxidize proteins, and the 
carbonyl groups of oxidized proteins can interact with lipids or carbohydrates to form 
compounds that can be inactive and resistant to degradation. Another hypothesis is that native 
proteins can be altered by products of lipid peroxidation and carbohydrates forming cross-linking 
stable products (AGEs, a group of glycated-end products) that accumulate in tissues [118,263]. It 
Figure 4-8: Structure of carnosine (A)  




























is suggested that the rejuvenation phenomena observed in human fibroblast cells is promoted by 
carnosine, which regulates the proteins degradation and possibly involves other unknown 
mechanisms [118,266]. Also, an inverse relation between carnosine and diabetes has been 
reported [268]. Lee and coworkers [224] used diabetic Balb/cA mice to study the effect of 
dietary supplementation of histidine and carnosine. It has been suggested that carnosine could be 
beneficial for people with diabetes, especially to control the secondary effects of diabetes [267]. 
Diabetes can produce poor glycemic control, which causes LDL oxidation and glycation, and the 
results of Lee et al. showed that histidine and carnosine protect LDL against glucose-induced 
oxidation. The results showed that supplementation of 1 g/l of histidine or carnosine increased 
the insulin levels (from 6.8±1.4 nmol/l to 9.7±1 nmol/l), reduced trygliceride and cholesterol 
levels (hyperlipidemia; tryglicerides in heart from 54.6±4 mg/g to 37.6±3.1 mg/g, cholesterol in 
heart from 7.4±0.6 mg/g to 5.7±5.7 mg/g), enhanced catalase activity, and suppressed tumor 
necrosis factor (TNF)-alpha. Carnosine can also provide potential therapeutic effects on 
neurodegenerative diseases related to high levels of zinc (Alzheimer) [223,269,270]. Finally, it 
has been shown that low density lipoproteins (LDL) were protected against glucose-induced 
oxidation and glycation by a peroxynitrate (ONOO-) dependent process. The relative 
electrophoretic mobility of LDLs (peroxynitrate oxidation of LDLs increases its electrophoretic 
mobility due to more charged APOB-100) is reduced by 94% at 10 mM of carnosine 
concentration [260]. Moreover, carnosine can inhibit the oxidation of LDLs when the oxidation 
is catalyzed by copper in vitro. Carnosine can chelate copper making it unavailable to oxidize the 
protein apo B-100 of LDLs particles [83,271].  
In summary, carnosine and its derivatives have potential benefits in several diseases 
related to oxidative processes, and it was selected as the hydrophilic antioxidant component for 
the proposed project. 
4.4 General Characterization Techniques for Antioxidants  
VECAR reactivity can be determined by several assays, which will provide a better 
understanding of the antioxidant behavior of the new molecules synthesized. These different 
assays provide information about the rate and time of protection, free radical scavenging 
properties, affinity to some radicals or oxidant molecules, pro-oxidant behavior, among others.  
The free radical scavenging properties can be analyzed by several methods [272-278]. 




hydrazyl (DPPH) radical is a stable free radical of purple color. The addition of an antioxidant 
reduces the DPPH radical, which can be appreciated by color change (to yellow) measured in a 
spectrophotometer at 518 nm. ABTS assay: The mixture of 2,2-α-azino-bis-(3-
ethylbenzthiazoline-6-sulfonic acid) (ABTS) and hydrogen peroxide produces ABTS radical 
(ABTS●). Further incubation with peroxidase results in production of radical cation ABTS•+. 
The addition of VECAR antioxidant causes an attenuation of the color change, which can be 
measured at 734 nm. The activity is usually expressed as an equivalent of the millimolar of a 
standard trolox solution.  
The superoxide anion scavenging properties can be evaluated by the following methods: 
Xanthine-xanthine oxidase system assay: The superoxide anion is formed by the reaction 
between xanthine and xanthine oxidase. The superoxide anion produced can be detected at 560 
nm due to change in color of nitroblue tetrazolium (NBT) [279]. Alkaline DMSO assay: alkaline 
DMSO is used to form superoxide anion and the reduction of NBT is measured with and without 
the antioxidant molecule at 560 nm [280]. 
The hydroxyl radical scavenging properties of VECAR can be measured by the following 
methods: p-nitroso dimethylaniline (pNDA) bleaching assay: The hydroxyl radical formed by 
reaction of hydrogen peroxide with ferric chloride results in bleaching of pNDA. The addition of 
VECAR changes the bleaching profile and the absorbance is measured at 440 nm [280]. 
Deoxiribose assay: hydroxyl radical degrades deoxyribose, and it can be measured 
colorimetrically. The hydroxyl radical can be generated by Fenton’s reaction of ferric chloride 
with hydrogen peroxide [280].  
The nitric oxide scavenging performance of VECAR can be evaluated by using 
nitroprusside, which at physiological pH liberates nitric acid, which is converted to nitrous acid 
and further forms nitrite ions on contact with air. The final reaction forms a pink color measured 
at 546 nm [281].  
The peroxynitrite scavenging performance can be determined by the following assays 
Tyrosine Nitration Assay: The peroxynitrite action produces nitration of tyrosine, and the 
addition of an antioxidant molecule generates some degree of inhibition, which can be measured 
[282]. Oxidation of dihydrorhodamine assay: The fluorescence of the oxidation of 




The action of VECAR against lipid peroxidation can be evaluated by several methods 
Thiobarbituric acid assay (TBARS): it is based on reaction of melondialdehyde (MDA), an end 
product of lipid peroxidation, with thiobarbituric acid [284]. Iodometric assay: This method can 
be used for PUFA peroxidation and protein peroxidation studies. Based on the I- ability to reduce 
the hydroperoxides formed in lipid peroxidation process [10,285]. Other techniques available 
are: conjugated dienes, fluorescent techniques, protein fragmentation with SDS-PAGE, surface 
charges by electrophoretic mobility of Apo B-100, electron spin resonance (ESR), nuclear 
magnetic resonance (NMR), and others. 
For in vivo measurements, different assays can be used to provide information on the 
VECAR reactivity of free radicals and oxidant molecules. The most used assays are totally 
reactive antioxidant potential (TRAP), total antioxidant activity (TAA), oxygen radical absorbing 
capacity (ORAC), and total antioxidant reactivity (TAR) [185,286,287].  
4.5 Hypothesis 
The cellular antioxidant defense system is vital for human life, responsible for balancing 
free radical species with antioxidant molecules such as natural antioxidant molecules, proteins, 
and enzymes. An imbalance between free radical species and antioxidant molecules is 
responsible for certain diseases as discussed in previous sections. Supplementation with natural 
antioxidants has been suggested as an important path for prevention and treatment of oxidative 
stress related diseases; however, some clinical trials performed in the last years showed poor 
results associated with supplementation of natural antioxidants for disease treatment in humans. 
The difference between results in vitro and in humans has been a topic of debate. In the quest for 
new insights to address the surfaced uncertainties, a new approach is proposed herein focused on 
conjugation of several natural antioxidants to form an antioxidant component of improved 
antioxidant performance when compared to that of the individual components due to synergetic 
effects between the components (Figure 4-9).  
The hypothesis is: 
Conjugation of vitamin E with carnosine, another potent natural antioxidant, by covalent 
bonding results in a new molecule with potent antioxidant properties capable of 






Several objectives were followed to assess the hypotheses previously established. 
a. Synthesis of vitamin E-carnosine: Synthesis of VECAR (12 carbon chain lengths) 
VECAR) (Figure 4-9) based on the protection of OH group, activation of carbonyl 
group, Wittig reaction for ylide, attachment of carnosine, and de-protection of OH 
group.  
b. Characterization of the molecular structure of VECAR by nuclear magnetic resonance 
(NMR) and analytic thin-layer chromatography (TLC)  
c. Testing antioxidant properties of VECAR by DPPH and TBARS.  
4.7 Materials 
The following chemicals were purchased from Acros Organics: trolox 97%, tert-
butylchlorodimethylsilane 98 %, and triethylamine 99%. Methanol anhydrous 99.8%, imidazole 
























Key structures for 
enzymatic recognition 
Figure 4-9: Schematic structure of VECAR. There is a hydrophilic section formed by the α-
tocopherol chromanol ring and the carnosine dipeptide. The hydrophobic section is provided by 
the carbon tail that links polar heads to important sections. The circles around chromanol ring 






M solution in hexane, 12-bromododecanoic acid 97%, acetonitrile anhydrous 99.8%, 
triphenylphosphine 99%, tetrahydrofuran <99.9%, lithium bis(trimethylsilyl)-amide (LiHMDS) 
1.0 M solution in tetrahydrofuran, palladium (Pd/C) 10 wt. % (dry basis) on activated carbon, 
wet, Degussa type E101 NE/W, L-carnosine 99%, and 4-(dimethylamino) pyridine (DMAP) 
99% were purchased from Sigma-Aldrich. Thionyl chloride 99+% and magnesium sulfate 99.5% 
were purchased from Alfa Aesar. The chemicals purchased from Mallinckrodt Chemicals were 
methanol, ethyl acetate, toluene, ammonium chloride, chloroform, sodium hydroxide, and 
sodium bicarbonate. Dichloromethane and hexanes 95% n-hexane were purchased from J.T. 
Baker. Silica gel Porosity: 60Å, Particle Size: 40-63 µm, Surface Area: 500-600 m2/g, pH Range: 
6.5-7.5, and silica gel of 300 Å, particle size of was purchased from Sorbent Technologies, and 
O-benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU), 99.58% was 
purchased from ChemPep Inc. The following chemicals were purchased from Fisher Chemical: 
1-propanol and sodium chloride. Sodium bicarbonate was purchased from EMD Chemicals. 
A stock solution of DPPH in methanol at 0.4 mM was prepared and kept at -20 °C in the 
dark prior to use. The sample was diluted with water (pH = 3.5 prepared by addition of acetic 
acid) to 1 ml. The sample was added to dilute DPPH stock in methanol to obtain a final sample 
volume of 2 ml with a 0.1 mM DPPH concentration. The ratio between water and methanol was 
1 to 1 v/v. The blank was prepared with 1 ml of water (pH=3.5) and pure methanol. The controls 
were prepared for each sample, with 1 ml of water (pH = 3.5) and 1 ml of DPPH in methanol 
solution. Absorption readings were taken after 30 min at 518 nm using a Geminys 6 
spectrophotometer (Thermo Scientific, Waltham, MA). The formula used to calculate the rate of 
oxidation was  
% change in activity = ((Abscontrol – Abssample)/Abscontrol)*100    [1] 
4.8 Methods and Results  
 The first step was the synthesis of the new molecule (VECAR), and the second step was 
VECAR characterization to assess its antioxidant behavior.  
4.8.1 Synthesis of α-tocopherol-carnosine (VECAR)  
The synthesis of α-tocopherol-Carnosine (VECAR) was based on the protection of OH 




protection. The method is based on Atkins and coworkers [288-299] and is described in more 
details below.   
4.8.2 Trolox Methyl Ester 
Synthesis of vitamin E-carnosine started with Trolox™. Trolox™ is a vitamin E 
derivative without the phytyl chain, which confers its hydrophilic behavior. S-trolox (3.5 g, 14 
mmol) and dry methanol (26 mL) was stirred at 0°C for 15 minutes (Figure 4-10). Thionyl 
Chloride (1.26 mL, 16.9 mmol) was added to the solution and stirred at 0°C for an additional 10 
minutes. The solution was refluxed for 1 hour at 70°C. Triethylamine (4 mL, 11 mmol) was 
added after 15 minutes. The solvent was evaporated and the crystals were re-dissolved in 
methanol. The re-crystallization from methanol yielded white crystals (2.89 g, 80%). 1H (CDCl3) 
NMR δ 4.24 (s, 1H, OH), 3.86 (s, 3H, OCH3), 2.63 (m, 2H), 2.51 (m, 1H), 2.19 (s, 3H), 2.17 (s, 





4.8.3 Protection of Hydroxyl Group 
The product obtained in the first reaction, (S)-methyl-6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylate (S1) (1.254 g, 4.7 mmol), was mixed with tert-
butyldimethylsilyl chloride (1.081g, 7.2mmol), and imidazole (1.339g, 19.7 mmol) in dry 
dimethylformamide (10 mL) (Figure 4-11). The mixture was stirred and heated in an oil bath 
under argon atmosphere at 85 °C for 5 h, at which point none of the starting material S1 was 
detected by TLC. The reaction mixture was poured into water and then extracted with ethyl 
acetate. The solution was dried over magnesium sulfate. Evaporation yielded a light yellow oil. 
The crude product was purified by column chromatography on silica gel using (CH2Cl2:hexane= 
3:1) [299]. The yield of S2 was 1.62 g (90%). 1H NMR (CDCl3) δ 3.66 (s, 3H, OCH3), 2.62 (m, 







2H), 2.44 (m, 2H), 2.15 (s, 3H), 1.87 (m, 3H), 1.85 (m, 1H), 1.60 (s, 3H), 1.04 (s, 9H), 0.12 (s, 
















4.8.4 Reduction of Ester to Aldehyde 
S2 (3.282 g, 8.67 mmol) was added to dry hexane (35 mL), and was cooled in an 
acetone/dry ice bath to -75 °C (Figure 4-12). Diisobutylaluminum hydride (DIBAL-H, 1.0 M in 
hexane, 16 mL, 16 mmol) was added using a syringe as not to exceed -70 °C. After 2 h the 
reaction was quenched with dry methanol (10 mL) and stirred for 15 minutes. The solution was 
removed from the acetone/dry ice bath and was allowed to cool to -8°C. Water (15 mL) was 
added to the solution by syringe. The solution was then poured into water and extracted with 
hexane/ethyl acetate (2:1). The solution was dried over magnesium sulfate and the solvent was 
evaporated. The crude product was purified by column chromatography using CH2Cl2:hexane 
(1:1 to 3:1) [299]. The yield was of S3 was 2.33 g (77%). 1H NMR (CDCl3) δ 9.63 (s, 1H), 2.56 
(m, 2H), 2.28 (m, 1H), 2.17 (s, 3H), 2.12 (s, 3H), 2.08 (s, 3H), 1.84 (m, 1H), 1.39 (s, 3H), 1.05 
(s, 9H), 0.12 (s, 6H). 
 
 
Figure 4-11: Synthesis of (S)-methyl 6-(tert-butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-
2-carboxylate (S2) to protect the hydroxyl group in position 6. 
Figure 4-12: Reduction of S2 ester to synthesize (S)-6-(tert-butyldimethylsilyloxy)-2,5,7,8-







4.8.5 Ylide Synthesis 
A solution of 12-bromododecanoic acid (1.66 g, 5.9 mmol) in dry acetonitrile (13 mL) 
was heated and stirred. Triphenylphosphine (1.637 g, 6.2 mmol) in dry acetonitrile (13 mL) was 
heated and stirred then added to the 12-bromododecanoic solution; the solution was refluxed 
overnight (Figure 4-13). The solvent was removed. The crystals were dissolved in DCM (14 
mL). Toluene (40 mL) was added and the solution was stirred and heated to remove the DCM. 
The solution was cooled and the phosphonium salts crystallized where removed by filtration. The 
solution was decanted with toluene. The yield of S4 was 3.01 g (93.5%). 1H NMR (CDCl3) δ 
7.84-7.68 (m, 15H), 3.68-3.50 (m, 4H), 2.36 (s, 2H), 1.61-1.19 (m, 16H). 
 
 
4.8.6 Wittig Reaction for Coupling the Phytyl Chain 
The suspension of phosphonium salts S4 (2.927 g, 5.4 mmol) was dissolved in dry THF 
(55 mL) at room temperature under argon. A solution of LiHMDS in THF (1 M in THF, 16 mL, 
13.4 mmol) was added dropwise via a syringe (Figure 4-14). The red ylide was stirred for 2 h 
under argon. A solution of S3 (1.85 g) in dry THF (8 mL) was added dropwise. The color 
changed from red to pale yellow. The suspension was stirred for an additional 3 h, until S3 
cannot be found by TLC. The reaction was quenched with saturated NH4Cl (80 mL) and water 
(80 mL) and then extracted with ethyl acetate. The solution was dried over magnesium sulfate. 
After solvent removal, trituration with cold hexane removed triphenylphosphine oxide. The 
hexane solution was evaporated, and the crude product was purified  by column chromatography 
on silica gel using ethyl acetate:hexane (1:1) [299].Yield of S5 was 1.99 g (71%). 1H NMR 
(CDCl3) δ 5.32 (d, 2H), 2.55 (t, 2H), 2.35 (m, 1H), 2.11 (s, 8H), 2.09 (s, 2H), 2.04 (s, 3H), 1.64 
(m, 2H), 1.46 (s, 4H), 1.24 (s, 9H), 1.04 (s, 9H), 0.11 (s, 6H).  
 










4.8.7 Saturation of Phytyl Chain 
Pd/C (0.505 g) was added to a solution of S5 (0.95 g, 3.67mmol) in ethyl acetate (85 
mL). A hydrogen balloon was attached to the reaction mixture and it was stirred for 18 h at room 
temperature (Figure 4-15). The mixture was filtered and evaporated to obtain S6 as an oil. The 
crude product was purified by column chromatography using hexane:ethyl acetate (4:1). The 
Yield of S6 was 0.91 g (94%) [299]. 1H NMR (CDCl3) δ 2.55 (t, 2H), 2.37 (t, 2H), 2.07 (t, 9H), 





Figure 4-14: Wittig reaction to synthesize (S,E)-13-(6-(tert-butyldimethylsilyloxy)-2,5,7,8-
tetramethylchroman-2-yl)tridec-12-enoic acid (S5).  
Figure 4-15: saturation reaction to synthesize (R)-13-(6-(tert-butyldimethylsilyloxy)-2,5,7,8-







4.8.8 Carnosine Methyl Ester Dihydrochloride 
Thionyl chloride (0.25 mL, 3.3 mmol) was added dropwise to a suspension of carnosine 
(602.9 mg, 2.7mmol) in anhydrous methanol (24 mL) at 0 °C and was stirred for 10 minutes. The 
solution was refluxed at 75°C for 1 hour (Figure 4-16). After cooling down to room temperature, 
the mixture was concentrated. The product was used in the next step without further purification 
[300]. 1H NMR (MeOH) δ 8.85 (s, 1H), 7.67 (s, 1H), 7.55 (s, 1H), 4.82 (m, 3H), 3.94 (s, 3H), 
3.30 (m, 2H), 3.01 (m, 2H), 2.70 (m, 2H).  
 
 
Figure 4-16: Carnosine esterification by acyl chlorides to synthesize methyl 2-(3-
aminopropanamido)-3-(1H-imidazol-4yl)propanoate dihydrochloride (S7).  
 
4.8.9 Coupling Carnosine Methyl Ester with Carboxylic Acid 
The carboxylic acid compound S6 (840 mg, 1.59 mmol), DMAP (19 mg, 0.16 mmol), 
carnosine-methyl ester hydrochloride (S7) (662 mg, 2.39mmol), and triethylamine (1.67 mL, 5 
equiv) were added to anhydrous DMF (13.4 ml) (Figure 4-17). The solution was cooled to 0°C in 
an ice bath. HBTU (721 mg, 1.9 mmol) in anhydrous DMF (3 mL) was added to the reaction 
mixture drop wise, and was stirred for an additional 20 minutes at 0°C. The reaction was stirred 
at room temperature over night. Next, the solvent was evaporated and dried under high vacuum. 
The washing and extraction steps were performed with chloroform and water without addition of 
magnesium sulfate. The organic phase was collected and evaporated under vacuum. The 
purification was performed with a reverse phase silica gel (C18).The silica gel used was 300 Å 
pore size with a mixture of methanol:water (7:3) as eluent. The yield of S7 was 0.62 g (43%). 
[301-303]. 1H NMR (MeOH) δ 8.52 (s, 1H), 7.24 (s, 1H), 3.74 (m, 3H), 2.57 (m, 2H), 2.41 (m, 
2H), 2.09 (m, 13H), 1.78 (m, 2H), 1.58 (m, 4H), 1.52 (m, 4H), 1.27 (s, 15H), 1.22 (s, 4H), 1.04 





Figure 4-17: Coupling reaction with HBTU to synthesize methyl 2-(3-(13-((R)-6-(tert-
butyldimethylsilyloxy)-2,5,7,8-tetramethylchroman-2-yl)tridecanamido)propanamido)-3-(1H-
imidazol-4-yl)propanoate (S8). 
4.8.10 De-protection of Hydroxyl Group of Chromanol Ring 
The de-protection of (S8) was performed by dissolving S8 (260 mg), in dry THF (10 ml) 
and the addition of TBAF (2.9 mL of a 1 M THF solution) was performed drop wise via a 
syringe (Figure 4-18). The solution was stirred for 1.5 hour at room temperature. The THF was 
evaporated and replaced with chloroform (200 ml). The solution was washed with water three 
times. The crude VECAR product was purified by flash chromatography on reverse phase silica 
gel (60 Å) using gradient elution, methanol:water (30%) and methanol:water:ammonium  
hydroxide (8:1:1). The first two fractions collected the impurities and pure VECAR was 














4.8.11 Reverse Phase Silica Gel 
The synthesis of reverse phase silica gel was performed to use it in the purification of 
VECAR after coupling reaction. Normal phase silica gel (100 mg) was suspended in toluene 
(500 ml), and 21 ml (0.52 mol) of octadecyltrichlorosilane (C18, ODTS) was added drop wise. 
After 10 min, triethylamine (28 ml, 4 equiv.) was added to the suspension, and the final 
suspension was refluxed for 24 hr at 125 °C. Finally, the reverse phase silica gel was washed 
with toluene (1 L), DCM (1 L), ethyl acetate (1 L), and methanol (4 L). The product was dried 
under high vacuum and storage for use. 
 
 
Figure 4-19: Rate of radical inhibition of VECAR by the DPPH method. 
4.9 Antioxidant Activity of VECAR by DPPH 
The antioxidant behavior of VECAR was studied with the DPPH assay to assess the 
antioxidant activity provided by the chromanol ring of VECAR. The deprotection of the 
hydroxyl group provides the antioxidant behavior of VECAR, similar to that of alpha-tocopherol.  
The measurements were performed at 5 concentrations (Figure 4-19) to determine IC50, 
which is the point at which 50% of DPPH has been reduced by VECAR. The IC50 was 24.9±1.4 
µM for VECAR, the value for alpha-tocopherol was 24.4±1.5 µM. These values confirm that 
VECAR has antioxidant activities that are similar to pure alpha-tocopherol which is the main 
hydrophobic antioxidant used in the synthesis.  
y = 24.065x - 0.0679
R² = 0.9991



























4.10 Conclusions  
The synthesis of VECAR (carnosine plus alpha-tocopherol derivative) was accomplished 
in nine steps. The different steps followed to synthesize VECAR were designed to form a phytyl 
chain with a reactive end group (carboxylic acid). The first step (Trolox esterification) was 
performed by an acid chloride (thionyl chloride) reaction. The selection was based on the yields 
and reaction time compared with p-toluenesulfonic acid as catalyst. The yields were increased 
from 50% to 78% and the time was reduced from 18 hrs to less than 2 hrs when thionyl chloride 
was used as catalyst. The second step was the protection of the hydroxyl group present in the 
chromanol ring of Trolox by using tert-butyldimethylsilyl chloride (TBDMS) as protecting 
agent. The protection allowed the recovery of the hydroxyl group at the last reaction step. The 
third step was the reduction of the acid to an aldehyde by using DIBAL at -70 °C. The reaction 
was difficult because the separation of the un-reacted ester with the aldehyde required gradient 
elution of the column chromatography. The water present in the sample reduced the yields and 
increased the complexity during purification with flash chromatography. The reaction yields of 
the first three steps were improved by elimination of the residual water present in the samples 
after purification. Next, the Wittig reaction was used to add a phytyl chain of 12 carbons to the 
chromanol ring. The phytyl chain used was provided by 12-bromododecanoic acid, which 
allowed the synthesis of a phosphonium salt prior to the Wittig reaction. The product was then 
saturated in the presence of hydrogen. The coupling reaction of carnosine was complicated due 
to the hydrophobic/hydrophilic behavior of the new molecule. Hence, the carnosine was 
modified to carnosine ester to improves its solubility in polar solvents and avoid reactions 
between the carboxylic groups of carnosine and the alpha-tocopherol analog. Different coupling 
reactions such as dicyclohexylcarbodiimide (DCC), conjugated anhydrides, and (2-(1H-
Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (HBTU) were attempted. 
The best results were achieved when HBTU was used as coupling reagent because the 
purification step was possible by using reverse phase column chromatography. Reverse phase 
silica gel was necessary because the molecule did not move through the normal silica gel. 
Finally, the de-protection was performed by tetrabutylammonium fluoride (TBAF) which is a 
standard protocol for elimination of TBDMS. The reaction times were reduced from over night 




silica was used in a flash column chromatography to purify VECAR after the coupling reaction 
and de-protection. The structure of VECAR was confirmed by H-NMR.  
The active phytyl chain, which can be used to attach other molecules for therapeutic 
purposes in further experiments, allowed for the antioxidant properties of alpha-tocopherol to be 
maintained. VECAR presented an antioxidant behavior as confirmed by the DPPH assay. The 
VECAR IC50 value (24.9±1.4 µM) was close to that of pure alpha-tocopherol (24.4±1.5 µM) 
which confirmed the recovery of the hydroxyl group in the chromanol ring of VECAR. Diseases 
such as Parkinson’s, Alzheimer’s, and atherosclerosis are linked to oxidation process and could 
potentially benefit from VECAR.  
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CHAPTER 5. CONCLUSIONS 
Natural antioxidants and vitamins have been shown to possess properties that could 
potentially improve human health. Targeted delivery of vitamins and antioxidants via polymeric 
nanoparticles offers several advantages over traditional delivery methods, which include 
protection of the bioactive component from degradation, an increase in the bioavailability of the 
vitamin, delivery of the component to the site of action in a controlled manner, as well as the 
possibility to integrate the bioactive component in various foods for enhanced food quality. 
Safety of the polymeric nanoparticles for antioxidant and vitamin delivery is a very important 
factor which must be considered in designing and building polymeric nanoparticles for targeted 
controlled delivery of antioxidants and vitamins.  
Several methods are available to synthesize polymeric nanoparticles with entrapped 
antioxidants/vitamins, by starting with a preformed polymer. Each method has its advantages and 
disadvantages; the selection of the most suitable method should be based on the chemical 
characteristics of the active component and that of the polymer, as well as on the final use of the 
nanoparticles. The methods which are based on the diffusion of the organic solvent to form 
nanoparticles are limited to low polymer concentration for nanoparticle mean sizes of less than 
200 nm. Methods that involve solvent evaporation are more time consuming and are more 
expensive, but are less sensitive to changes in the polymer concentration. Emulsion evaporation, 
in particular, can be used to entrap hydrophilic (w/o/w emulsion) or hydrophobic (w/o emulsion) 
antioxidants, which is an advantage. The salting-out method is suitable for formation of 
nanoparticles at higher polymer concentration, but the involved purification process is a 
limitation of this synthesis method. Surfactant concentration, polymer concentration, polymer 
molecular weight, solvents, surfactant concentrations, and phase ratios play an important role in 
controlling the size of the nanoparticles in all methods available for nanoparticles formation. All 
methods involve the use of surfactants. 
The next generation of antioxidant polymeric nanoparticles not only they will deliver 
antioxidants, but they will also provide intrinsic antioxidant action. One possibility of 





A new antioxidant surfactant made of vitamin E and vitamin C (EC) was successfully 
synthesized and it was used to form PLGA polymeric nanoparticles with antioxidant activity in 
this study. The EC surfactant was hydrophobic with a good solubility in polar solvents. 
Nanoprecipitation (self assembly) technique was used to synthesize self-assembled EC and Span 
80 nanostructures, as well as polymeric PLGA-span 80 and PLGA-EC nanoparticles. The EC 
nanostructures were spherical and measured between 12 and 140 nm depending on the salt and 
surfactant concentration. The polymeric PLGA-EC nanoparticles showed an antioxidant activity 
(IC50 of 36.3 to 42.1 mM as measured by DPPH assay). The antioxidant action of the PLGA-EC 
nanoparticles was provided by the vitamin C moiety of the EC surfactant which localized at the 
interface between the PLGA hydrophobic core and water. In comparison, PLGA-span80 
particles did not show any antioxidant activity (the antioxidant activity of α-tocopherol was lost 
in the synthesis). The antioxidant activity of EC and EC-PLGA nanoparticles has been confirmed 
by EPR measurements. Even though the scavenging activity of EC was about twice higher than 
that of EC-PLGA NPs, the antioxidant properties were in a similar range. The newly synthesized 
EC surfactant was therefore found successful in forming polymeric nanoparticles of intrinsic 
antioxidant properties. 
 The following step was to synthesize an amphiphilic molecule that maintained the 
intrinsic antioxidant activity of both antioxidants components used in the synthesis. Synthesis of 
VECAR (carnosine plus alpha-tocopherol derivative) was accomplished in eight steps. The 
approach developed was to form an active phytil chain which was used to attach carnosine. The 
H-NMR spectrum confirmed synthesis of VECAR. VECAR presented an antioxidant behavior as 
measured by DPPH (0.0236 mM) close to that of pure alpha-tocopherol (0.0229 mM) which 
confirmed the recovery of the hydroxyl group in the chromanol ring of VECAR. Diseases such 
as Parkinson’s, Alzheimer’s, and atherosclerosis are linked to oxidation process, and VECAR 
can prove as an effective antioxidant in vitro and in vivo, as well as potential new antioxidant 






CHAPTER 6. FUTURE WORK 
The antioxidant surfactants EC and VECAR were successfully synthesized and showed a 
good antioxidant activity. It is proposed that the next step for EC surfactant project should focus 
on covalent attachment of maleic acid to the OH groups that do not provide antioxidant action of 
vitamin E. The hydrophilic/lipophilic behavior of EC can be modified by attaching a molecule 
more hydrophilic than vitamin C, or the attachment of an additional ascorbic acid molecule. 
Another important area for EC surfactant is test the recovery of vitamin E antioxidant action 
after hydrolysis of EC into the components (vitamin E, vitamin C, and maleic acid) which occurs 
in the presence of esterases found in the body.   
The antioxidant behavior of antioxidant surfactants synthesized (EC and VECAR) should 
be completely characterized. Assays with different initiators should be performed to detect the 
effectiveness of EC and VECAR against ROS, RNS, and RSS. The antioxidant activity of 
polymeric nanoparticles synthesized in the presence of EC/VECAR should be tested with the 
same protocols to understand their intrinsic antioxidant behavior and to detect potential 
differences between the antioxidant activity of the surfactant placed on the surface of the 
particles or in the bulk. The preliminary results obtained herein suggest that VECAR is a good 
antioxidant molecule. VECAR must be tested with lipids and LDL in vitro to understand its 
antioxidant behavior. Moreover, the in vivo analysis will be required to analyze the fate of 
VECAR in the lipid transport mechanism of biological entities. LDL should transport VECAR to 
different tissues, and animal studies will confirm the validity of that hypothesis. VECAR’s 
ability to act as a surfactant should be tested, and VECAR should be used to make polymeric 
nanoparticles with inherent antioxidant activity. The method can be the same as the self 
assembly technique applied to make EC-PLGA polymeric nanoparticles. Additionally, other 
polymers besides PLGA can be used to study interactions between VECAR and polymer in 
formation of the nanoparticles. 
Very importantly, the understanding of the safety of the nanoparticle delivery system is 
critical for the final use of the system in biological systems and others. It involves analysis of the 
complex interactions between the nanoparticles and the cellular environment, and the mechanism 
involved in the delivery of the antioxidant/vitamin at the site of action. The antioxidant 




when it is part of a nanoparticle structure, to insure the safety of the materials for food or drug 
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APPENDIX B: SAS PROGRAMS AND OUTPUTS  
 
SAS program for salt concentration in EC and Span 80 nanostructures. Two salts 
(Sodium chloride and sodium bicarbonate), six salt concentrations (0, 1.5, 7.3, 15, 33, and 99 
mM), two surfactants (EC and Span80), triplicate data, and two independent experiments were 
evaluated with the following program. 
dm 'log;clear;output;clear'; 
OPTIONS nodate nocenter pageno=1 ls=161 ps=512; 
Title1 'Nanoparticle size with Span 80 and EC as surfactants'; 
Title2 'Carlos E. Astete'; 
ODS HTML style=minimal body='C:\Documents and Settings\Margarita\My Documents\Carlos\Dissertation for 
PhD\EC\EC Data for SAS\Analysis01.html'; 
DATA EC; infile cards missover; 
input OBS Su Sa Co Rep Exp Size PI; 
cards; RUN; 
1  1 1 1 1 1 26.15  0.492 
2  1 1 1 2 1 27.13  0.502 
3  1 1 1 3 1 27.83  0.378 
4  1 1 2 1 1 21.02  0.203 
5  1 1 2 2 1 20.9  0.204 
6  1 1 2 3 1 20.9  0.199 
7  1 1 3 1 1 29.93  0.161 
8  1 1 3 2 1 29.77  0.175 
9  1 1 3 3 1 29.46  0.172 
10  1 1 4 1 1 67.71  0.238 
11  1 1 4 2 1 67.71  0.24 
12  1 1 4 3 1 67.07  0.247 
13  1 1 5 1 1 82.48  0.254 
14  1 1 5 2 1 82.36  0.252 
15  1 1 5 3 1 81.51  0.261 
16  1 1 6 1 1 153.8  0.148 
17  1 1 6 2 1 153.1  0.16 
18  1 1 6 3 1 154.1  0.146 
19  1 2 1 1 1 26.15  0.492 
20  1 2 1 2 1 27.13  0.502 
21  1 2 1 3 1 27.82  0.378 
22  1 2 2 1 1 23.98  0.661 
23  1 2 2 2 1 22.99  0.712 
24  1 2 2 3 1 23.17  0.713 
25  1 2 3 1 1 16.68  0.411 
26  1 2 3 2 1 17.17  0.427 
27  1 2 3 3 1 16.44  0.472 
28  1 2 4 1 1 10.74  0.28 
29  1 2 4 2 1 10.76  0.275 
30  1 2 4 3 1 10.6  0.252 
31  1 2 5 1 1 16.99  0.46 
32  1 2 5 2 1 17.36  0.465 
33  1 2 5 3 1 17.37  0.464 
34  1 2 6 1 1 24.14  0.629 
35  1 2 6 2 1 25.87  0.486 




37  2 1 1 1 1 134.6  0.118 
38  2 1 1 2 1 135.3  0.122 
39  2 1 1 3 1 134.1  0.098 
40  2 1 2 1 1 160.1  0.022 
41  2 1 2 2 1 159.0  0.028 
42  2 1 2 3 1 153.9  0.074 
43  2 1 3 1 1 180.3  0.055 
44  2 1 3 2 1 184.0  0.124 
45  2 1 3 3 1 180.9  0.119 
46  2 1 4 1 1 225.3  0.209 
47  2 1 4 2 1 215.6  0.179 
48  2 1 4 3 1 226.5  0.206 
49  2 1 5 1 1 446.5  0.092 
50  2 1 5 2 1 439.7  0.127 
51  2 1 5 3 1 438.2  0.093 
52  2 1 6 1 1 .  . 
53  2 1 6 2 1 .  . 
54  2 1 6 3 1 .  . 
55  2 2 1 1 1 134.6  0.118 
56  2 2 1 2 1 135.3  0.122 
57  2 2 1 3 1 134.1  0.098 
58  2 2 2 1 1 157.0  0.09 
59  2 2 2 2 1 156.6  0.111 
60  2 2 2 3 1 156.9  0.066 
61  2 2 3 1 1 173.4  0.092 
62  2 2 3 2 1 173.9  0.092 
63  2 2 3 3 1 174.3  0.084 
64  2 2 4 1 1 170.6  0.108 
65  2 2 4 2 1 167.1  0.098 
66  2 2 4 3 1 163.0  0.098 
67  2 2 5 1 1 166.8  0.087 
68  2 2 5 2 1 170.0  0.101 
69  2 2 5 3 1 171.5  0.085 
70  2 2 6 1 1 184.5  0.101 
71  2 2 6 2 1 182.9  0.092 
72  2 2 6 3 1 182.7  0.102 
73  1 1 1 1 2 22.99  0.411 
74  1 1 1 2 2 23.46  0.394 
75  1 1 1 3 2 22.1  0.337 
76  1 1 2 1 2 24.08  0.332 
77  1 1 2 2 2 23.13  0.337 
78  1 1 2 3 2 22.07  0.326 
79  1 1 3 1 2 24.16  0.174 
80  1 1 3 2 2 24.17  0.198 
81  1 1 3 3 2 24.22  0.177 
82  1 1 4 1 2 44.52  0.235 
83  1 1 4 2 2 44.44  0.25 
84  1 1 4 3 2 45.16  0.242 
85  1 1 5 1 2 82.76  0.28 
86  1 1 5 2 2 84.39  0.264 
87  1 1 5 3 2 82.49  0.251 
88  1 1 6 1 2 122.5  0.202 
89  1 1 6 2 2 121.5  0.177 
90  1 1 6 3 2 121.9  0.214 
91  1 2 1 1 2 22.99  0.411 
92  1 2 1 2 2 23.46  0.394 




94  1 2 2 1 2 26.15  0.456 
95  1 2 2 2 2 29.4  0.412 
96  1 2 2 3 2 23.57  0.498 
97  1 2 3 1 2 18.06  0.384 
98  1 2 3 2 2 14.56  0.356 
99  1 2 3 3 2 13.56  0.308 
100  1 2 4 1 2 10.68  0.241 
101  1 2 4 2 2 12.11  0.204 
102  1 2 4 3 2 14.77  0.237 
103  1 2 5 1 2 23.76  0.397 
104  1 2 5 2 2 24.56  0.423 
105  1 2 5 3 2 21.09  0.405 
106  1 2 6 1 2 38.07  0.498 
107  1 2 6 2 2 31.06  0.533 
108  1 2 6 3 2 40.21  0.51 
109  2 1 1 1 2 137.2  0.092 
110  2 1 1 2 2 137.3  0.106 
111  2 1 1 3 2 137.1  0.088 
112  2 1 2 1 2 153.5  0.045 
113  2 1 2 2 2 148.9  0.075 
114  2 1 2 3 2 155.4  0.069 
115  2 1 3 1 2 180.0  0.02 
116  2 1 3 2 2 176.6  0.042 
117  2 1 3 3 2 179.5  0.041 
118  2 1 4 1 2 216.3  0.15 
119  2 1 4 2 2 253.6  0.055 
120  2 1 4 3 2 249.6  0.062 
121  2 1 5 1 2 481.7  0.084 
122  2 1 5 2 2 475.3  0.063 
123  2 1 5 3 2 478.0  0.089 
124  2 1 6 1 2 .  . 
125  2 1 6 2 2 .  . 
126  2 1 6 3 2 .  . 
127  2 2 1 1 2 137.2  0.092 
128  2 2 1 2 2 137.3  0.106 
129  2 2 1 3 2 137.1  0.088 
130  2 2 2 1 2 157.3  0.081 
131  2 2 2 2 2 158.7  0.081 
132  2 2 2 3 2 157.9  0.091 
133  2 2 3 1 2 171.7  0.07 
134  2 2 3 2 2 172.5  0.059 
135  2 2 3 3 2 169.8  0.087 
136  2 2 4 1 2 158.2  0.085 
137  2 2 4 2 2 158.8  0.072 
138  2 2 4 3 2 157.7  0.066 
139  2 2 5 1 2 167.3  0.112 
140  2 2 5 2 2 166.9  0.093 
141  2 2 5 3 2 167.4  0.084 
142  2 2 6 1 2 180.2  0.1 
143  2 2 6 2 2 179.1  0.091 
144  2 2 6 3 2 177.4  0.117 
; 
Proc print data=EC; 
title3 'raw data set'; 
run; 
PROC CONTENTS data=EC; 





proc mixed data=EC CL method=type3; 
 classes Su Sa Co Rep Exp ; 
 Title3 'Two way ANOVA with PROC mixed for nanoparticle size (salt effect)'; 
 MODEL Size = Su Sa Co Su*Sa / htype=3 DDFM=Satterthwaite OUTp=res ; 
 Random exp Exp*Su*Sa*Co;  
 lsmeans Su Sa Co Su*Sa / pdiff adjust=tukey cl; 
  ods output diffs=ppp lsmeans=mmm; 
        ods listing exclude diffs; 
RUN; 
 TITLE4 'Post hoc adjustment with macro by Arnold Saxton For nanoparticle size (Salt effect)'; 
 * SAS Macro by Arnold Saxton: Saxton, A.M. 1998. A macro for ; 
     * converting mean separation output to letter groupings in Proc Mixed. ; 
     * In Proc. 23rd SAS Users Group Intl., SAS Inst., Cary, NC, pp1243-246.; 
   %include 'C:\Documents and Settings\Margarita\My Documents\Carlos\SAS\pdmix800.sas'; 
   %pdmix800(ppp,mmm,alpha=0.05,sort=yes); 
run; 
proc print data=mmm; run; 
data new1; set mmm; if effect = 'Su*Sa'; run; 
OPTIONS ls=132 ps=52; 
proc plot data=new1; plot estimate*sa=su;  
run; 
OPTIONS ls=161 ps=512; 
proc univariate data=res normal plot;  var resid; 
title1 'Univariate Normality of Residuals for Size'; 
title2 'Carlos E data analysis'; 
run; 
proc mixed data=EC CL;* method=type3; 
 classes Su Sa Co Rep Exp ; 
     Title3 'Two way ANOVA with PROC mixed for nanoparticle size (Salt effect)'; 
    MODEL Size = Su | Sa | Co @2 / htype=3 DDFM=Satterthwaite OUTp=res ; 
  Random exp Exp*Su*Sa*Co;  
  lsmeans Su | Sa | Co @2 / pdiff adjust=tukey; 
     ods output diffs=ppp lsmeans=mmm; 
        ods listing exclude diffs;* lsmeans; 
RUN; 
 TITLE4 'Post hoc adjustment with macro by Arnold Saxton For nanoparticle size'; 
 * SAS Macro by Arnold Saxton: Saxton, A.M. 1998. A macro for ; 
 * converting mean separation output to letter groupings in Proc Mixed. ; 
 * In Proc. 23rd SAS Users Group Intl., SAS Inst., Cary, NC, pp1243-246.; 
 %include 'C:\Documents and Settings\Margarita\My Documents\Carlos\SAS\pdmix800.sas'; 
  %pdmix800(ppp,mmm,alpha=0.05,sort=yes); 
run; 
proc univariate data=res normal plot;  var resid; 
title1 'Univariate Normality of Residuals for Size (Salt effect)'; 
title2 'Carlos E data analysis'; 
run; 
proc mixed data=EC CL;* method=type3; 
 classes Su Sa Co Rep Exp ; 
     Title3 'Two way ANOVA with PROC mixed for nanoparticle size'; 
    MODEL PI = Su | Sa | Co @2 / htype=3 DDFM=Satterthwaite OUTp=res1 ; 
  Random exp Exp*Su*Sa*Co;  
  lsmeans Su | Sa | Co @2 / pdiff adjust=tukey; 
     ods output diffs=ppp lsmeans=mmm; 





 TITLE4 'Post hoc adjustment with macro by Arnold Saxton For nanoparticle size'; 
 * SAS Macro by Arnold Saxton: Saxton, A.M. 1998. A macro for ; 
 * converting mean separation output to letter groupings in Proc Mixed. ; 
 * In Proc. 23rd SAS Users Group Intl., SAS Inst., Cary, NC, pp1243-246.; 
 %include 'C:\Documents and Settings\Margarita\My Documents\Carlos\\SAS\pdmix800.sas'; 
  *%include 'C:\pdmix800.sas'; 
  %pdmix800(ppp,mmm,alpha=0.05,sort=yes); 
run; 
proc univariate data=res1 normal plot;  var resid; 
title1 'Univariate Normality of Residuals for PI (Salt effect)'; 
title2 'Carlos E data analysis'; 
run; 
quit; 
ODS HTML close;  
 
The group estimation in SAS output: 
Univariate Normality of Residuals for Size  
Carlos E data analysis 
Two way ANOVA with PROC mixed for nanoparticle size (Salt effect) 
Post hoc adjustment with macro by Arnold Saxton For nanoparticle size 
 
Effect=Su Method=Tukey-Kramer(P<0.05) Set=1 
Obs Su Sa Co Estimate Standard Error Letter 
Group 
1 2 _ _ 206.54 6.9031 A 
2 1 _ _ 39.9213 5.8342 B 
 
Effect=Sa Method=Tukey-Kramer(P<0.05) Set=2 
Obs Su Sa Co Estimate Standard Error Letter 
Group 
3 _ 1 _ 154.25 6.9031 A 
4 _ 2 _ 92.2092 5.8342 B 
 
Effect=Su*Sa Method=Tukey-Kramer(P<0.05) Set=3 
Obs Su Sa Co Estimate Standard Error Letter 
Group 
5 2 1 _ 250.09 11.0696 A 




7 1 1 _ 58.4158 8.2508 C 
8 1 2 _ 21.4267 8.2508 D 
 
Effect=Co Method=Tukey-Kramer(P<0.05) Set=4 
Obs Su Sa Co Estimate Standard Error Letter 
Group 
9 _ _ 5 182.77 10.1051 A 
10 _ _ 6 172.00 14.9883 A 
11 _ _ 4 115.36 10.1051 B 
12 _ _ 3 98.9617 10.1051 B 
13 _ _ 2 89.8567 10.1051 B 
14 _ _ 1 80.4379 10.1051 B 
 
Effect=Su*Co Method=Tukey-Kramer(P<0.05) Set=5 
Obs Su Sa Co Estimate Standard Error Letter Group 
15 2 _ 5 314.11 14.2908 A 
16 2 _ 6 259.66 26.3509 AB 
17 2 _ 4 196.86 14.2908 BC 
18 2 _ 3 176.41 14.2908 BC 
19 2 _ 2 156.27 14.2908 BCD 
20 2 _ 1 135.93 14.2908 CD 
21 1 _ 6 84.3408 14.2908 DE 
22 1 _ 5 51.4267 14.2908 E 
23 1 _ 4 33.8558 14.2908 E 
24 1 _ 1 24.9425 14.2908 E 




26 1 _ 3 21.5150 14.2908 E 
 
Effect=Sa*Co Method=Tukey-Kramer(P<0.05) Set=6 
Obs Su Sa Co Estimate Standard Error Letter 
Group 
27 _ 1 5 271.28 14.2908 A 
28 _ 1 6 238.00 26.3509 AB 
29 _ 1 4 143.63 14.2908 BC 
30 _ 2 6 106.00 14.2908 C 
31 _ 1 3 103.58 14.2908 C 
32 _ 2 3 94.3392 14.2908 C 
33 _ 2 5 94.2525 14.2908 C 
34 _ 2 2 91.1383 14.2908 C 
35 _ 1 2 88.5750 14.2908 C 
36 _ 2 4 87.0883 14.2908 C 
37 _ 1 1 80.4383 14.2908 C 
38 _ 2 1 80.4375 14.2908 C 
 
 
Univariate Normality of Residuals for Size (Salt effect) 
Carlos E data analysis 
The UNIVARIATE Procedure 
Variable: Resid (Residual) 
Moments 
N 138 Sum Weights 138 
Mean 0 Sum Observations 0 




Skewness -2.8309443 Kurtosis 33.179654 
Uncorrected SS 1187.94354 Corrected SS 1187.94354 
Coeff Variation . Std Error Mean 0.25066753 
 
Basic Statistical Measures 
Location Variability 
Mean 0.000000 Std Deviation 2.94468 
Median 0.036524 Variance 8.67112 
Mode 0.019455 Range 37.30000 
    Interquartile Range 1.07922 
 
 The mode displayed is the smallest of 2 modes with a count of 2. 
 
Tests for Location: Mu0=0 
Test Statistic p Value 
Student's t t 0 Pr > |t| 1.0000 
Sign M 7 Pr >= |M| 0.2684 
Signed Rank S 273.5 Pr >= |S| 0.5630 
 
Tests for Normality 
Test Statistic p Value 
Shapiro-Wilk W 0.61122 Pr < W <0.0001 
Kolmogorov-Smirnov D 0.235058 Pr > D <0.0100 
Cramer-von Mises W-Sq 2.667671 Pr > W-Sq <0.0050 





Quantiles (Definition 5) 
Quantile Estimate 




75% Q3 0.5573031 
50% Median 0.0365239 








Value Obs Value Obs 
-23.52187 118 3.79270 108 
-6.94656 47 3.95344 48 
-5.35730 107 5.17178 49 
-3.84299 66 9.77813 120 








Count Percent Of 
All Obs Missing Obs 
. 6 4.17 100.00 
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Univariate Normality of Residuals for PI (Salt effect) 
Carlos E data analysis 
Two way ANOVA with PROC mixed for nanoparticle PI 
Post hoc adjustment with macro by Arnold Saxton For nanoparticle size 
 
Effect=Su Method=Tukey-Kramer(P<0.05) Set=1 
Obs Su Sa Co Estimate Standard Error Letter 
Group 
1 1 _ _ 0.3445 0.01604 A 
2 2 _ _ 0.07536 0.01748 B 
 
Effect=Sa Method=Tukey-Kramer(P<0.05) Set=2 
Obs Su Sa Co Estimate Standard Error Letter 
Group 




Obs Su Sa Co Estimate Standard Error Letter 
Group 
4 _ 1 _ 0.1575 0.01748 B 
 
Effect=Su*Sa Method=Tukey-Kramer(P<0.05) Set=3 
Obs Su Sa Co Estimate Standard Error Letter 
Group 
5 1 2 _ 0.4326 0.01944 A 
6 1 1 _ 0.2565 0.01944 B 
7 2 2 _ 0.09222 0.01944 C 
8 2 1 _ 0.05851 0.02390 C 
 
Effect=Co Method=Tukey-Kramer(P<0.05) Set=4 
Obs Su Sa Co Estimate Standard Error Letter 
Group 
9 _ _ 1 0.2615 0.02233 A 
10 _ _ 2 0.2453 0.02233 A 
11 _ _ 5 0.2203 0.02233 A 
12 _ _ 4 0.1804 0.02233 A 
13 _ _ 3 0.1792 0.02233 A 
14 _ _ 6 0.1731 0.03055 A 
 
Effect=Su*Co Method=Tukey-Kramer(P<0.05) Set=5 
Obs Su Sa Co Estimate Standard Error Letter Group 
15 1 _ 2 0.4211 0.02934 A 
16 1 _ 1 0.4190 0.02934 AB 




Obs Su Sa Co Estimate Standard Error Letter Group 
18 1 _ 5 0.3480 0.02934 ABC 
19 1 _ 3 0.2846 0.02934 BC 
20 1 _ 4 0.2451 0.02934 CD 
21 2 _ 4 0.1157 0.02934 DE 
22 2 _ 1 0.1040 0.02934 E 
23 2 _ 5 0.09250 0.02934 E 
24 2 _ 3 0.07375 0.02934 E 
25 2 _ 2 0.06942 0.02934 E 
26 2 _ 6 -0.00315 0.05098 E 
 
Effect=Sa*Co Method=Tukey-Kramer(P<0.05) Set=6 
Obs Su Sa Co Estimate Standard Error Letter Group 
27 _ 2 2 0.3310 0.02934 A 
28 _ 2 6 0.3123 0.02934 AB 
29 _ 2 5 0.2647 0.02934 ABC 
30 _ 1 1 0.2615 0.02934 ABC 
31 _ 2 1 0.2615 0.02934 ABC 
32 _ 2 3 0.2368 0.02934 ABCD 
33 _ 1 4 0.1928 0.02934 BCDE 
34 _ 1 5 0.1758 0.02934 CDE 
35 _ 2 4 0.1680 0.02934 CDE 
36 _ 1 2 0.1595 0.02934 CDE 
37 _ 1 3 0.1215 0.02934 DE 





Univariate Normality of Residuals for PI (Salt effect) 
Carlos E data analysis 
The UNIVARIATE Procedure 
Variable: Resid (Residual) 
Moments 
N 138 Sum Weights 138 
Mean 0 Sum Observations 0 
Std Deviation 0.02280139 Variance 0.0005199 
Skewness -0.0562427 Kurtosis 3.2184454 
Uncorrected SS 0.07122677 Corrected SS 0.07122677 
Coeff Variation . Std Error Mean 0.00194098 
 
Basic Statistical Measures 
Location Variability 
Mean 0.00000 Std Deviation 0.02280 
Median -0.00060 Variance 0.0005199 
Mode -0.00556 Range 0.17434 
    Interquartile Range 0.02098 
 
 The mode displayed is the smallest of 3 modes with a count of 2. 
 
Tests for Location: Mu0=0 
Test Statistic p Value 
Student's t t 0 Pr > |t| 1.0000 
Sign M -3 Pr >= |M| 0.6705 





Tests for Normality 
Test Statistic p Value 
Shapiro-Wilk W 0.941515 Pr < W <0.0001 
Kolmogorov-Smirnov D 0.105816 Pr > D <0.0100 
Cramer-von Mises W-Sq 0.426112 Pr > W-Sq <0.0050 
Anderson-Darling A-Sq 2.461663 Pr > A-Sq <0.0050 
 
Quantiles (Definition 5) 
Quantile Estimate 




75% Q3 0.010643447 
50% Median -0.000602756 








Value Obs Value Obs 






Value Obs Value Obs 
-0.0737480 3 0.0440640 20 
-0.0500633 95 0.0502520 2 
-0.0492520 93 0.0553531 118 





Count Percent Of 
All Obs Missing Obs 
. 6 4.17 100.00 
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SAS program for effect of surfactant type and concentration. Two surfactants (EC and 
Span 80) dissolved in pure water (Span 80) or sodium bicarbonate (15 mM) or acetic acid 
solution 200 (mM) for EC, and 10 different surfactant concentrations (0, 1.5, 7.3, 15, 33, and 99 





OPTIONS nodate nocenter pageno=1 ls=161 ps=512; 
Title1 'Nanoparticle size of EC and Span 80 at different concentrations'; 
Title2 'Carlos E. Astete'; 
ODS HTML style=minimal body='C:\Documents and Settings\Margarita\My Documents\Carlos\Dissertation for 
PhD\EC\EC Data for SAS\Analysis04.html'; 
DATA EC2; infile cards missover; 
input obs Su Sa Co Rep Size PI; 
cards; RUN; 
1  1 1 1 1 .  . 
2  1 1 1 2  . . 
3  1 1 1 3 .  . 
4  1 1 2 1 .  . 
5  1 1 2 2 .  . 
6  1 1 2 3 .  . 
7  1 1 3 1 143.0  0.06 
8  1 1 3 2 125.2  0.074 
9  1 1 3 3 139.1  0.088 
10  1 1 4 1 .  . 
11  1 1 4 2 .  . 
12  1 1 4 3 .  . 
13  1 1 5 1 149.3  0.058 
14  1 1 5 2 145.4  0.079 
15  1 1 5 3 141.1  0.086 
16  1 1 6 1 .  . 
17  1 1 6 2 .  . 
18  1 1 6 3 .  . 
19  1 1 7 1 161.9  0.059 
20  1 1 7 2 159.2  0.092 
21  1 1 7 3 155.4  0.118 
22  1 1 8 1 .  . 
23  1 1 8 2 .  . 
24  1 1 8 3 .  . 
25  1 1 9 1 171.5  0.083 
26  1 1 9 2 185.5  0.09 
27  1 1 9 3 174.3  0.095 
28  1 1 10 1 207.8  0.159 
29  1 1 10 2 200.4  0.169 
30  1 1 10 3 204.5  0.15 
31  2 2 1 1 65.76  0.383 
32  2 2 1 2 71.63  0.35 
33  2 2 1 3 64.15  0.367 
34  2 2 2 1 25.13  0.281 
35  2 2 2 2 22.1  0.298 
36  2 2 2 3 24.55  0.273 
37  2 2 3 1 25.53  0.145 
38  2 2 3 2 28.97  0.138 
39  2 2 3 3 25.93  0.159 
40  2 2 4 1 33.04  0.185 
41  2 2 4 2 30.46  0.191 
42  2 2 4 3 32.39   0.169 
43  2 2 5 1 45.8  0.178 
44  2 2 5 2 41.23  0.159 
45  2 2 5 3 46.52  0.177 
46  2 2 6 1 52.24  0.202 
47  2 2 6 2 49.25  0.181 




49  2 2 7 1 60.13  0.17 
50  2 2 7 2 66.38  0.176 
51  2 2 7 3 60.26  0.167 
52  2 2 8 1 .  . 
53  2 2 8 2 .  . 
54  2 2 8 3 .  . 
55  2 2 9 1 376.4  0.869 
56  2 2 9 2 435.2  0.605 
57  2 2 9 3 458.5  0.643 
58  2 2 10 1 .  . 
59  2 2 10 2 .  . 
60  2 2 10 3 .  . 
61  2 3 1 1 .  . 
62  2 3 1 2 .  . 
63  2 3 1 3 .  . 
64  2 3 2 1 .  . 
65  2 3 2 2 .  . 
66  2 3 2 3 .  . 
67  2 3 3 1 36.43  0.498 
68  2 3 3 2 37.06  0.506 
69  2 3 3 3 41.77  0.576 
70  2 3 4 1 .  . 
71  2 3 4 2 .  . 
72  2 3 4 3 .  . 
73  2 3 5 1 16.45  0.315 
74  2 3 5 2 23.49  0.328 
75  2 3 5 3 18.01  0.301 
76  2 3 6 1 .  . 
77  2 3 6 2 .  . 
78  2 3 6 3 .  . 
79  2 3 7 1 18.51  0.255 
80  2 3 7 2 15.17  0.264 
81  2 3 7 3 19.11  0.241 
82  2 3 8 1 19.36  0.328 
83  2 3 8 2 24.56  0.293 
84  2 3 8 3 22.17  0.395 
85  2 3 9 1 39.73  0.344 
86  2 3 9 2 29.69  0.278 
87  2 3 9 3 35.21  0.276 
88  2 3 10 1 .  . 
89  2 3 10 2 .  . 
90  2 3 10 3 .  . 
; 
Proc print data=EC2; 
title3 'raw data set'; 
run; 
PROC CONTENTS data=EC2; 
   Title3 'Proc CONTENTS of data set EC'; 
RUN; 
proc mixed data=EC2 CL method=type3; 
classes Sa Co Rep; 
Title3 'Two way ANOVA with PROC mixed for Nanoparticle size of EC and Span 80 at different concentrations'; 
 MODEL Size = Sa Co Sa*Co/ htype=3 DDFM=Satterthwaite OUTp=res ; 
 Random  rep;  
 lsmeans Sa Co Sa*Co/ pdiff adjust=tukey cl; 




        ods listing exclude diffs; 
RUN; 
TITLE4 'Post hoc adjustment with macro by Arnold Saxton for Nanoparticle size of EC and Span 80 at different 
concentrations'; 
  * SAS Macro by Arnold Saxton: Saxton, A.M. 1998. A macro for ; 
     * converting mean separation output to letter groupings in Proc Mixed. ; 
     * In Proc. 23rd SAS Users Group Intl., SAS Inst., Cary, NC, pp1243-246.; 
   %include 'C:\Documents and Settings\Margarita\My Documents\Carlos\SAS\pdmix800.sas'; 
   %pdmix800(ppp,mmm,alpha=0.05,sort=yes); 
run; 
proc print data=mmm; run; 
data new1; set mmm; if effect = 'Sa*Co'; run; 
OPTIONS ls=132 ps=52; 
proc plot data=new1; plot estimate*Co=Sa;  
run; 
OPTIONS ls=161 ps=512; 
proc univariate data=res normal plot;  var resid; 
title1 'Univariate Normality of Residuals for Nanoparticle size (III) of EC and Span 80 at different concentrations'; 
title2 'Carlos E data analysis'; 
run; 
proc mixed data=EC2 CL;* method=type3; 
classes Sa Co Rep ; 
Title3 'Two way ANOVA with PROC mixed for Nanoparticle size (III) of EC and Span 80 at different 
concentrations'; 
MODEL Size =  Sa | Co @2 / htype=3 DDFM=Satterthwaite OUTp=res ; 
 Random  Sa*Co;  
 lsmeans Sa | Co | Sa*Co @2 / pdiff adjust=tukey; 
 ods output diffs=ppp lsmeans=mmm; 
 ods listing exclude diffs;* lsmeans; 
RUN; 
TITLE4 'Post hoc adjustment with macro by Arnold Saxton for Nanoparticle size (III) of EC and Span 80 at 
different concentrations'; 
 * SAS Macro by Arnold Saxton: Saxton, A.M. 1998. A macro for ; 
 * converting mean separation output to letter groupings in Proc Mixed. ; 
 * In Proc. 23rd SAS Users Group Intl., SAS Inst., Cary, NC, pp1243-246.; 
 %include 'C:\Documents and Settings\Margarita\My Documents\Carlos\SAS\pdmix800.sas'; 
  %pdmix800(ppp,mmm,alpha=0.05,sort=yes); 
run; 
proc univariate data=res normal plot;  var resid; 
title1 'Univariate Normality of Residuals for Nanoparticle size (III)of EC and Span 80 at different concentrations'; 
title2 'Carlos E data analysis'; 
run; 
proc mixed data=EC2 CL;* method=type3; 
classes Sa Co Rep ; 
Title3 'Two way ANOVA with PROC mixed for Nanoparticle PI of EC and Span 80 at different concentrations'; 
MODEL PI =  Sa | Co @2 / htype=3 DDFM=Satterthwaite OUTp=res1 ; 
 Random  Sa*Co;  
 lsmeans  Sa | Co @2 / pdiff adjust=tukey; 
 ods output diffs=ppp lsmeans=mmm; 
 ods listing exclude diffs; 
RUN; 
TITLE4 'Post hoc adjustment with macro by Arnold Saxton for Nanoparticle size of EC and Span 80 at different 
concentrations'; 
 * SAS Macro by Arnold Saxton: Saxton, A.M. 1998. A macro for ; 
 * converting mean separation output to letter groupings in Proc Mixed. ; 




 %include 'C:\Documents and Settings\Margarita\My Documents\Carlos\SAS\pdmix800.sas'; 
  *%include 'C:\pdmix800.sas'; 
  %pdmix800(ppp,mmm,alpha=0.05,sort=yes); 
run; 
proc univariate data=res1 normal plot;  var resid; 
title1 'Univariate Normality of Residuals for Nanoparticle PI of EC and Span 80 at different concentrations'; 
title2 'Carlos E data analysis'; 
run; 
quit; 
ODS HTML close; 
 An important SAS output: 
Univariate Normality of Residuals for Nanoparticle size (III) of EC and Span 80 at different 
concentrations 
Carlos E data analysis 
Two way ANOVA with PROC mixed for Nanoparticle size (III) of EC and Span 80 at different 
concentrations 
Post hoc adjustment with macro by Arnold Saxton for Nanoparticle size (III) of EC and Span 80 
at different concentrations 
 
Effect=Sa Method=LSD(P<0.05) Set=1 
Obs Sa Co Estimate Standard Error Letter 
Group 
1 1 _ . .   
2 2 _ . .   
3 3 _ . .   
 
Effect=Co Method=LSD(P<0.05) Set=2 
Obs Sa Co Estimate Standard Error Letter Group 
4 _ 9 211.78 3.5859 ABC 
5 _ 7 79.5622 3.5859 DEF 
6 _ 5 69.7000 3.5859 DEF 
7 _ 3 66.9989 3.5859 DEF 
8 _ 1 . .   
9 _ 2 . .   




Obs Sa Co Estimate Standard Error Letter Group 
11 _ 6 . .   
12 _ 8 . .   
13 _ 10 . .   
 
Effect=Sa*Co Method=Tukey(P<0.05) Set=3 
Obs Sa Co Estimate Standard Error Letter Group 
14 2 9 423.37 6.2110 A 
15 1 10 204.23 6.2110 B 
16 1 9 177.10 6.2110 BC 
17 1 7 158.83 6.2110 CD 
18 1 5 145.27 6.2110 CD 
19 1 3 135.77 6.2110 D 
20 2 1 67.1800 6.2110 E 
21 2 7 62.2567 6.2110 EF 
22 2 6 49.5967 6.2110 EFG 
23 2 5 44.5167 6.2110 EFG 
24 3 3 38.4200 6.2110 EFG 
25 3 9 34.8767 6.2110 EFG 
26 2 4 31.9633 6.2110 FG 
27 2 3 26.8100 6.2110 G 
28 2 2 23.9267 6.2110 G 
29 3 8 22.0300 6.2110 G 
30 3 5 19.3167 6.2110 G 






Univariate Normality of Residuals for Nanoparticle size (III)of EC and Span 80 at different 
concentrations 
Carlos E data analysis 
 
The UNIVARIATE Procedure 
Variable: Resid (Residual) 
Moments 
N 54 Sum Weights 54 
Mean 0 Sum Observations 0 
Std Deviation 8.86615982 Variance 78.6087899 
Skewness -1.6544175 Kurtosis 18.8256203 
Uncorrected SS 4166.26587 Corrected SS 4166.26587 
Coeff Variation . Std Error Mean 1.20653153 
 
Basic Statistical Measures 
Location Variability 
Mean 0.000000 Std Deviation 8.86616 
Median 0.203333 Variance 78.60879 
Mode . Range 82.10000 
    Interquartile Range 4.94000 
 
Tests for Location: Mu0=0 
Test Statistic p Value 
Student's t t 0 Pr > |t| 1.0000 
Sign M 2 Pr >= |M| 0.6835 





Tests for Normality 
Test Statistic p Value 
Shapiro-Wilk W 0.622006 Pr < W <0.0001 
Kolmogorov-Smirnov D 0.245121 Pr > D <0.0100 
Cramer-von Mises W-Sq 0.99747 Pr > W-Sq <0.0050 
Anderson-Darling A-Sq 5.678334 Pr > A-Sq <0.0050 
 
Quantiles (Definition 5) 
Quantile Estimate 




75% Q3 2.643333 
50% Median 0.203333 








Value Obs Value Obs 






Value Obs Value Obs 
-10.56667 8 7.23333 7 
-5.60000 25 8.40000 26 
-5.18667 86 11.83333 56 





Count Percent Of 
All Obs Missing Obs 
. 36 40.00 100.00 
 
Univariate Normality of Residuals for Nanoparticle size (III)of EC and Span 80 at different 
concentrations 
Carlos E data analysis 
Two way ANOVA with PROC mixed for Nanoparticle PI of EC and Span 80 at different 
concentrations 
Post hoc adjustment with macro by Arnold Saxton for Nanoparticle size of EC and Span 80 at 
different concentrations 
 
Effect=Sa Method=LSD(P<0.05) Set=1 
Obs Sa Co Estimate Standard Error Letter 
Group 
1 1 _ . .   
2 2 _ . .   
3 3 _ . .   
 




Obs Sa Co Estimate Standard Error Letter Group 
4 _ 9 0.3648 0.01339 ABC 
5 _ 3 0.2493 0.01339 DEF 
6 _ 5 0.1868 0.01339 GHI 
7 _ 7 0.1713 0.01339 GHI 
8 _ 1 . .   
9 _ 2 . .   
10 _ 4 . .   
11 _ 6 . .   
12 _ 8 . .   
13 _ 10 . .   
 
Effect=Sa*Co Method=Tukey(P<0.05) Set=3 
Obs Sa Co Estimate Standard Error Letter Group 
14 2 9 0.7057 0.02319 A 
15 3 3 0.5267 0.02319 B 
16 2 1 0.3667 0.02319 C 
17 3 8 0.3387 0.02319 C 
18 3 5 0.3147 0.02319 C 
19 3 9 0.2993 0.02319 CD 
20 2 2 0.2840 0.02319 CDE 
21 3 7 0.2533 0.02319 CDEF 
22 2 6 0.1907 0.02319 DEFG 
23 2 4 0.1817 0.02319 DEFG 




Obs Sa Co Estimate Standard Error Letter Group 
25 2 7 0.1710 0.02319 EFG 
26 1 10 0.1593 0.02319 FG 
27 2 3 0.1473 0.02319 FG 
28 1 7 0.08967 0.02319 G 
29 1 9 0.08933 0.02319 G 
30 1 5 0.07433 0.02319 G 
31 1 3 0.07400 0.02319 G 
 
 
Univariate Normality of Residuals for Nanoparticle PI of EC and Span 80 at different 
concentrations 
Carlos E data analysis 
 
The UNIVARIATE Procedure 
Variable: Resid (Residual) 
Moments 
N 54 Sum Weights 54 
Mean 0 Sum Observations 0 
Std Deviation 0.0331076 Variance 0.00109611 
Skewness 1.79155778 Kurtosis 11.9060104 
Uncorrected SS 0.058094 Corrected SS 0.058094 
Coeff Variation . Std Error Mean 0.00450537 
 
Basic Statistical Measures 
Location Variability 
Mean 0.00000 Std Deviation 0.03311 




Basic Statistical Measures 
Location Variability 
Mode . Range 0.26400 
    Interquartile Range 0.02200 
 
Tests for Location: Mu0=0 
Test Statistic p Value 
Student's t t 0 Pr > |t| 1.0000 
Sign M -1 Pr >= |M| 0.8919 
Signed Rank S -67 Pr >= |S| 0.5689 
 
Tests for Normality 
Test Statistic p Value 
Shapiro-Wilk W 0.771385 Pr < W <0.0001 
Kolmogorov-Smirnov D 0.225086 Pr > D <0.0100 
Cramer-von Mises W-Sq 0.62033 Pr > W-Sq <0.0050 
Anderson-Darling A-Sq 3.42766 Pr > A-Sq <0.0050 
 
Quantiles (Definition 5) 
Quantile Estimate 








Quantiles (Definition 5) 
Quantile Estimate 
50% Median -0.000166667 








Value Obs Value Obs 
-0.1006667 56 0.0283333 21 
-0.0626667 57 0.0446667 85 
-0.0456667 83 0.0493333 69 
-0.0306667 19 0.0563333 84 





Count Percent Of 
All Obs Missing Obs 








SAS program for PLGA nanoparticles synthesized with EC and Span 80 surfactants. The 
effect of PLGA/surfactant ratio was evaluated by using four concentration/ratios (0, 40%, 80%, 
and 120% w/w ratio of PLGA/surfactant). The surfactant mass was fixed at 1 mg/ml. The 
aqueous solution was with sodium bicarbonate 15 mM. The data was in triplicate with four 
independent samples (experiments).  
dm 'log;clear;output;clear'; 
OPTIONS nodate nocenter pageno=1 ls=96 ps=512; 
Title1 'PLGA Nanoparticle size with Span 80 and EC as surfactants'; 
Title2 'Carlos E. Astete'; 
ODS HTML style=minimal body='C:\Documents and Settings\Margarita\My Documents\Carlos\Dissertation for 
PhD\EC\EC Data for SAS\Analysis02.html'; 
DATA ECP; infile cards missover; 
input OBS Su PLGA Rep Exp Size PI; 
cards; RUN; 
1 1 1 1 1 45.88  0.577 
2 1 1 2 1 48.19  0.57 
3 1 1 3 1 48.73  0.65 
4 1 1 1 2 17.36  0.41 
5 1 1 2 2 19.84  0.394 
6 1 1 3 2 21.26  0.365 
7 1 1 1 3 33.47  0.53 
8 1 1 2 3 29.94  0.436 
9 1 1 3 3 35.45  0.401 
10 1 1 1 4 37.97  0.428 
11 1 1 2 4 31.21  0.486 
12 1 1 3 4 41.26  0.547 
13 1 2 1 1 89.61  0.166 
14 1 2 2 1 90.98  0.15 
15 1 2 3 1 92.37  0.143 
16 1 2 1 2 85.11  0.15 
17 1 2 2 2 84.18  0.165 
18 1 2 3 2 82.75  0.169 
19 1 2 1 3 85.51  0.134 
20 1 2 2 3 84.32  0.161 
21 1 2 3 3 83.56  0.143 
22 1 2 1 4 93.28  0.171 
23 1 2 2 4 92.96  0.142 
24 1 2 3 4 91.96  0.146 
25 1 3 1 1 107.3  0.072 
26 1 3 2 1 104.8  0.176 
27 1 3 3 1 105.0  0.128 
28 1 3 1 2 113.9  0.085 
29 1 3 2 2 112.7  0.117 
30 1 3 3 2 111.5  0.13 
31 1 3 1 3 129.3  0.107 
32 1 3 2 3 127.0  0.129 
33 1 3 3 3 128.2  0.095 
34 1 3 1 4 114.6  0.158 
35 1 3 2 4 115.0  0.116 
36 1 3 3 4 113.5  0.122 
37 1 4 1 1 122.0  0.176 




39 1 4 3 1 121.4  0.114 
40 1 4 1 2 121.8  0.09 
41 1 4 2 2 120.0  0.115 
42 1 4 3 2 119.9  0.118 
43 1 4 1 3 130.1  0.133 
44 1 4 2 3 130.0  0.104 
45 1 4 3 3 128.8  0.095 
46 1 4 1 4 128.2  0.099 
47 1 4 2 4 128.7  0.069 
48 1 4 3 4 127.3  0.099 
49 2 1 1 1 150.6  0.062 
50 2 1 2 1 151.2  0.073 
51 2 1 3 1 151.1  0.12 
52 2 1 1 2 155.3  0.074 
53 2 1 2 2 155.1  0.078 
54 2 1 3 2 154.5  0.052 
55 2 1 1 3 162.2  0.074 
56 2 1 2 3 159.1  0.1 
57 2 1 3 3 160.9  0.094 
58 2 1 1 4 153.2  0.065 
59 2 1 2 4 152.6  0.092 
60 2 1 3 4 152.3  0.049 
61 2 2 1 1 172.7  0.136 
62 2 2 2 1 173.7  0.123 
63 2 2 3 1 177.3  0.092 
64 2 2 1 2 178.5  0.084 
65 2 2 2 2 178.8  0.064 
66 2 2 3 2 178.6  0.116 
67 2 2 1 3 182.1  0.123 
68 2 2 2 3 181.2  0.108 
69 2 2 3 3 180.8  0.095 
70 2 2 1 4 184.3  0.133 
71 2 2 2 4 184.5  0.092 
72 2 2 3 4 183.9  0.136 
73 2 3 1 1 200.6  0.13 
74 2 3 2 1 204.6  0.12 
75 2 3 3 1 205.4  0.114 
76 2 3 1 2 193.1  0.131 
77 2 3 2 2 191.7  0.139 
78 2 3 3 2 190.5  0.108 
79 2 3 1 3 179.8  0.138 
80 2 3 2 3 181.8  0.127 
81 2 3 3 3 179.6  0.136 
82 2 3 1 4 184.0  0.107 
83 2 3 2 4 186.3  0.137 
84 2 3 3 4 182.6  0.137 
85 2 4 1 1 178.9  0.171 
86 2 4 2 1 188.4  0.147 
87 2 4 3 1 187.7  0.06 
88 2 4 1 2 197.4  0.138 
89 2 4 2 2 190.5  0.135 
90 2 4 3 2 190.9  0.129 
91 2 4 1 3 239.4  0.218 
92 2 4 2 3 236.1  0.189 
93 2 4 3 3 233.3  0.19 
94 2 4 1 4 227.3  0.163 




96 2 4 3 4 224.9  0.178 
; 
Proc print data=ECP; 
title3 'raw data set'; 
run; 
PROC CONTENTS data=ECP; 
   Title3 'Proc CONTENTS of data set EC'; 
RUN; 
proc mixed data=ECP CL method=type3; 
 classes Su PLGA Rep Exp ; 
 Title3 'Two way ANOVA with PROC mixed for PLGA-surfactant Nanoparticle Size'; 
  MODEL Size = Su PLGA Su*PLGA / htype=3 DDFM=Satterthwaite OUTp=res ; 
 Random exp Exp*Su*PLGA;  
 lsmeans Su PLGA Su*PLGA / pdiff adjust=tukey cl; 
 ods output diffs=ppp lsmeans=mmm; 
 ods listing exclude diffs; 
RUN; 
 TITLE4 'Post hoc adjustment with macro by Arnold Saxton For PLGA-Surfactant Nanoparticle size'; 
 * SAS Macro by Arnold Saxton: Saxton, A.M. 1998. A macro for ; 
     * converting mean separation output to letter groupings in Proc Mixed. ; 
     * In Proc. 23rd SAS Users Group Intl., SAS Inst., Cary, NC, pp1243-246.; 
  %include 'C:\Documents and Settings\Margarita\My Documents\Carlos\SAS\pdmix800.sas'; 
   %pdmix800(ppp,mmm,alpha=0.05,sort=yes); 
run; 
proc print data=mmm; run; 
data new1; set mmm; if effect = 'Su*PLGA'; run; 
OPTIONS ls=90 ps=30; 
proc plot data=new1; plot estimate*PLGA=su;  
run; 
OPTIONS ls=105 ps=512; 
proc univariate data=res normal plot;  var resid; 
title1 'Univariate Normality of Residuals for PLGA-surfactant Nanoparticle Size'; 
title2 'Carlos E data analysis'; 
run; 
OPTIONS ls=96 ps=512; 
proc mixed data=ECP CL;* method=type3; 
 classes Su PLGA Rep Exp ; 
 Title3 'Two way ANOVA with PROC mixed for PLGA-Surfactant Nanoparticle size'; 
 MODEL Size = Su | PLGA @2 / htype=3 DDFM=Satterthwaite OUTp=res ; 
  Random exp Exp*Su*PLGA;  
  lsmeans Su | PLGA @2 / pdiff adjust=tukey; 
  ods output diffs=ppp lsmeans=mmm; 
        ods listing exclude diffs;* lsmeans; 
RUN; 
 TITLE4 'Post hoc adjustment with macro by Arnold Saxton For PLGA-Surfactant Nanoparticle size'; 
 * SAS Macro by Arnold Saxton: Saxton, A.M. 1998. A macro for ; 
 * converting mean separation output to letter groupings in Proc Mixed. ; 
 * In Proc. 23rd SAS Users Group Intl., SAS Inst., Cary, NC, pp1243-246.; 
 %include 'C:\Documents and Settings\Margarita\My Documents\Carlos\SAS\pdmix800.sas'; 
  %pdmix800(ppp,mmm,alpha=0.05,sort=yes); 
run; 
OPTIONS ls=105 ps=512; 
proc univariate data=res normal plot;  var resid; 
title1 'Univariate Normality of Residuals for PLGA-Surfactant Nanoparticle Size'; 





OPTIONS ls=96 ps=512; 
proc mixed data=ECP CL;* method=type3; 
 classes Su PLGA Rep Exp ; 
 Title3 'Two way ANOVA with PROC mixed for PLGA-Surfactant Nanoparticle PI'; 
 MODEL PI = Su | PLGA  @2 / htype=3 DDFM=Satterthwaite OUTp=res1 ; 
 Random exp Exp*Su*PLGA;  
 lsmeans Su | PLGA @2 / pdiff adjust=tukey; 
 ods output diffs=ppp lsmeans=mmm; 
        ods listing exclude diffs; 
RUN; 
 TITLE4 'Post hoc adjustment with macro by Arnold Saxton For PLGA-Surfactant Nanoparticle PI'; 
  * SAS Macro by Arnold Saxton: Saxton, A.M. 1998. A macro for ; 
  * converting mean separation output to letter groupings in Proc Mixed. ; 
  * In Proc. 23rd SAS Users Group Intl., SAS Inst., Cary, NC, pp1243-246.; 
 %include 'C:\Documents and Settings\Margarita\My Documents\Carlos\SAS\pdmix800.sas'; 
  *%include 'C:\pdmix800.sas'; 
  %pdmix800(ppp,mmm,alpha=0.05,sort=yes); 
run; 
OPTIONS ls=105 ps=512; 
proc univariate data=res1 normal plot;  var resid; 
title1 'Univariate Normality of Residuals for PLGA-Surfactant Nanoparticle PI '; 
title2 'Carlos E data analysis'; 
run; 
proc print data=mmm; run; 
data new2; set mmm; if effect = 'Su*PLGA'; run; 
OPTIONS ls=90 ps=30; 
proc plot data=new2; plot estimate*PLGA=su;  
run; 
OPTIONS ls=96 ps=512; 
quit; 
ODS HTML close; 
Univariate Normality of Residuals for PLGA-surfactant Nanoparticle Size 
Carlos E data analysis 
Two way ANOVA with PROC mixed for PLGA-Surfactant Nanoparticle size 
Post hoc adjustment with macro by Arnold Saxton For PLGA-Surfactant Nanoparticle size 
 
Effect=Su Method=Tukey-Kramer(P<0.05) Set=1 
Obs Su PLGA Estimate Standard Error Letter 
Group 
1 2 _ 183.69 2.9996 A 
2 1 _ 90.6198 2.9996 B 
 
Effect=PLGA Method=Tukey-Kramer(P<0.05) Set=2 





Obs Su PLGA Estimate Standard Error Letter 
Group 
3 _ 4 167.60 4.0908 A 
4 _ 3 152.62 4.0908 A 
5 _ 2 133.87 4.0908 B 
6 _ 1 94.5275 4.0908 C 
 
Effect=Su*PLGA Method=Tukey-Kramer(P<0.05) Set=3 
Obs Su PLGA Estimate Standard Error Letter 
Group 
7 2 4 210.22 5.6753 A 
8 2 3 190.00 5.6753 AB 
9 2 2 179.70 5.6753 BC 
10 2 1 154.84 5.6753 C 
11 1 4 124.98 5.6753 D 
12 1 3 115.23 5.6753 D 
13 1 2 88.0492 5.6753 E 
14 1 1 34.2133 5.6753 F 
 
 
Univariate Normality of Residuals for PLGA-Surfactant Nanoparticle Size 
Carlos E data analysis 
 
The UNIVARIATE Procedure 
Variable: Resid (Residual) 
Moments 
N 96 Sum Weights 96 
Mean 0 Sum Observations 0 





Skewness -0.5748819 Kurtosis 3.0546504 
Uncorrected SS 261.087401 Corrected SS 261.087401 
Coeff Variation . Std Error Mean 0.16919812 
 
Basic Statistical Measures 
Location Variability 
Mean 0.000000 Std Deviation 1.65780 
Median 0.107279 Variance 2.74829 
Mode . Range 10.83769 
    Interquartile Range 1.68052 
 
Tests for Location: Mu0=0 
Test Statistic p Value 
Student's t t 0 Pr > |t| 1.0000 
Sign M 3 Pr >= |M| 0.6101 
Signed Rank S 88 Pr >= |S| 0.7496 
 
Tests for Normality 
Test Statistic p Value 
Shapiro-Wilk W 0.945054 Pr < W 0.0005 
Kolmogorov-Smirnov D 0.088628 Pr > D 0.0630 
Cramer-von Mises W-Sq 0.218939 Pr > W-Sq <0.0050 





Quantiles (Definition 5) 
Quantile Estimate 




75% Q3 0.883860 
50% Median 0.107279 








Value Obs Value Obs 
-6.37020 85 2.68296 63 
-5.58251 11 3.12980 86 
-3.03947 8 3.40591 91 
-2.77947 73 4.29165 88 
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Univariate Normality of Residuals for PLGA-Surfactant Nanoparticle Size 
Carlos E data analysis 
Two way ANOVA with PROC mixed for PLGA-Surfactant Nanoparticle PI 
Post hoc adjustment with macro by Arnold Saxton For PLGA-Surfactant Nanoparticle PI 
 
Effect=Su Method=Tukey-Kramer(P<0.05) Set=1 
Obs Su PLGA Estimate Standard Error Letter 
Group 
1 1 _ 0.2168 0.009363 A 
2 2 _ 0.1177 0.009363 B 
 
Effect=PLGA Method=Tukey-Kramer(P<0.05) Set=2 
Obs Su PLGA Estimate Standard Error Letter 
Group 
3 _ 1 0.2803 0.01264 A 
4 _ 4 0.1344 0.01264 B 
5 _ 2 0.1309 0.01264 B 





Effect=Su*PLGA Method=Tukey-Kramer(P<0.05) Set=3 
Obs Su PLGA Estimate Standard Error Letter 
Group 
7 1 1 0.4828 0.01742 A 
8 2 4 0.1575 0.01742 B 
9 1 2 0.1533 0.01742 B 
10 2 3 0.1270 0.01742 B 
11 1 3 0.1196 0.01742 B 
12 1 4 0.1113 0.01742 B 
13 2 2 0.1085 0.01742 B 
14 2 1 0.07775 0.01742 B 
 
 
Univariate Normality of Residuals for PLGA-Surfactant Nanoparticle PI  
Carlos E data analysis 
 
The UNIVARIATE Procedure 
Variable: Resid (Residual) 
Moments 
N 96 Sum Weights 96 
Mean 0 Sum Observations 0 
Std Deviation 0.02409855 Variance 0.00058074 
Skewness 0.1314266 Kurtosis 2.16098655 
Uncorrected SS 0.05517032 Corrected SS 0.05517032 
Coeff Variation . Std Error Mean 0.00245955 
 





Basic Statistical Measures 
Location Variability 
Mean 0.00000 Std Deviation 0.02410 
Median -0.00010 Variance 0.0005807 
Mode 0.00477 Range 0.15101 
    Interquartile Range 0.02434 
 
 The mode displayed is the smallest of 2 modes with a count of 2. 
 
Tests for Location: Mu0=0 
Test Statistic p Value 
Student's t t 0 Pr > |t| 1.0000 
Sign M -1 Pr >= |M| 0.9188 
Signed Rank S -44 Pr >= |S| 0.8732 
 
Tests for Normality 
Test Statistic p Value 
Shapiro-Wilk W 0.95262 Pr < W 0.0016 
Kolmogorov-Smirnov D 0.089843 Pr > D 0.0551 
Cramer-von Mises W-Sq 0.202487 Pr > W-Sq <0.0050 
Anderson-Darling A-Sq 1.402209 Pr > A-Sq <0.0050 
 
Quantiles (Definition 5) 
Quantile Estimate 









75% Q3 0.011328460 
50% Median -0.000104772 








Value Obs Value Obs 
-0.0743641 87 0.0430342 37 
-0.0610598 9 0.0508828 26 
-0.0581291 10 0.0608709 12 
-0.0531172 25 0.0679402 7 
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SAS program for nanoparticles synthesized with a mixture of EC and Span 80 
surfactants. The effect of EC/Span 80 (% mol ratio) mixture on size and PI was evaluated by 
using five molar ratios (100%, 65%, 38%, 17%, and 0% of EC/PLGA). The aqueous solution 
was with sodium bicarbonate 15 mM. The data was in triplicate with two independent samples 
(experiments).  
dm 'log;clear;output;clear'; 
OPTIONS nodate nocenter pageno=1 ls=96 ps=512; 
Title1 'Mixture of EC and Span 80 on Nanostructures Size'; 
Title2 'Carlos E. Astete'; 
ODS HTML style=minimal body='C:\Documents and Settings\Margarita\My Documents\Carlos\Dissertation for 
PhD\EC\EC Data for SAS\Analysis03.html'; 
DATA ECSpan; infile cards missover; 
input OBS Su co Rep Exp Size PI; 
cards; RUN; 
1 1 1 1 1 23.98  0.501 
2 1 1 2 1 26.99  0.398 
3 1 1 3 1 24.17  0.413 
4 1 2 1 1 16.68  0.411 
5 1 2 2 1 17.17  0.327 
6 1 2 3 1 16.44  0.472 
7 1 3 1 1 10.74  0.28 
8 1 3 2 1 10.76  0.325 
9 1 3 3 1 10.6  0.252 
10 1 4 1 1 16.99  0.46 
11 1 4 2 1 17.36  0.274 
12 1 4 3 1 17.37  0.464 
13 1 5 1 1 24.14  0.629 
14 1 5 2 1 25.87  0.386 
15 1 5 3 1 25.84  0.489 
16 2 1 1 1 66.65  0.294 
17 2 1 2 1 60.01  0.288 
18 2 1 3 1 66.85  0.293 
19 2 2 1 1 57.01  0.173 




21 2 2 3 1 57.97  0.195 
22 2 3 1 1 75.9  0.156 
23 2 3 2 1 72.94  0.169 
24 2 3 3 1 72.07  0.167 
25 2 4 1 1 73.4  0.183 
26 2 4 2 1 71.78  0.214 
27 2 4 3 1 68.2  0.207 
28 2 5 1 1 109.4  0.319 
29 2 5 2 1 112.3  0.318 
30 2 5 3 1 106.3  0.309 
31 3 1 1 1 79.52  0.121 
32 3 1 2 1 76.93  0.107 
33 3 1 3 1 75.12  0.14 
34 3 2 1 1 92.69  0.107 
35 3 2 2 1 91.01  0.118 
36 3 2 3 1 89.2  0.112 
37 3 3 1 1 113.2  0.064 
38 3 3 2 1 109.2  0.067 
39 3 3 3 1 110.8  0.038 
40 3 4 1 1 110.3  0.09 
41 3 4 2 1 103.0  0.105 
42 3 4 3 1 107.8  0.1 
43 3 5 1 1 138.9  0.236 
44 3 5 2 1 135.3  0.212 
45 3 5 3 1 135.0  0.212 
46 4 1 1 1 134.1  0.087 
47 4 1 2 1 134.3  0.075 
48 4 1 3 1 133.8  0.086 
49 4 2 1 1 162.6  0.146 
50 4 2 2 1 161.6  0.136 
51 4 2 3 1 162.7  0.117 
52 4 3 1 1 158.5  0.147 
53 4 3 2 1 159.1  0.109 
54 4 3 3 1 159.9  0.118 
55 4 4 1 1 177.8  0.157 
56 4 4 2 1 178.2  0.158 
57 4 4 3 1 178.5  0.151 
58 4 5 1 1 164.3  0.089 
59 4 5 2 1 163.6  0.073 
60 4 5 3 1 163.2  0.095 
61 5 1 1 1 149.0  0.09 
62 5 1 2 1 156.6  0.111 
63 5 1 3 1 156.9  0.066 
64 5 2 1 1 173.4  0.092 
65 5 2 2 1 170.3  0.092 
66 5 2 3 1 178.5  0.084 
67 5 3 1 1 166.8  0.108 
68 5 3 2 1 169.3  0.098 
69 5 3 3 1 161.1  0.098 
70 5 4 1 1 165.2  0.087 
71 5 4 2 1 177.3  0.101 
72 5 4 3 1 171.5  0.085 
73 5 5 1 1 184.5  0.101 
74 5 5 2 1 195.2  0.092 
75 5 5 3 1 180.1  0.102 
76 1 1 1 2 14.84  0.272 




78 1 1 3 2 16.49  0.295 
79 1 2 1 2 23.88  0.473 
80 1 2 2 2 29.35  0.568 
81 1 2 3 2 24.62  0.544 
82 1 3 1 2 21.66  0.153 
83 1 3 2 2 16.15  0.348 
84 1 3 3 2 23.06  0.324 
85 1 4 1 2 38.99  0.142 
86 1 4 2 2 28.74  0.561 
87 1 4 3 2 33.45  0.514 
88 1 5 1 2 44.63  0.5 
89 1 5 2 2 43.5  0.474 
90 1 5 3 2 43.37  0.477 
91 2 1 1 2 56.02  0.194 
92 2 1 2 2 54.57  0.206 
93 2 1 3 2 55.67  0.19 
94 2 2 1 2 66.39  0.177  
95 2 2 2 2 65.47  0.169  
96 2 2 3 2 64.83  0.188 
97 2 3 1 2 59.5  0.186 
98 2 3 2 2 59.11  0.165 
99 2 3 3 2 59.26  0.185 
100 2 4 1 2 69.37  0.172 
101 2 4 2 2 68.52  0.171 
102 2 4 3 2 68.11  0.171 
103 2 5 1 2 93.74  0.193 
104 2 5 2 2 94.08  0.218 
105 2 5 3 2 93.72  0.208 
106 3 1 1 2 86.73  0.105 
107 3 1 2 2 86.85  0.132 
108 3 1 3 2 86.34  0.108 
109 3 2 1 2 100.4  0.106 
110 3 2 2 2 99.35  0.107 
111 3 2 3 2 99.38  0.098 
112 3 3 1 2 116.6  0.075 
113 3 3 2 2 115.9  0.06 
114 3 3 3 2 116.5  0.072 
115 3 4 1 2 139.9  0.102 
116 3 4 2 2 140.6  0.087 
117 3 4 3 2 141.2  0.125 
118 3 5 1 2 130.4  0.163 
119 3 5 2 2 129.4  0.145 
120 3 5 3 2 129.0  0.15 
121 4 1 1 2 120.9  0.095 
122 4 1 2 2 120.1  0.091 
123 4 1 3 2 119.8  0.076 
124 4 2 1 2 164.8  0.096 
125 4 2 2 2 163.9  0.098 
126 4 2 3 2 162.9  0.091 
127 4 3 1 2 124.7  0.147 
128 4 3 2 2 123.7  0.148 
129 4 3 3 2 122.8  0.132 
130 4 4 1 2 141.5  0.165 
131 4 4 2 2 140.0  0.176 
132 4 4 3 2 141.2  0.167 
133 4 5 1 2 122.2  0.092 




135 4 5 3 2 121.8  0.075 
136 5 1 1 2 157.3  0.081 
137 5 1 2 2 158.7  0.081 
138 5 1 3 2 157.9  0.091 
139 5 2 1 2 171.7  0.07 
140 5 2 2 2 172.5  0.059 
141 5 2 3 2 169.8  0.087 
142 5 3 1 2 158.2  0.085 
143 5 3 2 2 158.8  0.072 
144 5 3 3 2 157.7  0.066 
145 5 4 1 2 167.3  0.112 
146 5 4 2 2 166.9  0.093 
147 5 4 3 2 167.4  0.084 
148 5 5 1 2 180.2  0.1 
149 5 5 2 2 179.1  0.091 
150 5 5 3 2 177.4  0.117 
; 
Proc print data=ECSpan; 
title3 'raw data set of Size and PI of nanostructures for Mixture of EC and Span 80'; 
run; 
PROC CONTENTS data=ECSpan; 
   Title3 'Proc CONTENTS of data set EC and Span 80 Mixtures'; 
RUN; 
proc mixed data=ECSpan CL method=type3; 
 classes Su co Rep Exp ; 
 Title3 'Two way ANOVA with PROC mixed for EC-Span 80 Surfactants on Nanoparticle Size'; 
 MODEL Size = Su Co Su*Co / htype=3 DDFM=Satterthwaite OUTp=res ; 
 Random exp Exp*Su*Co;  
 lsmeans Su co Su*co / pdiff adjust=tukey cl; 
 ods output diffs=ppp lsmeans=mmm; 
        ods listing exclude diffs; 
RUN; 
TITLE4 'Post hoc adjustment with macro by Arnold Saxton For EC-Span 80 Surfactants on Nanoparticle Size'; 
 * SAS Macro by Arnold Saxton: Saxton, A.M. 1998. A macro for ; 
  * converting mean separation output to letter groupings in Proc Mixed. ; 
  * In Proc. 23rd SAS Users Group Intl., SAS Inst., Cary, NC, pp1243-246.; 
 %include 'C:\Documents and Settings\Margarita\My Documents\Carlos\SAS\pdmix800.sas'; 
   %pdmix800(ppp,mmm,alpha=0.05,sort=yes); 
run; 
proc print data=mmm; run; 
data new1; set mmm; if effect = 'Su*Co'; run; 
OPTIONS ls=90 ps=30; 
proc plot data=new1; plot estimate*Co=su;  
run; 
OPTIONS ls=105 ps=512; 
proc univariate data=res normal plot;  var resid; 
title1 'Univariate Normality of Residuals for EC-Span 80 Surfactants on Nanoparticle Size'; 
title2 'Carlos E data analysis'; 
run; 
OPTIONS ls=96 ps=512; 
proc mixed data=ECSpan CL;* method=type3; 
 classes Su Co Rep Exp ; 
 Title3 'Two way ANOVA with PROC mixed for EC-Span 80 Surfactants on Nanoparticle Size'; 
 MODEL Size = Su | Co @2 / htype=3 DDFM=Satterthwaite OUTp=res ; 
 Random exp Exp*Su*Co;  




    ods output diffs=ppp lsmeans=mmm; 
        ods listing exclude diffs;* lsmeans; 
RUN; 
TITLE4 'Post hoc adjustment with macro by Arnold Saxton For EC-Span 80 Surfactants on Nanoparticle Size'; 
  * SAS Macro by Arnold Saxton: Saxton, A.M. 1998. A macro for ; 
  * converting mean separation output to letter groupings in Proc Mixed. ; 
  * In Proc. 23rd SAS Users Group Intl., SAS Inst., Cary, NC, pp1243-246.; 
 %include 'C:\Documents and Settings\Margarita\My Documents\Carlos\SAS\pdmix800.sas'; 
 %pdmix800(ppp,mmm,alpha=0.05,sort=yes); 
run; 
OPTIONS ls=105 ps=512; 
proc univariate data=res normal plot;  var resid; 
title1 'Univariate Normality of Residuals for EC-Span 80 Surfactants on Nanoparticle Size'; 
title2 'Carlos E data analysis'; 
run; 
OPTIONS ls=96 ps=512; 
proc mixed data=ECSpan CL;* method=type3; 
 classes Su Co Rep Exp ; 
     Title3 'Two way ANOVA with PROC mixed for EC-Span 80 Surfactants on Nanoparticle PI'; 
    MODEL PI = Su | Co  @2 / htype=3 DDFM=Satterthwaite OUTp=res1 ; 
  Random exp Exp*Su*Co;  
  lsmeans Su | Co @2 / pdiff adjust=tukey; 
     ods output diffs=ppp lsmeans=mmm; 
        ods listing exclude diffs; 
RUN; 
 TITLE4 'Post hoc adjustment with macro by Arnold Saxton EC-Span 80 Surfactants on Nanoparticle PI'; 
  * SAS Macro by Arnold Saxton: Saxton, A.M. 1998. A macro for ; 
  * converting mean separation output to letter groupings in Proc Mixed. ; 
  * In Proc. 23rd SAS Users Group Intl., SAS Inst., Cary, NC, pp1243-246.; 
 %include 'C:\Documents and Settings\Margarita\My Documents\Carlos\SAS\pdmix800.sas'; 
 %pdmix800(ppp,mmm,alpha=0.05,sort=yes); 
run; 
OPTIONS ls=105 ps=512; 
proc univariate data=res1 normal plot;  var resid; 
title1 'Univariate Normality of Residuals for EC-Span 80 Surfactants on Nanoparticle PI '; 
title2 'Carlos E data analysis'; 
run; 
proc print data=mmm; run; 
data new2; set mmm; if effect = 'Su*Co'; run; 
OPTIONS ls=90 ps=30; 
proc plot data=new2; plot estimate*Co=su;  
run; 
OPTIONS ls=96 ps=512; 
quit; 
ODS HTML close;  
 
Univariate Normality of Residuals for EC-Span 80 Surfactants on Nanoparticle Size 
Carlos E data analysis 
Two way ANOVA with PROC mixed for EC-Span 80 Surfactants on Nanoparticle Size 






Effect=Su Method=Tukey(P<0.05) Set=1 
Obs Su co Estimate Standard Error Letter 
Group 
1 5 _ 168.55 3.8833 A 
2 4 _ 146.85 3.8833 B 
3 3 _ 109.55 3.8833 C 
4 2 _ 71.9410 3.8833 D 
5 1 _ 23.4263 3.8833 E 
 
Effect=co Method=Tukey(P<0.05) Set=2 
Obs Su co Estimate Standard Error Letter 
Group 
6 _ 5 118.99 3.8833 A 
7 _ 4 109.60 3.8833 AB 
8 _ 2 102.85 3.8833 BC 
9 _ 3 99.8183 3.8833 BC 
10 _ 1 89.0697 3.8833 C 
 
Effect=Su*co Method=Tukey(P<0.05) Set=3 
Obs Su co Estimate Standard Error Letter Group 
11 5 5 182.75 8.6834 A 
12 5 2 172.70 8.6834 AB 
13 5 4 169.27 8.6834 AB 
14 4 2 163.08 8.6834 ABC 
15 5 3 161.98 8.6834 ABC 
16 4 4 159.53 8.6834 ABC 




Obs Su co Estimate Standard Error Letter Group 
18 4 5 143.03 8.6834 ABCD 
19 4 3 141.45 8.6834 ABCD 
20 3 5 133.00 8.6834 ABCD 
21 4 1 127.17 8.6834 BCDE 
22 3 4 123.80 8.6834 BCDE 
23 3 3 113.70 8.6834 CDEF 
24 2 5 101.59 8.6834 DEFG 
25 3 2 95.3383 8.6834 DEFG 
26 3 1 81.9150 8.6834 EFGH 
27 2 4 69.8967 8.6834 FGHI 
28 2 3 66.4633 8.6834 FGHI 
29 2 2 61.7933 8.6834 GHIJ 
30 2 1 59.9617 8.6834 GHIJ 
31 1 5 34.5583 8.6834 HIJ 
32 1 4 25.4833 8.6834 IJ 
33 1 2 21.3567 8.6834 IJ 
34 1 1 20.2383 8.6834 IJ 
35 1 3 15.4950 8.6834 J 
 
 
Univariate Normality of Residuals for EC-Span 80 Surfactants on Nanoparticle Size 
Carlos E data analysis 
The UNIVARIATE Procedure 







N 150 Sum Weights 150 
Mean 0 Sum Observations 0 
Std Deviation 1.95880451 Variance 3.83691512 
Skewness 0.15610324 Kurtosis 4.20019104 
Uncorrected SS 571.700352 Corrected SS 571.700352 
Coeff Variation . Std Error Mean 0.15993572 
 
Basic Statistical Measures 
Location Variability 
Mean 0.00000 Std Deviation 1.95880 
Median -0.01607 Variance 3.83692 
Mode . Range 15.10000 
    Interquartile Range 1.27513 
 
Tests for Location: Mu0=0 
Test Statistic p Value 
Student's t t 0 Pr > |t| 1.0000 
Sign M -2 Pr >= |M| 0.8066 
Signed Rank S -31 Pr >= |S| 0.9539 
 
Tests for Normality 
Test Statistic p Value 
Shapiro-Wilk W 0.89092 Pr < W <0.0001 




Tests for Normality 
Test Statistic p Value 
Cramer-von Mises W-Sq 1.16582 Pr > W-Sq <0.0050 
Anderson-Darling A-Sq 6.038103 Pr > A-Sq <0.0050 
 
Quantiles (Definition 5) 
Quantile Estimate 




75% Q3 0.6688278 
50% Median -0.0160702 








Value Obs Value Obs 
-6.45150 75 3.61391 68 
-6.10730 70 4.45055 66 






Value Obs Value Obs 
-4.88282 86 5.99270 71 
-4.58609 69 8.64850 74 
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Univariate Normality of Residuals for EC-Span 80 Surfactants on Nanoparticle Size 
Carlos E data analysis 
Two way ANOVA with PROC mixed for EC-Span 80 Surfactants on Nanoparticle PI 






Effect=Su Method=Tukey-Kramer(P<0.05) Set=1 
Obs Su co Estimate Standard Error Letter 
Group 
1 1 _ 0.4001 0.01292 A 
2 2 _ 0.2092 0.01292 B 
3 4 _ 0.1163 0.01292 C 
4 3 _ 0.1155 0.01292 C 
5 5 _ 0.08987 0.01292 C 
 
Effect=co Method=Tukey-Kramer(P<0.05) Set=2 
Obs Su co Estimate Standard Error Letter 
Group 
6 _ 5 0.2254 0.01292 A 
7 _ 2 0.1904 0.01292 AB 
8 _ 4 0.1893 0.01292 AB 
9 _ 1 0.1788 0.01292 AB 
10 _ 3 0.1471 0.01292 B 
 
Effect=Su*co Method=Tukey-Kramer(P<0.05) Set=3 
Obs Su co Estimate Standard Error Letter Group 
11 1 5 0.4925 0.02653 A 
12 1 2 0.4658 0.02653 A 
13 1 4 0.4025 0.02653 AB 
14 1 1 0.3595 0.02653 ABC 
15 1 3 0.2803 0.02653 BCD 
16 2 5 0.2608 0.02653 BCDE 




Obs Su co Estimate Standard Error Letter Group 
18 3 5 0.1863 0.02653 DEFG 
19 2 4 0.1863 0.02653 DEFG 
20 2 2 0.1833 0.02653 DEFG 
21 2 3 0.1713 0.02653 DEFG 
22 4 4 0.1623 0.02653 DEFG 
23 4 3 0.1335 0.02653 DEFG 
24 3 1 0.1188 0.02653 EFG 
25 4 2 0.1140 0.02653 EFG 
26 3 2 0.1080 0.02653 FG 
27 3 4 0.1015 0.02653 FG 
28 5 5 0.1005 0.02653 FG 
29 5 4 0.09367 0.02653 G 
30 5 3 0.08783 0.02653 G 
31 4 5 0.08683 0.02653 G 
32 5 1 0.08667 0.02653 G 
33 4 1 0.08500 0.02653 G 
34 5 2 0.08067 0.02653 G 
35 3 3 0.06267 0.02653 G 
 
Univariate Normality of Residuals for EC-Span 80 Surfactants on Nanoparticle PI  
Carlos E data analysis 
The UNIVARIATE Procedure 
Variable: Resid (Residual) 
Moments 





Mean 0 Sum Observations 0 
Std Deviation 0.04055668 Variance 0.00164484 
Skewness -1.4606383 Kurtosis 14.2460802 
Uncorrected SS 0.24508181 Corrected SS 0.24508181 
Coeff Variation . Std Error Mean 0.00331144 
 
Basic Statistical Measures 
Location Variability 
Mean 0.00000 Std Deviation 0.04056 
Median -0.00024 Variance 0.00164 
Mode -0.00612 Range 0.41900 
    Interquartile Range 0.02155 
 
 The mode displayed is the smallest of 5 modes with a count of 2. 
 
Tests for Location: Mu0=0 
Test Statistic p Value 
Student's t t 0 Pr > |t| 1.0000 
Sign M -2 Pr >= |M| 0.8066 
Signed Rank S 28.5 Pr >= |S| 0.9576 
 
Tests for Normality 
Test Statistic p Value 
Shapiro-Wilk W 0.732621 Pr < W <0.0001 




Tests for Normality 
Test Statistic p Value 
Cramer-von Mises W-Sq 2.201264 Pr > W-Sq <0.0050 
Anderson-Darling A-Sq 11.90277 Pr > A-Sq <0.0050 
 
Quantiles (Definition 5) 
Quantile Estimate 




75% Q3 0.011687000 
50% Median -0.000243345 








Value Obs Value Obs 
-0.259683 85 0.0755585 80 
-0.129317 11 0.1032421 1 






Value Obs Value Obs 
-0.112864 14 0.1301359 13 
-0.112225 5 0.1593174 86 
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APPENDIX C: H-NMR  
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